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Summary
Although the interleukin (IL)-6 related cytokine Oncostatin M (OSM) affects a variety of 
inflammatory events associated with disease progression, the function of OSM in the face of 
an inflammatory challenge remains unclear. In this thesis a peritoneal model of inflammation, 
in association with in vitro studies using human primary cell lines, has been used to define the 
influence of OSM on chemokine-mediated leukocyte recruitment. When compared to wild 
type mice (WT) the induction of peritoneal inflammation in Oncostatin M receptor-p deficient 
mice (OSMR-KO) resulted in enhanced monocytic cell trafficking, with no differences in 
neutrophil or lymphocyte recruitment observed, suggesting that OSM control of leukocyte 
recruitment is functionally distinct from that of IL-6. Subsequent in vitro studies and an in 
vivo appraisal of inflammatory chemokine expression following peritoneal inflammation 
inferred that OSM regulation of CCL5 might account for the observed difference in 
monocytic cell trafficking. The OSM-mediated control of CCL5 is clearly distinct from the 
actions of IL-6, which acts as a more prominent in vivo regulator of CCL2 expression than 
OSM. Mechanistically, these studies inferred a hitherto unidentified interplay between 
OSM-mediated STAT signalling and NF-kB activation. In this respect, EMSA analysis of 
nuclear extracts from peritoneal membranes isolated during course of the inflammatory 
response showed that OSMR-KO mice display an enhanced profile of NF-kB activation as 
compared to WT mice. Initial in vivo appraisal of the role of OSMRP-mediated signalling in 
repeated episodes of inflammation and associated tissue damage suggest that OSM continues 
to regulate monocytic cell trafficking throughout recurrent inflammatory episodes and does 
not play a significant role in inflammation-associated peritoneal tissue damage, again a 
finding clearly distinct from the observed effects of IL-6 in tissue injury. These findings 
suggest that activation of gp 130 by IL-6 and OSM trigger distinct inflammatory responses to 
affect individual aspects of leukocyte trafficking.
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Chapter 1
General Introduction
1.1 Overview of thesis objectives
The initiation of an immune response and ensuing inflammation is integral in 
clearance of any pathogen and returning the body to homeostasis. During these 
processes cytokines play an important role, not only in the initiation of an immune 
response, but also in the resolution of inflammation. Therefore understanding the role 
of individual cytokines during inflammation is important when considering potential 
therapeutic targets for chronic inflammatory conditions. One such factor is the 
inflammatory cytokine Interleukin (IL)-6, whose involvement in disease processes has 
led to the development of blocking agents (for example, the anti-IL-6 receptor 
antibody, Tocilizumab®) for therapeutic intervention. However, the contribution of 
other IL-6-related family members remains less well defined. Of particular interest in 
this study is the role of Oncostatin M (OSM). IL-6 and OSM elicit signalling through 
distinct receptor complexes, with IL-6 utilising gpl30 homodimers and OSM utilising 
receptor complexes comprised of gpl30 associated with alternative p-signal 
transducing subunits, OSMRp or LIFRp. Therefore there is a potential for OSM to 
have roles in inflammation and tissue injury unique from those elicited by IL-6. This 
thesis aims to delineate the role of OSM-mediated signalling in acute inflammation 
and compare these roles with those known to be elicited by IL-6, therefore assessing 
the potential for OSM as a therapeutic target for modulating inflammatory conditions.
1.2 Inflammation and the immune system
The immune system is a defence mechanism comprised of a variety of highly 
specialised defence cells, which utilise and respond to a series of communication 
molecules that work in unison to protect the body from infection and disease. This 
system enables the detection and subsequent removal of foreign pathogens with the 
aim of clearing the causative agent and restoring normal tissue architecture. 
Regulation of this immunological outcome is governed by activation of an 
inflammatory response.
Inflammation is a normal physiological response to infection, trauma or 
immunological challenge involving both innate and adaptive immunity, and can be 
characterised by the orderly recruitment of specific leukocyte subsets to sites of 
infection or tissue damage. The inflammatory response, initiated by inflammatory 
cytokines, involves a combination of cells, plasma components and cellular products,
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the main aim of which is to regulate the recruitment, activation and the final clearance 
of leukocytes to bring about the effective resolution of the immune response. It is 
therefore a highly specialised communication system between leukocytes and stromal 
tissue cells local to the inflammatory insult or challenge.
During episodes of acute inflammation release of pro-inflammatory cytokines, 
predominantly IL-1 and tumour necrosis factor (TNF)-a, initiates the inflammatory 
process by inducing various cell types, including leukocytes and stromal cells to 
produce inflammatory mediators. At the onset of inflammation, leukocytes migrate to 
post-capillary venules surrounding the damaged tissue in a directional and selective 
manner, via chemotaxis. Many factors released by stromal cells and recruited 
leukocytes as well as the causative agent can act as chemoattractants, including 
phospholipid metabolites such as platelet activating factor (PAF), bacterial products 
(formylated N-terminal methionine groups), breakdown products of the complement 
cascade such as C5a, and possibly most importantly, the chemotactic cytokines 
(chemokines) (Hartmann et al, 1997; Zabel et al, 2006). Chemokines enable selective 
trafficking of individual leukocyte subsets dependent on the cell surface expression of 
specific chemokine-associated receptors. In addition to selective chemotaxis, 
chemoattractants perform other important roles during inflammation including 
leukocyte activation (eg. degranulation, NADPH oxidase activation), growth 
modulation of myeloid progenitor cells, induction of angiogenesis and sensitisation of 
cells to respond to sub-optimal levels of other inflammatory mediators (Baggiolini, 
1998; Sallusto & Baggiolini, 2008).
After initiation of an immune response, the first cells to respond are typically 
neutrophils which initiate a rapid non-specific phagocytic response. This initial 
response is augmented by a secondary influx of monocytes and specific subsets of T 
and B cells, which accumulate at the site of inflammation and become activated to 
produce a more specialised or targeted immune response (Topley et al, 1996). The 
culmination of these activities comes from the orchestration of two immunological 
processes: innate immunity (a non-specific response to all potential foreign bodies), 
and acquired immunity (a specific response to a recognised pathogen).
3
1.2.1 Innate Immunity
Innate immunity is the first line of defence against all pathogens and involves not only 
a cellular response but also comprises anatomical and humoral barriers which act 
together to provide an initial rapid response. The innate defence mechanisms include 
the skin and mucosal membranes as well as leukocytes including neutrophils, 
macrophages, eosinophils and basophils. The innate response is a fast acting, non­
specific response which does not change or evolve.
1.2.2 Polymorphonuclear neutrophils
Neutrophils are critical as a first line of anti-microbial defence and are the primary 
cell type involved in the innate immune response. Neutrophils differentiate from 
myeloid precursors in the bone marrow and are released into the periphery, where 
during incidences of infection or injury, they are rapidly recruited to the site of 
inflammation (Borregaard & Cowland, 1997). The initial phase in neutrophil 
recruitment is adhesion to the blood vessel wall, facilitating trans-migration from the 
circulation to the inflammatory site. Initially low affinity selectins facilitate 
neutrophil ‘rolling’ along stromal tissue cells, followed by firm attachment mediated 
by binding to adhesion molecules such as intracellular adhesion molecule (ICAM)-l. 
Tight adhesion is followed by extravasation into the damaged tissue (Faurschou & 
Borregaard, 2003). Neutrophils are trafficked to the site of inflammation by 
following a chemotaxis and can respond to a variety of stimuli including chemotactic 
agents such as C5a (a breakdown product of the complement cascade), lipid mediators 
(leukotrienes, eicosanoids) and neutrophil-activating chemokines including CXCL8 
(formerly IL-8). Once at the site of inflammation, neutrophil activation leads to the 
phagocytosis of pathogens or cellular debris utilising degradative proteolytic enzymes 
and reactive oxygen species to clear the causative problem. In addition to 
phagocytosis, neutrophils also play an important role in the further recruitment of 
leukocytes to the site of inflammation through the release of cytokines and 
chemokines, including CXCL8 and receptor molecules including soluble CD62L (L- 
Selectin) and the soluble IL-6 receptor (sIL-6R) (Scapini et al, 2000).
Neutrophils are short-lived cells (typically 3 days) and are unable to proliferate but 
undergo constitutive apoptosis, which is vital not only in the regulation of basal 
neutrophil production but also in limiting excessive non-selective tissue inflammation
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(Akgul et al, 2001). In this respect, self limiting shedding of CD62L and IL-6 R 
reduces neutrophil recruitment and aids resolution (Venturi et al, 2003). Apoptotic 
neutrophils are recognised and phagocytosed by macrophages, depending on specific 
cell surface receptors expressed on the apoptotic cell.
1.3 Acquired Immunity
Adaptive or acquired immunity is a highly specific response involving recognition 
and targeting of the pathogen, then conferring ‘immunologic memory’ providing 
lasting protection against the targeted antigen. The adaptive immune response can be 
split into two categories; cell mediated, which is governed by T cells, and humoral, 
which is controlled by B cells, however, both these responses act in unison to convey 
host defence.
1.3.1 Cell mediated Immunity
Cell mediated immunity involves direct recognition and binding of T cells to antigen, 
via the T cell receptor (TCR), the composition of which is unique to an individual T 
cell. Antigens are classified as a specific peptide presented on the surface of a cell in 
association with an appropriate major histocompatibility complex (MHC) molecule. 
There are two classes of MHC; class I, which is expressed on all nucleated cells and is 
recognised by the TCR of CD8 + cytotoxic T cells, and class II which are present only 
on the surface of antigen presenting cells (APC; for example macrophages, B-cells 
and dendritic cells (DCs)) and are recognised by CD4+ T helper cells. CD8 + T cells 
monitor MHC Class I expressed on the surface of all cells and are therefore able to 
distinguish ‘self antigens from virally infected cells (ie. the MHC presentation of 
virally-encoded antigens) or tumourigenic cells (Krogsgaard & Davis, 2005). CD8 + T 
cells destroy infected cells by increasing membrane permeability and promoting 
apoptosis.
Following activation, peripheral CD4+ T helper cells can differentiate into several 
distinct subsets, which are characterised by the secretion of a distinct profile of 
inflammatory cytokines. As a result, each T-helper subset is considered to convey a 
specific function.
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1.3.2 CD4+ T effector cell subsets
1.3.2.1 Thl Cells
T cells activated by dendritic cells and macrophages induce cell-mediated 
inflammatory responses which are characterised by the type of cytokines they secrete 
and the expression of specific transcription factors. The Thl subset can be 
characterised by high expression of interferon (IFN)-y and require IL-12 for 
differentiation (Figure 1.1). EFN-y signalling through STAT (signal transducers and 
activators of transcription) 1 activates the T-box differentiation factor, T-bet, which in 
turn upregulates expression of IL-12RJ32. IL-12, utilising IL-12R activates STAT4 
thereby stabilising IFN-y production and development of terminally differentiated Thl 
cells (Murphy & Reiner, 2002; Szabo et al, 2000). Thl cell responses are associated 
with eradication of intracellular pathogens, but are largely associated with the 
progression of chronic inflammation (Takeda et al, 1999; Harrington et al, 2006; 
Leonard et al, 1995).
1.3.2.2 Th2 Cells
Th2 cells recognise MHC class II expressed on antigen presenting cells and aid 
antibody secretion by activated B-cells (see Section 1.3.5). Th2 cells are associated 
with elimination of parasitic infections and the development of allergic responses. In 
this respect Th2 cells are characterised by production of IL-4, IL-5 and IL-13, which 
are potent activators of B-cell immunoglobulin (Ig)E production, eiosinophil 
recruitment and mucous production (Harrington et al, 2006). Differentiation of Th2 
cells is initiated through IL-4 mediated induction of STAT6  and activation of the 
TCR, which promotes expression of the transcription factor GAT A3, which in turn 
upregulates production of IL-4, IL-5 and IL-13, while suppressing Thl differentiation 
by blocking STAT4 activation (Zhang & Flavell, 1997; Ouyang et al, 1998; Ouyang 
et al, 2000). Dysregulation of Th2 responses is associated with allergy and asthma 
(Larche et al, 2003).
1.3.2.3 Thl 7 Cells
An additional T-helper population was recently characterised by its capacity to secrete 
IL-17. These cells (termed Thl 7 cells) are characterised by production of IL-17A, IL- 
17F, IL-21, IL-22, IL-23 and expression of IL-23R (Harrington et al, 2005). IL-17 is 
a pleiotropic cytokine consisting of a number of isoforms which induces pro-
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inflammatory cytokine and chemokine expression, angiogenesis and regulates 
neutrophil chemotaxis and dendritic cell maturation (Kolls et al, 2004).
Differentiation to a Thl 7 phenotype is dependent on several cytokines including IL-6 , 
transforming growth factor (TGF)-p, IL-21 and IL-23, and can be blocked by the 
cytokines associated with promoting differentiation to either a Thl or Th2 phenotype 
(McGeachy & Cua, 2008). Analysis of Jak-STAT pathway involvement in Thl7 cell 
differentiation in response to IL- 6  and TGFp activation outlines a role for STAT3 and 
to a lesser extent STAT4, in the differentiation of Thl 7 cells. Further STAT3 driven 
signalling via IL-23 is subsequently needed to maintain the effector properties of 
Thl7 cells (Yang et al, 2007; Mathur et al, 2006). Analysis of the transcription 
factors important in Thl7 cell differentiation has shown a role for STAT3 driven 
activation of the transcription factor ROR-yt (Retinoic acid-related orphan nuclear 
hormone receptor-yt) (Ivanov et al, 2006).
Thl7 cells are considered important in autoimmune responses as demonstrated in a 
variety of autoimmune conditions including murine models of rheumatoid arthritis 
and experimental autoimmune encephalomyelitis (EAE), where IL-17A deficient 
mice demonstrate decreased inflammation and tissue destruction and overexpression 
of IL-17 exacerbates disease severity (Nakae et al, 2003; Lubberts et al, 2001; Bettelli 
et al, 2007).
1.3.3 CD4+ memory T cells
Memory T cells can be generated by clonal expansion and differentiation of effector T 
cells, the functions and migratory properties of which are imprinted during the 
interaction of T cells with antigen presenting cells. There are two general subsets of 
memory T cells; central memory cells (Tcm), which can be distinguished from a 
second subset, effector memory cells (Tem), by the expression of CD27, CD62L and 
CCR7 (Campbell et al, 1998; Forster et al, 1999; Henger et al, 2003). Tcm provide 
reactive memory, they have little effector function but are homed to T cell areas 
within secondary lymphoid organs via CCR7 where they can readily proliferate and 
differentiate to effector cells in response to antigenic stimulation. Conversely, Tem 
migrate to inflamed peripheral tissues and display immediate effector function 
(Lanzavecchia & Sallusto, 2000).
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1.3.4 CD4+ T cell regulatory subsets
In addition to effector T cells, CD4+ T cells can be induced to differentiate into 
regulatory T cells (Treg), which are characterised by expression of CD25 (IL-2Ra) 
and the transcription factor FoxP3 (Figure 1.1) (Roncarolo et al, 2006; Chen et al,
2003). Tregs are widely accepted as immunological suppressor cells preventing 
autoimmune and chronic inflammatory conditions and their activity is governed by 
cytokines including IL-10, TGFp and IL- 6  (Vignali et al, 2008). In addition to 
inducible regulatory T cells, which are adapted from effector CD4+ T cells, naturally 
occurring FoxP3+ Tregs develop in the thymus and display a diverse TCR repertoire 
that is specific for self antigens (Fontenot et al, 2005). Antigen presenting cells, when 
exposed to a given pathogen in the periphery, initiate both effector T cell and natural 
Treg responses (Vignali et al, 2008). Critically IL- 6  has been shown to suppress Treg 
activity and differentiation. In this respect Treg are considered to be derived from the 
same T cell lineage as Thl7 cells (Bertelli et al, 2007; Pasare & Medzhitof, 2003).
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Figure 1.1 Differentiation of T cell subsets
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Fig 1.1. Differentiation of T cell subsets. Peripheral nai've CD4+ T cells (Th0  
cells) can differentiate into at least three effector subsets (expressing unique 
transcription factors) dependent upon cytokine stimulation; Thl, Th2 and Thl7, 
each of which have important but unique roles in host defence. In addition Tho 
cells can also differentiate into regulatory T cells including induced Treg (iTreg) 
cells and T rl cells (another class of regulatory T cell). Naturally occurring Tregs 
(nTreg) are generated from CD4+ thymic T cell precursors. (Adapted from 
Bettelli et al, 2007).
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1.3.5 Humoral Immunity
Humoral immunity involves the production of antibodies by B cells in response to the 
recognition of specific antigenic epitopes. Naive B cells can be activated in either a T 
cell dependent or independent manner. Activation is through binding of antigens on 
the pathogen to a specific B cell receptor (BCR), which have a typical 
immunoglobulin (Ig) structure and resemble either IgD or monomeric IgM.
Naive B cells are responsible for the primary humoral response, however, after 
exposure to cytokines including IL-4, IL-6 , IL-10, IL-13, IL-21 and TGFP, and 
repeated TCR activation, B cells can be induced to differentiate to give a memory 
phenotype. This involves Ig ‘class switching’ where naive B cells, in response to 
specific stimuli, can be induced to switch Ig isotype from secretory IgM (either 
pentameric or heptameric) to IgA, IgG or IgE enabling a more robust specialised 
response (Tangye & Hodgkin, 2004). Memory B cells also demonstrate increased 
expression of MHC class II, CD80, CD8 6  and CD95 which enable them to act as 
antigen presenting cells for CD4+ T cells (Lui et al, 1995) (see Section 1.3.2). 
Memory B cells can be induced to secrete Ig, and thus become antibody releasing 
cells after continued exposure to the T cell and certain regulatory molecules including 
CD40L (Arpin et al, 1995).
The primary source of serum antibodies are terminally differentiated plasma cells, 
which differ from memory B cells through alterations in cell surface marker 
expression. Plasma cells downregulate expression of membrane bound Ig and MHC 
Class II, but acquire expression of CD38 (Abney et al, 1978; Halper et al, 1978; 
Tangye & Hodgkin, 2004). Unlike memory B cells, plasma cells do not process and 
present antigen, instead the main function of plasma cells appears to be production 
and secretion of large quantities of specific antibody (Slifka et al, 1998).
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1.4 Mononuclear phagocytes
Mononuclear phagocytes are integral to host immune defence but also play a crucial 
role in development and tissue homeostasis (Gordon, 1986; Gordon, 1998). 
Macrophages can be split into two very broad categories, ‘resident’ tissue 
macrophages and ‘inflammatory’ macrophages; however, both are derived from 
circulating bone marrow-derived monocytes (Volkman & Gowans, 1965; Gordon & 
Taylor, 2005). Monocytes can also give rise to antigen presenting dendritic cells (see 
Section 1.4.2) (Taylor et al, 2005). Tissue macrophages are highly heterogeneous 
populations, with differences in their activities dependent on the local environment 
and function they are required to perform (Taylor et al, 2005). In addition to 
lymphoid organs, many other organ systems including the liver, lung, nervous system, 
gut and epidermis have distinct populations of specialised tissue macrophages (Taylor 
et al, 2005). A major role of the macrophage in homeostasis and after infection or 
injury is the phagocytic removal of apoptotic and senescent cells (Fadok et al, 1998; 
Pickering et al, 2000). In response to immune stimulation or triggering of the 
inflammatory response, additional monocytes are recruited from the periphery where 
they adapt to their new microenvironment by altering cell surface receptor expression 
(Taylor et al, 2005).
Studies into human peripheral blood monocyte heterogeneity demonstrate that in 
addition to morphological heterogeneity, these cells can be characterised as two 
distinct subsets: ‘inflammatory’ CD 16' monocytes, which show high expression of 
CD 14, the classical human monocyte marker which forms part of the receptor for 
lipopolysaccharide (LPS), an endotoxin present in the cell wall of gram-negative 
bacteria; and ‘resident’ CD14+CD16+ monocytes, which in addition to expressing 
CD 14, also express CD 16, an Fc receptor for IgGl (Passilick et al, 1989). Several 
phenotypic and physiological differences have been observed between these two 
subsets. Each demonstrates individual chemokine receptor expression, for example 
CD14h,CD16' monocytes express CCR2, whereas CD14+CD16+ cells express CCR5 
(Weber et al, 2000). The specific receptor expression for each subset is outlined in 
Table 1.1. Each subset also display a unique cytokine and chemokine profile, with 
‘inflammatory’ monocytes associated with high expression of pro-inflammatory 
cytokines including IL-1, TNF-a and IL-6 , whereas ‘resident’ monocytes are 
associated with the release of IL-12 and IFN-a (Akiyama et al, 1985; Elias et al,
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1985; Fernandez et al, 1986; Szabo et al, 1990). As in humans, mice also exhibit two 
distinct monocyte subsets, each determined by unique receptor expression (Figure
1.2). Monocytes in mice can be identified as F4/80+CDllb+, but can be further 
divided by expression of CD62L (L-selectin), CCR2, CXsC-chemokine receptor 1 
(CX3 CRI) and Ly6 C (Gordon & Taylor, 2005; Palframan et al, 2001). Studies have 
shown that CCR2+CD62L+CX3CRllowLy6C+ monocytes are functionally equivalent 
to CD14hlCD16' ‘inflammatory’ monocytes in humans, whereas the CCR2'CD62L' 
CX3CRlhlLy6 C' monocytes relate to human CD14+CD16+ ‘resident’ monocytes 
(Gordon & Taylor, 2005).
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Table 1.1 Monocyte phenotype in humans and mice
Human
CD14WCD16'
‘inflammatory’
monocytes
Human
CD14+CD16+
‘resident’
monocytes
Mouse CCR2+ 
CX3CR1,ow 
‘inflammatory’ 
monocytes
Mouse CCR2' 
CX3C R lhi 
‘resident’ 
monocytes
Chemokine receptors
CCR1 + -
CCR2 + - + -
CCR4 + -
CCR5 - +
CCR7 + -
CXCR1 + -
CXCR2 + -
CXCR4 + ++
CX3CR1 + ++ + ++
Other receptors
CD4 + +
C D lla + ++
C D llb ++ ++ ++ ++
C D llc ++ +++ - +
CD14 +++ +
CD31 -H-+ +++ ++ +
CD32 -H-+ +
CD33 +++ + +
CD43 - -
CD49b + -
CD62L ++ - +
CD86 + ++ ++
CD115 ++ ++ ++ ++
CD116 ++ ++ ++
F4/80 + +
Ly6C + -
MHC Class II + + - -
Table 1.1. Cell surface marker expression of mouse and human ‘inflammatory’ 
and ‘resident’ monocytes (Adapted from Gordon & Taylor, 2005).
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Figure 1.2 Maturation of mononuclear phagocytes in mice
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Fig 1.2. Maturation of mononuclear phagocytes in mice. Ly6 C+ monocytes are 
generated from haematopoietic stem cells in the bone marrow and released into 
the peripheral blood, where they are thought to adopt a Ly6 Cmid phenotype, both 
of which are able to respond to pro-inflammatory chemokines and are therefore 
recruited to sites of inflammation. Most ‘inflammatory’ monocytes differentiate 
into macrophages, but some migrate into draining lymph nodes where they 
acquire dendritic cell-like phenotypes. In the absence of inflammation, Ly6 C' 
monocytes enter the tissue where they replenish the resident macrophage and 
dendritic cell populations. (Adapted from Gordon & Taylor, 2005).
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1.4.1 Macrophage activation
Cell mediated macrophage activation can follow two pathways: classical activation, 
which relies on IFN-y, and alternative activation, which is triggered after stimulation 
by IL-4 or IL-13 (Nathan et al, 1983; Stein et al, 1992; Goerdt et al, 1999) (Figure
1.3).
Classical activation requires two signals, IFN-y (Nathan et al, 1983) and a secondary 
signal which sensitises the macrophages to respond to IFN-y. Both CD4+ Thl and 
CD8 + cytotoxic T cells produce IFN-y, Thl cells provide the other signal by 
expressing CD40 ligand (CD40L) on their cell surface, which when bound to CD40 
on the macrophage, sensitise the macrophage to respond to IFN-y (Stout et al, 1996). 
Alternative secondary signals include LPS and other conserved pathogen-associated 
molecular patterns (PAMPs) binding to pathogen recognition receptors (PRRs) 
expressed on the surface of the macrophage (see Table 1.2) thus inducing TNF 
production (Taylor et al, 2005); and endogenous factors including heat shock protein 
(Van Ginderachter et al, 2006). Classical activation is associated with a pro- 
inflammatory response, inducing increased anti-microbial activity, increased cytotoxic 
activities, increased expression of pro-inflammatory cytokines including TNFa, EL-1, 
IL-6 , IL-12 and IL-23, and stimulates increased expression of MHC class II and 
CD40L (Mytar et al, 1999; Stuehr & Nathan, 1989; Urban et al, 1986). Due to the 
cytokine profile exhibited by classically activated macrophages, this pathway is 
associated with promoting Thl immune responses.
In addition to IFN-y-induced regulation of macrophage function, a pro-inflammatory 
class of macrophages can be activated through stimulation with Toll-like receptor 
(TLR) ligands, such as LPS (Boldrick et al, 2002; Nau et al, 2002). This form of 
activation is associated with a rapid, innate immune response, rather than cell- 
mediated. Innate activation is associated with increased production of pro- 
inflammatory cytokines as well as upregulation of reactive oxygen species (ROS) and 
inducible nitric-oxide synthase (iNOS), therefore increasing the phagocytic activity of 
the macrophage (Gordon, 2003).
The targeted recognition of bacterial, apoptotic or necrotic cells for phagocytic 
removal is highly complex and dependent on a wide array of specific receptor
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complexes. Receptors including TLRs, mannose and p-glucan receptors, fibronectins 
and integrins expressed on the surface of both classically and innate activated 
macrophage bind to specific molecular patterns expressed on the surface of the target. 
These include markers such as phosphatidyl serine expressed on the surface of 
apoptotic or senescent cells (Taylor et al, 2005). Once recognition has occurred, the 
particle is internalised and exposed to detrimental levels of reactive oxygen species 
including superoxide and nitric oxide, which together with the degranulation of 
degradative enzymes leads to the clearance of the pathogen or cellular debris.
Table 1.2 Pathogen associated molecular patterns (PAMPs) and associated 
pathogen recognition receptors (PRR)
PRR family Examples of associated PAMPs (PRR ligands)
Scavenger (collagenous) eg. 
SR-A
Polyanionic ligands, LDL (low density lipoproteins)
Scavenger (noncollagenous) 
eg. CD36
Oxidised LDL, apoptotic cells
GPI-anchored eg. CD 14 LPS, LTA (lipoteichoic acid), PGN (prostaglandin), 
apoptotic cells
Integrin eg. CD lib Apoptotic cells
Ig superfamily eg. CD33 Siacylic acid
NK-like C-type lectin-like 
eg. Dectin-1
B-glucan polysaccharides
Multiple CTLD eg. 
Mannose receptor
Mannose, fucose, N-acetylglucosamine
Toll-like receptor eg. TLR2, 
TLR4
LPS, peptodoglycan
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Alternative activation is mediated through the Th2 cytokines, IL-4 and IL-13 
(Gordon, 2003; Stein et al, 1992). Macrophages activated by IL-4 and IL-13 display 
increased expression of both MHC class II and the mannose receptor, facilitating 
endocytosis and antigen presentation; and suppression of pro-inflammatory cytokines 
(such as IL-1 and IL-6 ). Instead, alternatively activated macrophages secrete anti­
inflammatory cytokines including TGFp and IL-10, and direct Th2-type responses 
through the control of CCR4+ CD4+ T cell recruitment via secretion of CCL22 and 
CCL17 (Bonnechi et al, 1998; Andrew et al, 1998; Imai et al, 1999; Gordon, 2003). 
The anti-inflammatory cytokine IL-10 (also released by Th2 cells) also serves to 
suppress macrophage function by limiting MHC class II expression and anti­
inflammatory mediator production (Fiorentino et al, 1989). As a result, alternatively 
activated macrophages are associated with tissue repair and have a general anti­
inflammatory phenotype.
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Figure 1.3 Activation pathways of macrophages
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Fig 1.3. Activation pathways of macrophages. Innate activation occurs in 
response to recognition of microbial PAMPs (pattern-associated molecular 
patterns) by pattern-recognition receptors such as TLRs. Stimulation results in 
the release of pro-inflammatory cytokines such as IFNs, and reactive oxygen 
species (ROS) and nitric oxide (NO) thus promoting phagocytosis. Classical 
activation is mediated by IFN-y followed by a secondary microbial stimulus such 
as LPS. Stimulation results in upregulation of MHC class II molecules, the 
release of pro-inflammatory cytokines such as IL-1 and IL - 6  and initiation of the 
respiratory burst. The net effect of classical macrophage activation is 
microbicidal and conveys cellular immunity. Alternative activation is mediated 
by IL-4 and IL-13 and results in upregulation of MHC class II and Mannose 
receptor resulting in increased antigen endocytosis. Stimulation also results in 
the release of anti-inflammatory cytokines IL-10 and TGF0, the net response of 
which is to mediate allergic and anti-parasitic responses and to induce tissue 
repair. (Adapted from Gordon, 2003).
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1.4.2 Dendritic cells
Dendritic cells (DCs) are an additional class of antigen presenting cell, derived from 
circulating and bone-marrow derived monocytes. DCs are distinct from macrophages 
in their ability to present antigen to naive T cells, whereas macrophages can only 
activate primed T cells (Inaba et al, 1990; Knight et al, 1985). There are two main 
categories of DC: plasmacytoid and conventional (also referred to as lymphoid and 
myeloid), which are distinguished by the presence of specific cell surface markers 
(Shortman & Naik, 2007). Plasmacytoid DCs produce large quantities of type-I EFN 
(IFNa, IFNP) and express many lymphoid markers including CD 123, CD45Ra, 
BDCA-2/4 (blood dendritic cell antigen-2/4), CCR6  and CCR7, whereas conventional 
DCs express CD lib , CD 11c, CD la and DC-SIGN (dendritic cell-specific 
intercellular adhesion molecule (ICAM) 3-grabbing nonintegrin) (Barchet et al, 
2005). Numerous agents activate DCs including PAMPs (binding to PRRs), TLR 
signalling and damage-associated molecular pattern molecules (DAMPs), including 
heat shock proteins and uric acid expressed by dying cells (Janeway & Medzhitov, 
2000; Calderwood et al, 2005; Pulendran, 2004). DCs secrete a wide array of 
inflammatory cytokines, chemokines and co-stimulatory molecules which aid the 
activation of naive T cells, and their polarisation into Thl, Th2, Thl 7 or Treg cells.
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1.5 Cytokines
Cytokines are a group of polypeptides produced and released by a variety of stromal 
cells and leukocytes. Cytokines act as intracellular and extracellular signalling 
mediators, which regulate cellular responses through juxtracrine, paracrine and 
autocrine mechanisms, affecting both homeostatic ‘house-keeping’ function and 
immunological processes. In this respect, cytokines are important regulators of the 
innate and adaptive immunity and affect proliferation, cellular differentiation, 
haematopoiesis and apoptotic regulation of cell survival or death (Yarden & Ullrich, 
1988; Thomson, 1991). Proteins with cytokine-like properties include growth factors, 
interleukins, interferons and members of the TNF superfamily.
1.5.1 Interleukins
The interleukins (derived from communicates ‘inter’ with leukocytes) refer to a group 
of cytokines able to provide communication signals between different populations of 
leukocytes (Aarden et al, 1979). There are currently 35 members of the interleukin 
family (Niedbala et al, 2007). Although the name implies that these factors only 
affect leukocytes, many interleukins are produced by non-haematopoietic cells and 
affect the functions of a diverse range of somatic cells. Of particular interest in this 
study are IL- 6  and its related cytokines which will be discussed in further detail in 
Section 1.7.
1.5.2 Interferons
Interferons (IFN) are cytokines originally defined by their ability to inhibit virus 
replication and can be sub-divided into type I and type II interferons. Type I (IFNa/p) 
are induced by virally infected cells and can respond to almost any cell type (Roberts 
et al, 1998). In addition the type I IFNs have been shown to induce many activities 
linking innate and acquired immunity including dendritic cell maturation, B-cell 
differentiation and NK activation (Biron, 2001). Whereas type II IFN (IFNy) is 
induced following antigenic stimulation of T cells and has a wide variety of actions 
including macrophage activation and upregulation of MHC class II (see Section 1.4.1) 
(Schroder et al, 2004).
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1.5.3 TNF superfamily members
The tumour necrosis factor (TNF) superfamily currently consists of 19 ligands and 
orchestrates a wide range of biological functions including host defence, 
inflammation, cell death and development of the immune system (Zhang, 2004; 
Bodmer et al, 2002).
1.5.4 Functional redundancy within cytokine networks
Cytokines elicit similar or overlapping functions on the same cell types (functional 
redundancy). In this way a cytokine network is established, enabling the precise 
control of cellular proliferation, differentiation and activation of a variety of cell 
types, as well as controlling the further production and release of inflammatory 
mediators. Consequently cytokines provide an inflammatory cascade of signalling 
molecules, which function to fine-tune the inflammatory response dictating the 
duration and magnitude. This response therefore finely balances both beneficial and 
detrimental outcomes. As a result, the cytokine network is tightly regulated. 
Cytokines are only transiently expressed and are highly specific depending on cell 
surface expression of receptors corresponding to a particular cytokine. Other 
regulatory mechanisms exist including decoy and soluble receptors and specific 
cytokine antagonists which will be discussed in Section 1.6.6.
21
1.6 Cytokine Receptors
Cytokine receptors are expressed on the membranes of a wide variety of cell types, 
including leukocytes and stromal cells, whist some are also present in soluble form. 
Their ability to alter signalling in a wide variety of cell types is vital to their role in 
physiological processes. Membrane bound cytokine receptors are transmembrane 
glycoproteins, comprising an extracellular amino-terminal ligand binding domain and 
an intracellular carboxy-terminal domain. Based on this structural organisation 
cytokine receptors can be split into families which dictate ligand specificity and 
biological function.
1.6.1 Type I cytokine receptors
Type I cytokine receptors are transmembrane glycoproteins comprising an 
extracellular ligand-binding domain, a short hydrophobic transmembrane region and a 
carboxy-terminal intracellular domain. All receptors belonging to this group share 
structural homology in a 2 1 0  amino acid region in the ligand-binding domain, 
including four highly conserved cysteine residues and a repeated tryptophan-serine 
motif separated by one random amino acid (WSXWS motif) proximal to the 
transmembrane domain (Hibi et al, 1990). There is little sequence homology in the 
intracellular domains, however, none of the type I receptors have intrinsic tyrosine 
kinase activity so rely on activation of cytoplasmic tyrosine kinases, the activity of 
which are discussed in Section 1.8. Many cytokines utilise type I receptors including 
members of the interleukin-related family of cytokines, therefore these receptors will 
be discussed in further detail in Sections 1.7 and 1.8.
1.6.2 Type II cytokine receptors
Type II cytokine receptors are tripartite single pass transmembrane proteins 
characterised by structural similarities in their extracellular domain, which includes 
the ligand binding motif. Similar to type I receptors, members of the type II cytokine 
receptor family lack intrinsic tyrosine kinase activity. However, type II receptors are 
distinguished from type I receptors by the absence of the carboxy terminal WSXWS 
motif. Instead class II receptors have a variety of sequences which appear to be 
important in preservation of the three-dimensional fold of the extracellular domain of 
the receptor (Langer et al, 2004). Ligands utilising the class II family of receptors 
include the type I interferons (IFN-a, IFN-P and IFN-k) which utilise IFNAR-1 and
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IFNAR-2 (Roberts et al, 1998), the type II interferon IFN-y which utilises the 
IFNGR-1 and IFNGR-2 receptors (Schroder et al, 2004), IL-10 (and other related 
interleukins including IL-19, IL-22, IL-24 and IL-26) (Fickenscher et al, 2002) and 
factor Vila, the ligand for tissue factor. Class II cytokines have varied roles in both 
innate and acquired immune responses including DC maturation, B cell 
differentiation, macrophage activation, T helper cell biasing and suppression of 
tumour development (Langer et al, 2004).
1.6.3 Tumour necrosis factor superfamily receptors
Tumour necrosis factor (TNF) family members and their corresponding receptors play 
a pivotal role in the development and function of the immune system. Due to the 
roles of TNF superfamily proteins in human disease, pharmaceuticals to inhibit TNF 
have been developed to treat inflammatory conditions such as rheumatoid arthritis and 
inflammatory bowel disease (Maini & Taylor, 2000; Papadakis & Targan, 2000). 
Members of the TNF superfamily include TNFa, CD40L and TRAIL (TNF-related 
apoptosis ligand). TNF family ligands exist as trimers, with each monomer composed 
of structurally conserved p strands organised in two layered sheets. Tumour necrosis 
family receptors (TNFR) are type I transmembrane proteins that form elongated 
structures on a scaffold of disulphide bridges forming cysteine-rich domains which 
are important in ligand recognition and binding (Locksley et al, 2001). The 
cytoplasmic domain of TNFRs functions as docking sites for signalling molecules. 
Signalling occurs through the engagement of adaptor proteins, either TRAFs (TNF 
receptor associated factors), or DD (‘death domain’) molecules, which are associated 
with receptors that generally result in caspase activation and subsequent cell death 
such as Fas. Association of TRAF proteins with TNF receptors results in activation 
of pathways such as NF-kB through direct interaction with IRAK (see Figure 1.4) 
(Muzio et al, 1998).
1.6.4 IL-l/Toll-like receptors
Toll-like receptors (TLRs) are type I integral membrane glycoproteins and on the 
basis of shared structural homology in the intracellular region, belong to a larger 
superfamily including IL-1 receptors. Conversely there is little homology in the 
extracellular domain, with the extracellular region of TLRs consisting of 19-25 
tandem copies of a leucine-rich repeat (LRR) region, whereas the extracellular region
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of IL-1 receptors contains three immunoglobulin-like domains. The LRR domains 
form a horseshoe structure, which is thought to be directly involved in pathogen 
recognition. Members of this superfamily share a conserved region of approximately 
200 amino acids in the cytoplasmic region, the Toll/IL-IR (TIR) domain, which 
comprises three conserved boxes essential for signalling (Akira et al, 2001).
After ligand binding TLRs dimerise and undergo a conformational change enabling 
the binding of subsequent downstream signalling molecules as demonstrated in Figure 
1.4. In the case of some TLRs including TLR2 and TLR4 signalling, TLR dimers 
associate with the adaptor molecule myeloid differentiation primary-response protein 
8 8  (MyD8 8 ), which in turn recruits IL-1-receptor associated kinase (IRAK) proteins 
(Wesche et al, 1997; Li et al, 2002). Activation by phosphorylation initiates a 
cascade resulting in activation of both the inhibitor of nuclear factor-xB kinase (IKK) 
complex and mitogen-activated protein (MAP) kinase cascade (Wesche et al, 1997). 
NF-kB is present in the circulation in an inactive form bound to inhibitor proteins 
(inhibitor of NF-kB (IkB)), which are broken down by IKKs, allowing translocation 
of NF-kB subunits to the nucleus (Karin & Ben-Neriah, 2000). Other TLRs, 
including TLR4 also utilise a MyD8 8 -independent pathway, instead activating 
IFN-regulatory factor (IRF3) and resulting in expression of IFNp and IFN-inducible 
gene products (Fitzgerald et al, 2003; Hoebe et al, 2003).
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Figure 1.4 TLR-mediated activation of the NF-kB pathway
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Fig 1.4. TLR mediated activation of the N F -k B  pathway. A) MyD8 8  (myeloid 
differentiation primary response protein 8 8 ) activation involves the association 
of the MyD8 8  to the intracellular domain of TLRs and subsequent recruitment 
of IRAK4 (IL-lR-associated kinase 4), which induces phosphorylation of IRAKI 
and additional association of TRAF6  (tumour-necrosis-factor-receptor- 
associated factor 6 ) with the receptor complex. Phosphorylated IRAKI and 
TRAF6  dissociate from the receptor complex and associate with TAK1 
(transforming-growth-factor-P-activated kinase), TAB1 (TAKl-binding protein 
1) and TAB2 resulting in the phosphorylaytion of TAB2 and TAK1 and 
recruitment of ubiquitin ligases which ubiquitylate TRAF6 , activating TAK1. 
TAK1 activates both the MAPK pathway and phosphorylates the IKK (inhibitor 
of nuclear factor kB  (iKB)-kinase) complex (comprising NEMO, IKK1 and 
IKK2), which in turn phosphorylates Ik B  leading to its ubiquitylation and 
subsequent degredation. This allows N F -k B  subunits to translocate to the 
nucleus. B) MyD8 8 -independent pathways activate IRF3 and late-phase N F -k B . 
(Adapted from Akira et al, 2004; Li et al, 2002; Beinke et al, 2004).
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1.6.5 Seven-transmembrane cytokine receptors
Seven-transmembrane receptors form the functional receptors for the family of 
chemotactic cytokines, referred to as chemokines.
1.6.5.1 Chemokines
Chemokines are a population of chemotactic cytokines that are characterised by four 
highly conserved cysteine residues within their amino acid sequence. There are two 
main families of chemokines, distinguished by the position of the first two cysteines 
which lie either adjacent to one another (CC chemokines) or are separated by one 
amino acid (CXC chemokines) (Baggiolini et al, 1997). Exceptions to this are 
fractalkine (CX3CL1), which has three amino acids separating the first two cysteine 
residues (CX3C) (Bazan et al, 1997) and lymphotactin, which has only two cysteines 
(C) (Houck et al, 1977). Chemokines were originally characterised by their capacity 
to direct leukocyte chemotaxis and activation (for example, degranulation, respiratory 
burst) during inflammation, however, it is now understood that chemokines also play 
roles in homeostasis, cell proliferation, haematopoiesis, angiogenesis and cancer 
metastasis (Bagglioni & Loetscher, 2000). Chemokines can be clustered into two 
subgroups, either constitutive or inducible; however, there is overlap between the two 
groups. Constitutive chemokines are responsible for the physiological control of 
leukocyte homing, this group includes CXCL12 (stromal cell derived factor-1; 
SDF-1), CCL12 (secondary lymphoid tissue chemokine; SLC), CCL17 (thymus- and 
activation-regulated chemokine; TARC) and CCL25 (thymus-expressed chemokine; 
TECK). Inducible chemokines are produced in response to immune or inflammatory 
signals and are responsible for the observed increase in leukocytic trafficking under 
these conditions. In this respect they are often termed ‘inflammatory’ chemokines, 
and their activities will be dealt with in more detail in subsequent sections.
1.6.5.2 Chemokine receptor interactions
Chemokine signalling is achieved through binding to specific G-protein coupled 
seven-transmembrane domain receptors (Kuang et al, 1996; Wu et al, 1993). 
Chemokine receptors function as allosteric molecular relays where chemokine binding 
to the extracellular portion of the receptor creates a conformational change allowing 
the intracellular portion to bind to and activate heteromeric G protein (Kuang et al, 
1996). Heteromeric G proteins consist of a, p, and y subunits, and ligand binding to
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the receptor allows exchange of GDP for GTP on the alpha subunit, triggering its 
dissociation from the GPy complex subunit. Both dissociated subunits are able to 
activate further downstream signalling cascades including mobilisation of intracellular
7+Ca and the activation of the mitogen-activated protein kinase (MAPK) cascade, 
phosphatidylinositol 3-kinase (PI3K) and nuclear factor kB  (N F -kB ) pathways (Rossi 
& Zlotnik, 2000).
As demonstrated in Table 1.3, there is high redundancy in the chemokine family as 
multiple chemokines utilise the same receptor. In general CC chemokine receptors 
are more promiscuous than CXC receptors. Cellular distribution of each chemokine 
receptor is also regulated, with some receptors being cell-type specific and others 
expressed on multiple leukocyte subsets (Moser & Willimann, 2004). In this respect, 
receptors such as CXCR4 have a more widespread cellular distribution than 
chemokine receptors including CXCR3 which is restricted to defined T cell subsets. 
In addition to the functional signal transducing chemokine receptors, there are several 
‘decoy receptors’ which bind chemokines with high affinity but do not elicit signal 
transduction (Mantovani et al, 2007), these are further discussed in Section 1.6.6.2. 
These regulatory features of the chemokine system allow for fine tuned specific 
responses and ensure that the effects of the chemokine are only short-lived.
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Chemokine receptors Ligands Cellular distribution
CXCR1 CXCL6, CXCL8 Neutrophils
CXCR2 CXCL1-3, CXCL5-8 Neutrophils
CXCR3 CXCL9-11 Thl cells
CXCR4 CXCL12 Neutrophils, monocytes, T cells, B cells, 
DCs
CXCR5 CXCL13 Memory B cells, memory T cells
CXCR6 CXCL16 T cells
CXCR7 CXCL11, CXCL12 Monocytes, B cells, T cells
CCR1 CCL3-5, CCL8, Monocytes, eosinophils, basophils,
CCL14-16, CCL23 activated T cells
CCR2 CCL2, CCL7, CCL8, CCL13 Monocytes, basophils, activated T cells
CCR3 CCL5, CCL8, CCL11, CCL13, 
CCL24, CCL26
Th2 cells, eosinophils, basophils
CCR4 CCL17, CCL22 T cells, thymocytes
CCR5 CCL3-5, CCL7, CCL13 Thl cells, monocytes
CCR6 CCL20 T & B cells, immature DCs
CCR7 CCL19, CCL21 Naive T cells, mature DCs
CCR8 CCL1 Th2 cells
CCR9 CCL25 Memory T cells, B cells
CCR10 CCL27, CCL28 Memory T cells
XCR1 XCL1, XCL2 Neutrophils, B cells, T cells
CX3CR1 CX3CL1 T cells, mast cells
Table 1.3. Human chemokine receptors. Cellular distribution and ligands 
associated with each receptor.
1.6.5.3 CXC chemokines
In addition to the classification of chemokines based on the position of the cysteine 
residues, CXC chemokines can be functionally defined by the presence or absence of 
a three amino acid sequence (Glu-Leu-Arg (ELR) motif), in the Nth-terminal portion 
directly preceding the first cysteine. Chemokines which possess the ELR motif 
(ELR+ chemokines, CXCL1-8), signal through CXCR1 and CXCR2 which are 
chemokine receptors expressed on the surface of neutrophils. For this reason ELR+ 
chemokines, such as CXCL8  (IL-8 ) and CXCL1 (gro protein a, GROa) are 
specifically neutrophil chemoattractants and also possess the ability to induce 
angiogenesis (Strieter et al, 2005). In addition to chemotaxis, CXC chemokines are 
also important in pathogenic destruction through their ability to promote 
degranulation and the production of superoxide (Jones et al, 1996; Jones et al, 1997). 
CXC chemokines that do not possess this motif (ELR' chemokines, CXCL9-16) 
signal via a range of receptors expressed on T lymphocytes, this includes the
28
IFN-inducible chemokines CXCL9 (monokine induced by interferon-y; MIG), 
CXCL10 (lOkDa interferon-y induced protein; IP-10), and CXCL11 (interferon- 
inducible T cell a chemoattractant; I-TAC), all of which signal via CXCR3 (Loetscher 
et al. 1996). An exception to this is the ELR' chemokine CXCL12 (stromal-derived 
factor-la; SDF-la) which utilises the chemokine receptor CXCR4 expressed on many 
cell types including neutrophils, monocytes, T cells and stromal cells. CXCL12 is 
involved in lymphocyte maturation and other homeostatic functions such as 
embryonic development of peripheral tissue, trafficking progenitor cells into the 
appropriate maturation sites in the bone marrow (Baggiolini, 1998; Lapidot et al, 
2005).
1.6.5.4 CC chemokines
CC chemokines tend to be more promiscuous than their CXC counterparts exerting 
their effects on multiple leukocyte subsets including monocytes, basophils, 
eosinophils, T cells, dendritic cells and natural killer cells (Baggiolini, 1998). 
Constitutive homeostatic CC chemokines including CCL12, CCL17 and CCL25 are 
expressed in the thymus, lymph nodes and other lymphoid tissues and are responsible 
for coordination of T cell homing to and from the secondary lymph nodes and may aid 
T cell development (Kim et al, 1998). Inducible CC chemokines of note include the 
MCP (monocyte chemoattractant protein) family (comprising four members in 
humans and five in mice), which are potent monocyte chemoattractants utilising 
CCR2 (Charo et al 1994) and CCL5 (regulated upon activation, normal T cell 
expressed and secreted; RANTES), which signals via a range of receptors (CCR1, 
CCR3 and CCR5), expressed on lymphocytes as well as other mononuclear cells 
(Baggiolini, 1998).
Chemokines, although potentially damaging in chronic inflammatory conditions due 
to their ability to induce monocytic cell trafficking into the affected area, provide 
potential therapeutic agents for certain cancers where increased leukocyte trafficking 
may be beneficial (Reckamp et al, 2008). Some chemokines, for example CCL3, 
CCL4 and CCL5, can also act as human immunodeficiency virus (HIV) suppressive 
factors, as HIV utilises certain chemokine receptors namely CXCR4 (T-cell tropic) 
and CCR5 (macrophage tropic) and to a lesser extent CCR2, CCR3 and CX3CRI. 
Selective blockade of these specific chemokine receptors with suitable antagonists or
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modified chemokines, may attenuate HIV progression (Princen & Schols, 2005). 
Anti-chemokine based therapy may also aid the management of chronic inflammatory 
conditions such as rheumatoid arthritis and Crohn’s disease (Rossi & Zlotnik, 2000). 
However, to date clinical trials therapeutically targeting the chemokine receptor 
CCR2 in rheumatoid arthritis patients have been unsuccessful (Proudfoot, 2008).
1.6.6 Regulation of cytokine activity
1.6.6.1 Soluble receptors
Soluble forms of many cytokine receptors have been discovered both in culture 
supernatants and biological fluids. Once bound to their respective ligands, soluble 
receptors serve four primary functions: they can be either agonistic (eg. sIL-6 R) or 
antagonistic (eg. sTNFRl), they can act as carrier molecules (eg. sIL-4R) and can 
protect the cytokine, thereby increasing the cytokines half life. In this respect, soluble 
cytokine receptors have been identified for IL-2, IL-4, IL-6 , IL-7, IFNy, TNFa, TNFp 
and leukaemia inhibitory factor (LIF) (Rose-John & Heinrich, 1994). Soluble forms 
of conventional signalling receptor complexes can be generated through a variety of 
mechanisms including proteolytic cleavage, phospholipase C mediated cleavage and 
alternative splicing (Levine, 2008).
Soluble receptor complexes retain an ability to bind their ligand and can act as natural 
antagonists binding ligand in circulation and preventing its association with the 
membrane bound receptor and therefore inhibiting signalling. Examples of this 
include the soluble receptor for TNF (p75/type II TNFR), which is used 
therapeutically (for example Enbrel/Etanercept) to sequester and retain TNF in the 
circulation (Maini & Taylor, 2000). Soluble receptors can also act as agonists, an 
example of this is soluble IL- 6  receptor (sIL-6 R), which can facilitate IL- 6  signalling 
in cells not expressing membrane bound IL-6 R (Mackiewicz et al, 1992), this 
relationship will be further discussed in Section 1.8.
1.6.6.2 Decoy receptors
Decoy receptors possess high affinity binding for a specific ligand, but are structurally 
incapable of signalling (Mantovani et al, 2001). The primary role of decoy receptors, 
unlike soluble receptors, appears to be to fine-tune the action of primary inflammatory 
cytokines such as members of the IL-1 and TNF family and inflammatory
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chemokines. Examples of decoy receptors include IL-1RII (Colotta et al, 1993), 
which competes with IL-1RI for IL-1 binding and also engages with IL-1R accessory 
protein (IL-1 RAP) preventing signal transduction. Another example of a decoy 
receptor is osteoprotegerin (OPG), which binds members of the TNF family and is 
associated with the regulation of osteoclastogenesis by RANKL (Simonet et al, 1997). 
Decoy receptors in the chemokine system can either be ‘silent’ which are structurally 
incapable of signalling (such as DARC (Duffy antigen receptor for chemokines)) 
(Mantovani et al, 2001), or ‘functional’ which are structurally identical to signalling 
receptors but are induced to dissociate from the signal transducing subunits (D’Amico 
et al, 2000). This latter response is highly regulated and cytokines like IL-10 induce 
functional decoys for the CC chemokine receptors CCR1, CCR2 and CCR5 on 
dendritic cell and monocytes (D’Amico et al, 2000).
The role of soluble cytokine receptors in inhibiting the actions of pro-inflammatory 
cytokines has been exploited by several viruses which synthesise homologues of 
mammalian cytokine receptors in order to evade host defence mechanisms. Viruses 
including poxviruses and herpes viruses encode proteins that mimic either cytokines 
or cytokine receptors to modulate cytokine activity during infection (Alcami, 2003). 
Examples of cytokines mimicked by viruses include viral IL- 6  encoded by human 
herpesvirus 8  (HHV8 ), which is a structural and functional homologue of human IL- 6  
(Mullberg et al, 2000; Fielding et al, 2005). Viral IL- 6  is able to activate the Jak- 
STAT pathway in a similar manner to that exhibited by human IL- 6  and is thought to 
be of significance in several conditions associated with viral infection including 
Kaposi’s sarcoma (Molden et al, 1997).
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1.7 Interleukin (IL)-6 related cytokines
IL- 6  and several other pleiotropic cytokines are related through their utilisation of 
receptor complexes composed of at least one subunit of the signal transducing protein, 
glycoprotein 130 (gpl30). This family includes Oncostatin M (OSM), IL-11, 
leukaemia inhibitory factor (LIF), IL-6 , IL-27, ciliary neurotrophic factor (CNTF), 
granulocyte colony-stimulating factor (G-CSF), cardiotrophin-1 (CT-1) and B-cell 
stimulating factor-3 (BSF-3 also known as NNT; novel neurotrophin-1 and CLC; 
CNTF-like cytokine) (Heinrich et al, 2003; Senaldi et al, 1999; Pflanz et al, 2004). 
All IL-6 -related cytokines are polypeptides with molecular weights of approximately 
20kDa, comprising four a-helices connected by loop domains to allow two anti­
parallel bundles (Heinrich et al, 1998). Members of this family have both pro- and 
anti-inflammatory properties as well as being involved in neuronal differentiation and 
development, haematopoiesis and remodelling of the extra-cellular matrix (Heinrich 
et al, 2003).
1.7.1 Interleukin-6
Interleukin (IL) - 6  was originally characterised through its ability to induce the 
differentiation and proliferation of B-cells, and as such was termed B-cell growth 
factor or B-cell differentiation factor. Cloning of these factors in 1986 lead to the 
discovery of a novel cytokine (originally named B-cell stimulatory factor-2, 
hepatocyte stimulating factor and Interferon P2 , later re-named IL-6 ) able to induce 
acute phase reactions and induce the differentiation of myeloid precursor cells 
(Kishimoto, 2006). Further studies demonstrated IL- 6  as a pleiotropic cytokine that 
influences antigen-specific immune responses and inflammatory reactions (Kopf et al, 
1994). The specific roles of IL- 6  in inflammation will be further discussed in Section 
1.9. IL- 6  signalling follows one of two pathways: in cells expressing membrane 
bound IL-6 R, signalling follows the classical pathway; whilst cells not expressing IL- 
6 R can also respond to IL- 6  signalling through its soluble receptor.
As discussed in Section 1.2, inflammation is characterised by alterations in the 
concentration of a group of plasma proteins, termed acute phase proteins defined as a 
group of plasma proteins whose concentrations deviate by at least 25% during 
inflammatory progression. These hepatocyte-derived proteins are important 
regulators of inflammation and include C reactive protein (CRP), serum amyloid A
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(SAA) and fibrinogen. Cytokines induced during the onset of inflammation including 
IL-ip, TNFa, IFNy and TGFp are capable of stimulating the release of acute phase 
proteins, however IL- 6  is the primary stimulator of many of the acute phase proteins 
(Andus et al, 1988).
Studies using IL- 6  deficient (IL-6 KO) mice have demonstrated a role for IL- 6  in the 
resolution of acute inflammation through the control of chemokine-mediated 
leukocyte trafficking, control of pro-inflammatory cytokines (Schindler et al, 1990; 
Romain et al, 1997) and promoting the release of the anti-inflammatory mediators IL- 
1 receptor antagonist and the soluble p55 TNFa receptor (Tilg et al, 1994), thereby 
directing transition from neutrophil to mononuclear cell recruitment (Hurst et al, 
2001). In addition, IL- 6  deficient mice demonstrate impaired viral and bacterial 
clearance (Onogawa, 2005; Ramshaw et al, 1997). However, in instances of chronic 
inflammation IL- 6  signalling is detrimental, as demonstrated by the resistance of IL- 6  
deficient mice to a variety of experimental autoimmune conditions (Nowell et al, 
2003; Ohshima et al, 1998; Mihara et al, 1998).
1.7.1.1IL-6R classical signalling
Classical IL- 6  receptor signalling is initiated by cytokine binding to IL-6 Ra (CD 126), 
a non-signalling a-chain. IL- 6  binding to IL-6 Ra is essential for interaction with the 
signal transducing p-chain gpl30 and subsequent receptor homodimerisation, which is 
required for signal transduction. Although gpl30 is ubiquitously expressed, the 
cellular distribution of the membrane-bound IL-6 R is largely restricted to hepatocytes 
and leukocyte subsets (Rose-John et al, 2006).
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1.7.1.2 IL-6 trans-signalling
As outlined in Section 1.6.6.1, soluble forms for many cognate a-receptor chains have 
been identified in serum and urine (Rose-John & Heinrich, 1994). Although many of 
these soluble receptors act in an antagonistic manner, sequestering free cytokine in the 
circulation and preventing association with the respective signal transducing (3 chains 
(see Section 1.6.6.1), soluble forms of IL-6 Ra form an agonistic complex with IL- 6  in 
the circulation which binds to membrane bound gpl30 to initiate signalling (Rose- 
John et al, 2006). As gpl30 is ubiquitously expressed, the trans-signalling pathway 
enables cell types typically unresponsive to IL- 6  to become activated by IL-6 . The 
ability of IL- 6  to signal via two distinct pathways is responsible for its role in the 
‘switch’ between innate and adaptive immunity (Hurst et al, 2001; Jones, 2005). IL- 6  
trans signalling is important in the pathophysiology of many chronic inflammatory 
disorders including rheumatoid arthritis, inflammatory bowel disease and some types 
of cancer (Atreya et al, 2000; Nowell et al, 2003; Richards et al, 2006; Becker et al,
2004). However, IL- 6  trans-signalling is also vital during development as embryonic 
stem cells, early haematopoietic progenitor cells and neural cells are only responsive 
to IL- 6  in the presence of soluble IL-6 Ra (Humphrey et al, 2004; Peters et al, 1997; 
Marz et al, 1999).
1.7.1.3 Generation of soluble IL-6R
Soluble IL- 6  receptor subunits lacking the cytoplasmic domains have been detected in 
biological fluids of both healthy individuals and in various disease states (Muller- 
Newen et al, 1996). Two mechanisms for the generation of soluble receptors exist: 
proteolytic cleavage of the cognate IL-6 R (receptor shedding) (PC-sIL-6 R) and 
differential IL-6 R mRNA splicing (DS-sIL-6 R) (Jones et al, 2001). Although both 
forms are structurally related, the differentially spliced isoform possesses a novel 1 0  
amino acid C terminal sequence (GSRRRGSCGL), which is introduced during the 
splicing process (Horiuchi et al, 1994).
During an inflammatory response, chemotactic agents including CXCL1, CXCL8 , 
C5a and CRP promote IL-6 R shedding from the infiltrating neutrophils (Jones et al, 
1999; Marin et al, 2001; McLoughlin et al, 2004). In addition apoptosis is a natural 
stimulus of IL-6 R shedding, due to upregulation of the metalloproteinase ADAM 17 (a 
disintegrin and metalloproteinase 17) which acts as an IL-6 R cleavage enzyme
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(Chalaris et al, 2007). Conversely, differential mRNA splicing appears to be 
responsible for basal production of sIL-6 R in certain cell lines, including monocytic 
THP-1 cells (Jones et al, 1998). During episodes of acute inflammation however, 
emergence of differentially spliced sIL-6 R corresponds with the influx of 
mononuclear cell infiltration suggesting a potential role for DS-sIL-6 R in later stages 
of the immune response (Hurst et al, 2001).
A soluble isoform of gpl30 exists as a natural antagonist to IL- 6  trans signalling 
(Jostock et al, 2001). Soluble gpl30 (sgpl30) specifically binds to sIL-6 R, once 
bound with IL-6 , leaving membrane bound ‘classical’ IL- 6  signalling unaffected. As 
such sgpl30 provides a potential therapeutic agent for chronic inflammatory 
conditions such as Crohn’s disease and rheumatoid arthritis, where IL- 6  trans­
signalling is damaging (Rose-John, 2006). The application of the inhibitory 
properties of sgpl30 has been instrumental in defining the physiological involvement 
of IL- 6  trans-signalling in vivo.
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Figure 1.5 Classical IL-6 R signalling and trans-signalling pathways utilised by
IL - 6
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Fig 1.5. IL - 6  utilises two signalling pathways, classical (A) and trans-signalling 
(B). Classical signalling involves IL - 6  binding to membrane-bound IL-6 Ra, 
which then associates with membrane-bound gpl30, resulting in receptor 
complex dimerisation. Trans-signalling involves IL- 6  binding to soluble IL-6 Ra 
(either released by proteolytic cleavage or differential mRNA splicing), which 
binds to membrane-bound gpl30 again resulting in receptor dimerisation and 
subsequent signal transduction (as demonstrated in figures 1.8 and 1.9). The 
trans-signalling pathway can be selectively blocked by soluble gpl30 binding to 
sIL-6 Ra/IL - 6  complexes, thereby preventing its association with membrane- 
bound gpl30 (C). Soluble gpl30 lacks the signal transducing subunits, therefore 
binding of IL-6 /sIL-6 Ra complexes prevents IL - 6  trans-signalling. (Adapted 
from Rose-John et al, 1994; Rose-John, 2003).
1.7.2 Oncostatin M
Oncostatin M (OSM) is a multifunctional cytokine belonging to the IL- 6  superfamily. 
OSM has a diverse range of biological functions including the ability to modulate 
tumour cell growth, regulate the inflammatory response, affect re-modelling of the 
extracellular matrix and modulate haematopoiesis (Zarling et al, 1986; Zhang et al, 
1994; Modur et al, 1997; Richards et al, 1993; Tanaka et al, 1999).
Human OSM (hOSM) is a 28KDa secreted glycoprotein monomer consisting of four 
a-helical chains and three inverting helix regions (Hoffman et al, 1996). Initially 
isolated from PMA-stimulated human hystiocytic lymphoma U937 cells (Zarling et 
al, 1986), it was originally identified by its ability to inhibit the proliferation of 
various tumour cells including the A375 human melanoma line (Zarling et al, 1986). 
Human OSM cDNA encodes a precursor protein of 252 amino acids with a short 
signal peptide of 25 amino acids (Malik et al, 1989). Subsequently it was shown that 
the C-terminal region of 31 residues is cleaved from the precursor to form a mature 
protein of 196 amino acid residues (Linsley et al, 1990).
The corresponding murine OSM gene was cloned in 1996 and found to be a cytokine- 
inducible gene; specifically regulated by IL-2, IL-3 and erythropoietin through the 
Jak-STAT5 pathway (Yoshimura et al, 1996).
OSM is closely structurally and functionally related to LIF, sharing 27% sequence 
homology in humans. In addition the genes for both cytokines are closely sited on the 
same chromosomal locus (22ql2, in humans) (Rose & Bruce, 1991; Jeffery et al, 
1993; Nicola et al, 1993). LIF and OSM share some biological functions, however 
OSM has several unique functions, potentially due to activation through the OSM 
specific receptor (gpl30 bound to OSMRp) (Mosely et al, 1996). These unique 
activities include growth inhibition of A375 melanoma cells (Bruce et al, 1992), 
autocrine growth stimulation of AIDS-related Kaposi’s sarcoma cells (Miles et al, 
1992) and upregulation of a 1-proteinase inhibitor in lung derived epithelial cells 
(Cichy et al, 1998).
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1.7.2.1 Oncostatin M receptor complexes
In humans two types of functional receptor exist for OSM: Type I is identical to the 
high affinity LIF receptor consisting of LIFRp and gpl30 (Gearing et al, 1992); Type 
II is comprised of gpl30 and OSMRp, which also forms the p-receptor subunit for 
another cytokine, IL-31 (Mosley et al, 1996). OSMRp has been found on a wide 
variety of cell types including endothelial cells, keratinocytes, hepatic cells, lung cells 
and many tumour cell lines (Linsley et al, 1989; Mosley et al, 1996). However, under 
basal conditions peripheral blood leukocytes do not express either OSMRp or LIFRp 
(Hurst et al, 2002; Godard et al, 1992).
1.7.2.2 Murine OSM receptor complex
In mice OSM is unable to signal through the LIF receptor, relying solely on signal 
transduction through OSMRp (Tanaka et al, 1999). This implies that there is only 
one functional receptor for OSM in mice, composed of gpl30 and murine OSMRp. 
Such differences may explain the observed differences in function between mouse and 
human OSM (Ichihara et al, 1997). It has unique roles in mouse embryo development 
relating to hematopoiesis, including maturation of hepatic cells (Kamiya et al, 1999; 
Kinoshita et al, 1999), none of which are exhibited by human OSM or LIF. Instead 
these activities are governed by other human gpl30 activating cytokines (Tanaka et 
al, 1999). In this regard, human OSM is unable to signal via murine OSMRp, but 
instead activates cells through LIFRp (Lindberg et al, 1998).
1.7.3 Interleukin-31 and IL-31Ra
Interleukin (IL)-31 is a novel cytokine derived from Th2 cells, which has been 
implicated in allergic responses (Dillon et al, 2004). Transgenic mice over-expressing 
IL-31 develop severe dermatitis (Dillon et al, 2004). However, mice deficient in 
IL-31 Ra show increased type 2 inflammation in lung epithelial cells (Perrigoue et al, 
2007). In a similar manner to OSM, cellular activation by IL-31 has been shown to 
induce the release of pro-inflammatory cytokines, chemokines and matrix 
metalloproteinases (MMPs) (Yagi et al, 2007; Ip et al, 2007).
IL-31 signals through a receptor comprising a specific IL-31 Ra subunit bound to the 
OSM receptor OSMRp. IL-31 Ra (also referred to as gpl30-like receptor, GLR) is a 
member of the type I group of cytokine receptors, sharing many of their structural
38
motifs including the cytokine receptor homology domain comprising two pairs of 
conserved cysteine residues and a WSXWS sequence in the extracellular domain. 
IL-31 Ra is closely related to gpl30, sharing 28% sequence homology. In humans 
both are located in tandem on chromosome 5 with opposite transcriptional translation, 
suggesting the evolution of IL-31 Ra as a result of gene duplication (Ghilardi et al, 
2002; Diveu et al, 2003). Cells expressing IL-31 Ra include monocytic cells, 
activated CD4+ and CD8 + T cells and skin and lung epithelial cells (Dreuw et al, 
2004). Expression of OSMRp, which as previously stated forms the p-subunit of the 
receptor complex, has been detected on a variety of cell types including skin and lung 
epithelial cells, and can be induced on monocytic cells (Dillon et al, 2004). Cellular 
expression of IL-31 Ra is closely related to the apparent role of IL-31 in allergic 
responses, in particular asthma and allergic dermatitis (Dreuw et al, 2004; Dillion et 
al, 2004).
Signalling through IL-31 Ra utilises the Jak-STAT pathway, primarily activating 
STAT3 and STAT5 through tyrosine residues 721 and 652 respectively, but only 
weakly transducing STAT1 (Dreuw et al, 2004). Conversely activation of the MAP 
kinase cascade appears to require IL-31 Ra heterodimerisation with OSMRp, as 
IL-31 Ra cannot directly phosphorylate ERK1/2 or recruit either SHP2 or She (Dreuw 
et al, 2004). Therefore, when considering the role of OSMRp signalling in vivo, it is 
important to note the contribution of both IL-31 and OSM.
39
1.8 Signalling of IL-6 related cytokines
Receptor-mediated activation leads to gpl30-dimerisation or gpl30 interaction with 
its related receptors LIFRp or OSMRp. This leads to signalling events via extrinsic 
tyrosine kinase regulation. The following sections summarise details relating to these 
activation processes.
1.8.1 The signal transducing protein, gpl30
Glycoprotein 130 (gpl30) is a ubiquitously expressed type I cytokine receptor, which 
acts as the signal transducing P-receptor subunit for all IL-6 -related cytokines. Signal 
transduction through gpl30 is essential in development, as the phenotype of gpl30 
deficient mice is lethal in utero as evidenced by the requirement of LIF in maintaining 
embryonic cell totipotency (Ernst & Jenkins, 2004; Shellard et al, 1996; Yoshida et 
al, 1996). As described in Section 1.6.1 all members of this family share several 
common features in the extracellular domain: four conserved cysteine residues in the 
amino-terminal portion and a WSXWS motif adjacent to the transmembrane domain 
(Hibi et al, 1990). The conserved cysteine residues are critical in maintaining the 
structural and functional integrity of the receptor, with the WSXWS motif essential 
for facilitating interaction between ligand and receptor, as such this domain is termed 
the cytokine-binding module (Cosman, 1993; Bravo et al, 1998). The extracellular 
region of gpl30 consists of an N-terminal immunoglobulin-like domain followed by 
the cytokine binding module and three additional fibronectin type Ill-like domains, 
which appear necessary for recognition of the non-signalling cognate a-subunit of the 
receptor complex (Heinrich et al, 1998; Kurth et al, 2000).
Signalling through gpl30 is integral to the IL- 6  family of cytokines. Receptor 
complexes can be subdivided into two classes: those which utilise non-signalling 
ligand-specific a-receptors (including IL-6 Ra, IL-llRa, IL-27Ra/WSX-l and 
CNTFRa), and signal transducing p-receptors (including OSMRp and LIFRP) 
(Heinrich et al, 2003). Cytokine binding to its receptor leads to either the 
homodimerisation or heterodimerisation of gpl30 and subsequent signal transduction.
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Fig 1.6. Structural organisation of the gpl30 protein. The extracellular domain 
comprises an Ig-like domain and two fibronectin-like domains (FNIII) which 
comprise the cytokine binding module containing several conserved cysteine 
residues and the highly conserved WSXWS motif which is integral in all type I 
receptors, gpl30 also has three additional fibronectin-like domains. The 
intracellular domain comprises box 1 and box 2 motifs which form the Jak 
(Janus kinase) binding site. In addition there are several tyrosine residues that 
are phosphorylated upon Jak association including y 757/759 (mouse/human 
respectively) which is integral for SHP2 (SH2-domain-containing tyrosine 
phosphatase) and SOCS3 (suppressor of cytokine signalling 3) binding; and 
Y765/\  Y812'5, Y904'5 and Y914'5, which form important STAT1 and STAT3 binding 
sites. TM -  transmembrane. (Adapted from Heinrich et al, 2003; Ernst & 
Jenkins, 2004).
1.8.1.1 Formation of gpl30 homodimers
Cytokines which signal utilising receptor complexes comprising gpl30 homodimers 
include IL-6 , IL-11 and IL-27. These cytokines initially bind specifically to their 
related non-signalling a-chains (IL-6 Ra, IL-1 IRa and IL-27Ra/WSX-l respectively), 
which is a vital step in receptor complex formation as neither the ligand or a-chain 
can effectively associate with gpl30 separately (Pflanz et al, 2004; Heinrich et al, 
2003). The function of integral binding to a-chains is to exert some control over 
cellular response to certain cytokines, although due to the presence of soluble forms 
for many of these receptors, in particular soluble IL-6 Ra, cell types not expressing 
membrane bound forms of the a-subunit receptor are still able to elicit responses to 
some of these cytokines (Hibi et al, 1990; Yasukawa et al, 1990) (see Section 
1.8.5.2). Mutagenesis studies have identified three specific ‘sites’ important for 
receptor complex formation. Site I binds to the cytokine binding module conferring
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specificity for the a-chain, site II and site III interact with two gpl30 subunits 
(Grotzinger et al, 1997; Simpson et al, 1997; Heinrich et al, 1998).
1.8.1.2 Formation of gpl30 heterodimers
In addition to the signal transducing receptor gpl30, two other gp 130-like p-chains 
exist in the IL-6 -related family of cytokine receptors which are capable of signal 
transduction, LIFRp and OSMRp. In both cases ligand binding induces association of 
either LIFRp or OSMRp with one subunit of gpl30 via interactions between site II 
and site III (Layton et al, 1994; Deller et al, 2000). LIF and OSM directly induce 
receptor heterodimerisation, however, several other cytokines (for example CNTF) 
utilise the LIFRP:gpl30 receptor complex through first binding to a non-signalling a- 
chain in a similar manner to that described for IL- 6  and IL-11 (Davis et al, 1991).
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Figure 1.7 Formation of gpl30 homo- and heterodimers.
A) gp130 homodimer formation
IL-6/CNTF signalling only
slL-6Ra
IL-6/CNTF
Ligand \or  ■
IL-6/IL-11 /I L-27
I
M em brane-bound Y759
receptor a-chain Y767
Y815
Y 7 6 7
Y905
Y915
Y905
Y915 gp 130 homodim er
B) gp130 heterodimer formation
LIF CT-1OSM u t -
□  o
/ \  /
sCNTFRa
CNTF/CLC
Y917
Y945
•S's
COo
Y759
Y767
Y815
Y905
Y915
Y 7 5 9  CO.mttmoa
Y 9 8 1  “ !
Y 1 0 0 1
Y905
Y915Y 1 0 2 8
Membrane-bound
CNTFRa
Fig 1.7. (A) Homodimer formation requires the binding of pre-formed 
ligand/non-signalling a-chain receptor complexes. These can be either 
membrane-bound a-chains (IL-6 R, IL-11R or WSX-1 for IL-6 , IL-11 and IL-27 
respectively) or for IL-6 , can be soluble. (B) Heterodimer formation involves the 
association of gpl30 with either LIFRp or OSMRp (both signal-transducing p- 
chains). Signal transduction can either involve direct cytokine binding to the 
receptor (OSM, LIF) or through association of the gpl30 heterodimer with the 
non-signalling a-chain CNTF in either a membrane bound or soluble form, in 
this way gpl30:LIFRp acts as the receptor complex for CNTF and CLC. 
(Adapted from Ernst & Jenkins, 2004; Schuster et al, 2003).
1.8.2 Jak-STAT mediated signalling
Due to the lack of intrinsic tyrosine kinase activity, IL-6 -related cytokine receptor 
signalling is mediated via the Janus kinases (Jaks) (Silvennoinen et al, 1997; Heinrich 
et al, 1998). Jaks are intracellular tyrosine kinases of approximately 120-140kDa. 
There are four identified mammalian Jaks, of which Jakl, Jak2 and tyrosine kinase 2 
(Tyk2) are of particular importance in IL-6 -related cytokine signalling (Stahl et al, 
1994). Of these, it is known that Jakl plays an essential role. Studies using IL- 6  and 
IL-11 in combination with their associated soluble receptors in Jakl negative cells 
demonstrated a lack of signalling (Guschin et al, 1995) and Jakl deficient mice fail to 
elicit efficient IL-6 -related signalling in vivo (Rodig et al, 1998).
Receptor association of the Jak proteins is mediated through binding to the 
membrane-proximal boxl/box2 regions which are present on gpl30, LIFRp and 
OSMRp (Gearing et al, 1991; Mosley et al, 1996; Murakami et al, 1991). The box 1 
sequence comprises a short proline-rich sequence that is essential for Jak association, 
whereas the box 2  region, comprising a short sequence of hydrophobic residues 
followed by several positively charged residues, is not always required (Heinrich et 
al, 1998). Jak activation occurs in response to receptor dimerisation because two Jaks 
are bought into close proximity, thus allowing trans-phosphorylation between the two 
Jak proteins. Activated Jaks phosphorylate highly conserved tyrosine residues on the 
proximal intracellular domain of the receptor, creating docking sites for ST AT (signal 
transducers and activators of transcription) proteins. However, in addition to 
activation of ST AT proteins, phosphorylation of a single tyrosine residue in gpl30 
(Y7 5 9  in humans, Y7 5 7 in mice) governs the recruitment and activation of the SH2- 
domain-containing tyrosine phosphatase, SHP2, and subsequent activation of the Ras- 
ERK1/2 MAP kinase cascade (Ernst & Jenkins, 2004). This tyrosine residue, 
however, serves a dual function and also binds suppressor of cytokine signalling 
(SOCS)-3, which is a negative suppressor of gpl30-mediated STAT3 signalling 
(Ernst & Jenkins, 2004).
STATs have conserved structural organisation consisting of several identified 
domains including a leucine zipper-like domain at the N-terminus, a DNA-binding 
domain in the middle and a C-terminal SH2 domain, which is responsible for both 
binding to the tyrosine phosphorylated Jak proteins, and dimerisation with other
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phosphorlyated STAT proteins (Heinrich et al, 1998). All IL- 6  type cytokines 
activate STAT3 and STAT1 (although to a lesser extent) via binding to 
phosphorylated YXXQ motifs on the signal transducing P-receptor chain. In human 
gpl30 these are present at positions Y7 6 7RHQ, Y8 1 5FKQ, Y905LPQ and Y9 1 5MPQ; in 
LIFRP Y9 8 1 QPQ, Y1001KPQ and Y1 0 2 8RPQ; and in OSMRp at Y9 1 7 and Y9 4 5  
(Hermanns et al, 2000; Chattopadhyay et al, 2007). Activated STAT proteins form 
homo- (STAT1:STAT1, STAT3:STAT3) or heterodimers (STAT1:STAT3). In 
addition, OSM is also able to trigger STAT5 signalling, however the mechanism of 
STAT5 activation requires further clarification as it is unclear whether this occurs via 
a specific tyrosine residue within the OSMRp subunit or via direct interaction of 
STAT5 with Jaks (Heinrich et al, 1998). The receptor bound STAT proteins are 
subsequently phosphorylated on single tyrosine residues (Y701 in STAT1 and Y7 0 5 in 
STAT3) in the SH2 domain, which enables STAT homo- or hetero-dimerisation, 
which is integral for translocation to the nucleus (Heinrich et al, 2003). Once in the 
nucleus, dimerised STATs bind specific regulatory sequences to either activate or 
repress transcription of target genes, including acute phase proteins and transcription 
factors (Heinrich et al, 1998).
1.8.3 Activation of the MAPK cascade
IL-6 -type cytokines not only signal via the Jak-STAT pathway but can also induce the 
mitogen activated protein kinase (MAPK) signalling cascade (Heinrich et al, 2003). 
MAP kinases are a group of serine/threonine kinases including ERK1/2, which have 
roles in cell survival and the control of the stress-activated members of the MAPK 
family p38 and JNK. Activation of the MAPK cascade is dependent on Jak 
phosphorylation creating binding sites for adaptor proteins such as SHP2 and SH2- 
and-collagen-homology-domain-containing (She) proteins. Phosphorylated SHP2 
binds the adaptor growth factor receptor bound protein 2 (Grb2) through a specific 
phosphorylated tyrosine (Y304) in the SH2 domain of SHP2. This receptor complex 
activates the guanine nucleotide releasing protein son of sevenless (SOS), which 
activates the GTPase ras allowing initiation of the Ras-Raf-MAPK cascade (Stancato 
et al, 1998; Heinrich et al, 2003).
OSMRp does not recruit SHP2, instead recruiting She through a specific
QiT 1
phosphorylated tyrosine residue (Y ) in the OSMRp chain (Figure 1.10) (Thoma et
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al, 1994; Hermanns et al, 2000). Activated She also recruits the adaptor protein Grb2 
through a phosphorylated tyrosine residue on She (Y317). Recruitment of SOS to the 
receptor complex allows Ras activation and subsequent initiation of the Ras-Raf- 
MAPK cascade (Stancato et al, 1998; Heinrich et al, 2003).
1.8.4 Mechanisms of signal termination and SOCS proteins
In addition to extracellular regulatory mechanisms designed to sequester and 
antagonise cytokine activity in the circulation, several mechanisms exist to terminate 
signal transduction. These include protein tyrosine phosphatases, which 
dephosphorylate activated tyrosine residues thereby terminating the signal, PIAS 
(protein inhibitor of activated STAT) proteins, which are important transcriptional co­
regulators of the Jak-STAT pathway and SOCS (suppressors of cytokine signalling) 
proteins (Heinrich et al, 2003). Most SOCS proteins are induced by cytokines, 
therefore providing a classical negative-feedback system to control cytokine-induced 
signal transduction. There are eight members of the SOCS family, each comprising a 
central SH2 domain, a variable N-terminal domain and a C-terminal 40 amino acid 
module, the SOCS box (Yoshimura et al, 2007). Of importance in IL-6 -related 
cytokine signalling are SOCS1, which binds directly to phosphorylated Jakl to 
terminate STAT1 signalling, and SOCS3 which is specific for STAT3 (Ernst & 
Jenkins, 2004). SOCS3 is recruited to the phosphorylated tyrosine residue (y757/759) 
required for SHP2 binding in gpl30 and LIFRp (Nicholson et al, 1999; Schmitz et al, 
2000).
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Figure 1.8 Activation of the Jak-STAT pathway
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Fig 1.8. Activation of the Jak-STAT pathway through gpl30-medaited pathways 
in humans. Cytokine binding induces homo- or heterodimerisation of each 
receptor subunit (as demonstrated in Fig 1.7) resulting in binding and activation 
of JAKs. Activated JAKs phosphorylate tyrosine residues on the intracellular 
domain of the receptor, creating docking sites for STAT proteins. Homo- or 
hetero-dimerization of the STAT proteins occurs after phosphorylation of the 
monomers, once again by the JAKs, which enables translocation and 
accumulation of the STATs in the nucleus. (Adapted from Heinrich et a/, 2003; 
Ernst & Jenkins, 2004).
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Figure 1.9 Activation of the MAPK pathway 
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Fig 1.9. Activation of the MAP kinase pathway by IL-6 -related cytokines in 
humans. SHP2 is recruited to the receptor subunit (either gpl30 or LIFRp) a 
site containing the phosphorylated tyrosine residue 757, which results in its 
phosphorylation and its subsequent association with the adaptor protein Grb2 or 
activation of the PI3K cascade. Association with Grb2 recruits SOS allowing 
activation of the Ras-Raf-MAPK cascade. Tyrosine 757 is also the binding site 
for SOCS3, which negatively regulates cytokine signalling. (Adapted from Ernst 
& Jenkins, 2004; Schmitz et al, 2000).
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Figure 1.10 Signalling pathways initiated by OSMRp-mediated signalling 
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Fig 1.10. Signalling through OSMRp:gp 130 heterodimers initiates both 
Jak/STAT and MAPK pathways. The Jak/STAT pathway is initiated as for all 
IL-6 -related cytokines resulting in the formation of STAT1:STAT3 homo- and 
heterodimers. In addition OSMRp also induces activation of STAT5 potentially 
through direct binding to Jak2 and the OSMRp subunit. Unlike gpl30 and 
LIFRp, OSMRp does not recruit SHP2, instead activation of the MAPK pathway 
is via a She cascade; phosphorylated She bound to OSMRp recruits Grb2, SOS 
binds to this adaptor protein allowing activation of the Ras-Raf-MAPK cascade. 
(Adapted from Heinrich et al, 2003; Hermanns et al, 2000).
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1.9 The role of IL-6-related cytokines in inflammation
A variety of studies have implicated overproduction of IL- 6  in the pathogenesis of 
various autoimmune and chronic inflammatory disorders. During episodes of acute 
inflammation IL- 6  is involved in the switch between early and late inflammation, 
acting to promote the clearance of neutrophils, activate and promote expansion of T 
cells and induce differentiation of B cells. However, if IL- 6  activity becomes 
exaggerated, as is evident in many chronic inflammatory conditions, its effects 
become detrimental. In this regard IL- 6  has been implicated in the retention of 
inflammatory cells, including effector T cells, at sites of disease and has been linked 
with tissue/cell proliferation and damage.
1.9.1 IL-6 in acute inflammation
During acute inflammation the initial neutrophil influx is replaced by a more 
sustained population of mononuclear cells, this marks a transition from an initial 
innate-type immune response to acquired immunity. IL- 6  trans-signalling is pivotal in 
this transition (see Section 1.7.1.2) through suppressing chemokine-directed 
neutrophil trafficking and steering T-cell recruitment and activation, promoting 
neutrophil apoptosis (in a mechanism involving caspase-3) and inducing B cell 
differentiation and subsequent antibody production (McLoughlin et al, 2003, 
McLoughlin et al, 2005; La Flamme & Pearce, 1999; Xing et al, 1998; Romani et al,
1996).
Stromal cells typically lack cognate IL-6 Ra expression instead relying on IL- 6  trans­
signalling to respond to IL-6 . Therefore local sIL-6 Ra concentrations determine the 
magnitude of the IL- 6  response. During an acute inflammatory response, shedding of 
membrane bound IL-6 Ra from infiltrating neutrophils (in response to chemotactic 
agents) is the source of sIL-6 Ra (Hurst et al, 2001). Interestingly, infiltrating 
neutrophils are also the predominant source of OSM during an acute immune 
response (Hurst et al, 2002), suggesting a potential link between these two IL-6 - 
related cytokines. IL- 6  driven transition from neutrophil to mononuclear cell 
trafficking is mediated through attenuation of the IL-1 and TNFa induced chemokines 
(which are predominantly neutrophil chemoattractants) and direct enhancement of 
mononuclear cell chemoattractants (including CCL2 and CCL8 ), complemented by 
additional upregulation of adhesion molecules. In this regard the role of IL- 6  appears
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to be critical for resolution of acute inflammation and is evidenced by the inability of 
IL-6 KO mice to effectively clear both bacterial and viral infection (Kopf et al, 1994; 
Onogawa et al, 2005; Longhi et al, 2008).
1.9.2 IL-6 in chronic inflammation
The transition from neutrophil to mononuclear cell recruitment is essential for the 
successful resolution of the immune response; however, if the mononuclear cell 
infiltrate (primarily T-cell) is not effectively cleared a chronic inflammatory state can 
ensue. Overproduction and increased signalling of IL- 6  has been associated with 
several chronic inflammatory and autoimmune conditions (including rheumatoid 
arthritis, Crohn’s disease, psoriasis and systemic lupus eryhthematosus), which 
through an undefined dysregulation of chemokine-mediated recruitment and 
leukocyte apoptosis, is potentially detrimental (Gross et al, 1992; Houssiau et al, 
1988; Swaak et al, 1989; Grossman et al, 1989). In this respect, IL-6 KO mice 
showed limited histological signs of disease in various models of experimental 
autoimmunity (Kallen et al, 2002).
As previously mentioned, IL- 6  trans-signalling is able to enhance production of 
several mononuclear cell chemoattractants from resident tissue cells (Jones, 2005). 
In addition to this, IL- 6  also has anti-apoptotic effects on T cells, which can result in 
retention of mononuclear cells at sites of inflammation as observed in the synovium of 
RA patients and in the lamina propria of Crohn’s disease patients (Salmon et al, 1997; 
Atreya et al, 2000). Both in vitro and in vivo studies have demonstrated the ability of 
IL- 6  trans-signalling to ‘rescue’ T cells from apoptosis through a mechanism 
involving STAT3 driven expression of the anti-apoptotic regulators Bcl-2 and B c 1 -x l  
(Teague et al, 2000; Atreya et al, 2000).
The detrimental effects of IL- 6  trans-signalling have been confirmed in many 
inflammatory models using IL- 6  deficient mice, which are protected against a variety 
of chronic inflammatory diseases including experimental models of arthritis Crohn’s 
disease, nephritis, uveitis and experimental autoimmune encephalomyelitis (Boe et al, 
1999; de Hooge et al, 2000; Kallen et al, 2002; Mihara et al, 1998). As such 
pharmaceutical agents have been developed to target IL- 6  signalling, including the 
anti-IL- 6  receptor blocking antibody MRA (Atlizumab, Tocilizumab), which have
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shown promise in the treatment of both Crohn’s disease and inflammatory arthritis 
(Choy et al, 2002; Ito et al, 2004). However, as previously mentioned, IL- 6  signalling 
is integral in the resolution of acute inflammation and also protects against septic 
shock (Barton et al, 1993; Ulich et al, 1991) so completely blocking IL- 6  signalling 
may have an undefined deleterious effect on the host’s ability to resolve bacterial 
infections (Onogawa et al, 2005). Such findings emphasise the need to define the 
balance between classical IL-6 R signalling and IL- 6  trans-signalling and underline the 
importance of developing second generation anti-IL- 6  blockers. In this respect, use of 
soluble gpl30 (sgpl30) as a therapeutic agent may provide a suitable alternative as 
sgpl30 is specific for IL- 6  trans-signalling, potentially leaving the classical signalling 
pathway unaffected (see Section 1.7.1.2).
1.9.3 The role of OSM in disease
OSM is a modulator of the inflammatory response, and as such has been demonstrated 
to be present in a variety of inflammatory disorders. OSM is below the level of 
detection in the serum or tissue of healthy individuals (Robak et al, 1997). However, 
OSM can be detected in biological fluids obtained from patients with certain 
inflammatory conditions. For example, OSM has been found in the synovium of 
patients with rheumatoid arthritis (Okamoto et al, 1997), the bronchial lavage fluid of 
patients with pneumonia (Grenier et al, 2001) and in the peritoneum of patients with 
acute bacterial peritonitis (Hurst et al, 2002) suggesting a potential role for OSM in 
these inflammatory conditions. OSM also has an important role in regulating the 
growth of certain cancers; inhibiting the growth of melanoma cells (Zarling et al, 
1986), breast and lung cancer cells (Lui et al, 1997) and glioma cells (Halfter et al, 
1998). In contrast OSM stimulates growth of AIDS-related Kaposi’s sarcoma cells 
(Miles et al, 1992). However, similarities in the biological action of IL- 6  and OSM in 
vitro have lead investigation to consider the therapeutic potential of modulating OSM 
in disease.
1.9.4 Inflammatory responses mediated via OSM
Although OSM affects processes associated with disease progression, the specific 
function of OSM in the face of an inflammatory challenge remains unclear. In vitro 
studies illustrate that OSM and IL- 6  share a similar capacity to control inflammatory 
processes, however, it remains to be established whether their control of common
52
biological activities provides a cytokine hierarchy with one factor over-riding the 
properties of the other. In this regard, the in vivo function of OSM in inflammation is 
not as well defined as IL-6 . However, several pro- and anti-inflammatory responses 
have been observed in vitro (Hurst et al, 2002; Wahl et al, 2001; Wallace et al, 1999; 
Modur et al, 1997). The anti-inflammatory effects of OSM include regulation of 
tissue inhibitor of metalloproteinase (TIMP)-l and TIMP-3 in several cell types 
(Cross et al, 2004; Li et al, 2001). The TIMP family are responsible for controlling 
the action of the MMPs, a group of enzymes that regulate extracellular matrix 
composition (Li et al, 2001). MMPs play a vital role in tissue remodelling under both 
physiological and pathological conditions, however, excessive activation, induced by 
pro-inflammatory cytokines such as IL-1 and TNFa, is associated with ECM (extra­
cellular matrix) destruction in inflammatory conditions such as arthritis (Lark et al,
1997). The TIMP proteins form complexes with MMPs, thereby preventing their 
action on the ECM, in addition many are also anti-tumourigenic and have anti- 
angiogenic and pro-apoptotic characteristics (Brew et al, 2000). Therefore, through 
the upregulation of TIMPs, OSM is able to protect against degradation of the ECM by 
MMPs.
OSM is also able to inhibit the production of the neutrophil chemoattractant CXCL8  
by the pro-inflammatory cytokine IL-1 in lung fibroblasts, in a similar manner to that 
of IL-6 , suggesting that OSM may also promote the clearance of neutrophils (Cross et 
al, 2004). Similarly IL- 6  and OSM are equally capable of promoting expression of 
the ELR+ CXC-chemokines CXCL5 and CXCL6  (Modur et al, 1997; McLoughlin et 
al, 2004). However, the function of CXCL5 and CXCL6  remains unclear and may 
not represent frontline PMN chemoattractants (McLoughlin et al, 2004).
Pro-inflammatory effects of OSM include the induction of adhesion and chemotaxis 
in neutrophils and increased production of chemokines in endothelial cells, synovial 
fibroblasts and human peritoneal mesothelial cells (HPMC) (Cross et al, 2004; Hurst 
et al, 2002). In a similar manner to IL- 6  trans-signalling, OSM has been shown to 
induce CCL2 production in mesothelial cells (Hurst et al, 2002) and fibroblasts 
(Brown et al, 1991; Nowell et al, 2006), as well as having as additive effect on CCL2 
expression after co-stimulation with the pro-inflammatory mediators IL-1 and TNFa. 
In addition OSM is also able to induce IL- 6  expression in a variety of cell types
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(Brown et al, 1991; Bernard et al, 1999; Hurst et al, 2002). The observed effects of 
OSM on mononuclear chemoattractants, in addition to its ability to regulate the 
production of IL- 6  suggest that OSM may be important in the progression of the 
immune response by promoting mononuclear cells activities.
1.9.5 OSM as a therapeutic target
Pro-inflammatory cytokines such as TNFa, IL-1 p and IL- 6  have been identified as 
promising therapeutic targets in the treatment of chronic inflammatory conditions 
(Maini & Taylor, 2000; Papadakis & Targan, 2000; Choy et al, 2002; Ito et al, 2004; 
Verbsky & White, 2004). As discussed in Section 1.9.4, OSM appears to have both 
pro- and anti-inflammatory roles in inflammation, therefore it is currently unclear 
whether it represents a significant therapeutic target (Pelletier & Martel-Pelletier, 
2003). However, studies using experimental models of arthritis have demonstrated 
some success of antibodies against OSM in limiting disease development, suggesting 
OSM may present a therapeutic target (Plater-Zyberk et al, 2001; Milner et al, 2003).
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1.10 Peritoneal dialysis associated infection and inflammation
Studies outlined within this thesis will adopt a model of inflammation designed to 
mimic inflammatory events observed during episodes of bacterial peritonitis seen in 
the peritoneal cavity of end-stage renal failure patients receiving peritoneal dialysis 
(PD). PD is a treatment strategy in cases of established renal failure (ERF).
1.10.1 Peritoneal dialysis
PD is an alternative treatment to haemodialysis, which involves the use of a highly 
concentrated sugar solution to remove solutes from the blood using the peritoneal 
lining as a dialysing membrane. Due to the highly concentrated nature of the fluid, an 
osmotic and chemical gradient is developed between dialysis fluid and the blood 
capillaries of the peritoneum. Water and small solutes including uremic metabolites 
move from the blood into the dialysate through a combination of osmotic pressure and 
hydrostatic ultrafiltration.
1.10.2 The peritoneal cavity
The peritoneal membrane is composed of two distinct layers: an epithelial layer 
known as the mesothelium; and an underlying connective tissue, the interstitium. 
These two layers are separated by a discontinuous basement membrane, composed of 
proteoglycans, type IV collagen and glycoproteins, which supports the mesothelium 
(Nagy & Jackman, 1998). The peritoneal membrane is highly vascularised to traffic 
molecules to and from the tissues and organs of the abdominal cavity (Nagy & 
Jackman, 1998). A lymphatic system is also present, which maintains the small 
volume of fluid present in the normal peritoneal cavity and has an important role in 
host defence within the peritoneum (Nagy & Jackman, 1998).
1.10.2.1 The mesothelium
The mesothelium lining the peritoneal cavity is composed of a monolayer of flattened 
mononuclear mesenchymal cells (human peritoneal mesothelial cells, HPMC). The 
major function of the mesothelium is to maintain normal homeostasis within the 
peritoneal cavity (Mutsaers, 2004); however, mesothelial cells also play an important 
role in regulating the inflammatory response after peritoneal infection or injury 
(Topley et al, 1993). Mesothelial cells represent the principle population lining the 
peritoneal cavity and serve a prominent role during inflammation providing the major
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source of inflammatory cytokines, chemokines and other mediators (Topley et al, 
1993; Lanfrancone et al, 1992).
1.10.3 Peritoneal dialysis associated peritonitis
Peritonitis, a generalised infection of the peritoneal cavity, is a major complication of 
PD treatment and recurrent bouts of infection can lead to progressive alterations in 
tissue architecture including vasculopathy, fibrosis and membrane thickening 
(Williams et al, 2002). Repeated episodes of peritonitis are directly related with 
increased susceptibility to further peritoneal infection due to the loss of the 
mesothelium and subsequent attenuation of host cell defence (Williams et al, 2002; 
Davies et al, 1996). The most common pathogens associated with PD peritonitis are 
gram-positive Staphlococci, including Staphylococcus epidermidis and 
Staphylococcus aureus.
Peritoneal infections trigger an immune response through the TLR-mediated 
production of pro-inflammatory cytokines from both HPMC and the small population 
of resident peritoneal macrophages (Park et al, 2007; Kato et al, 2004).
1.10.3.2 The inflammatory role of the mesothelium
In response to pathogen recognition and subsequent activation of both NF-kB and 
MAP kinase pathways, mesothelial cells and resident peritoneal macrophages express 
a variety of inflammatory mediators which serve to regulate the recruitment and 
activation of inflammatory leukocytes. As previously discussed in Section 1.2, the 
initial cells to respond during an immune assault are neutrophils, which are trafficked 
into the peritoneal cavity from the circulation in response to secretion of neutrophil 
chemoattractants such as mesothelial-derived CXCL8  (Topley et al, 1993; Visser et 
al, 1995). Other inflammatory mediators are released from both the mesothelial cells 
and infiltrating neutrophils, including members of the IL- 6  family (Topley et al, 1993; 
Hurst et al, 2002) which aid the progression of the immune response by inducing 
mesothelial secretion of mononuclear cell chemoattractants and the upregulation of 
specific cell surface adhesion molecules. Adhesion molecules including selectins, 
ICAM-1 and vascular cell adhesion molecule (VCAM)-l provide an interaction 
between the leukocyte and activated mesothelial cell enabling transmigration through 
the vascular endothelial cell layers into the peritoneal cavity.
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1.10.4 Peritoneal dialysis associated fibrosis
In acute episodes of bacterial peritonitis the influx of leukocytes efficiently clears the 
pathogen, thereby allowing resolution of inflammation. However, repeated episodes 
of peritonitis and long-term exposure to peritoneal dialysis fluids result in longitudinal 
changes in both peritoneal membrane structure and function (Williams et al, 2002). 
Examples of these changes include, thickening of the submesothelial tissue due to the 
deposition of collagen (fibrosis or sclerosis) and alterations in mesothelial cell 
integrity, including reduced regenerative capacities (Di Paulo et al, 1986; Williams et 
al, 2002; Devuyst et al, 2002). In cases of membrane thickening or ‘fibrosis’ the 
effectiveness of the cavity as a dialysing membrane is compromised, which ultimately 
leads to treatment failure.
Figure 1.11 Peritoneal membrane sections demonstrating normal and fibrosed
morphology
M esothelium —► A  , Altered m esothelium
Fig 1.11. A comparison of peritoneal membrane sections taken from a patient 
prior to therapy (A) showing normal morphology; the mesothelial layer covers a 
submesothelial zone consisting of collagen fibres as well as lymphatic and blood 
vessels. B shows a membrane section taken from a patient on long term PD 
demonstrating denuded mesothelium and increased vasculopathy and collagen 
deposition (Adapted from Williams et al, 2002)
Sub­
m esothelial
zo n e 500(jm
Fibrosed  
membrane: 
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1.10.5 The role of IL-6 related cytokines in peritoneal inflammation
Analysis of peritoneal dialysis fluid from patients with PD associated peritonitis has 
shown raised levels of both OSM and IL- 6  during bacterial infection coinciding with 
the influx of neutrophils into the peritoneal cavity (Hurst et al, 2002; Hurst et al, 
2001). Levels of LIF have also been analysed and shown to remain undetectable 
through the course of infection (Hurst et al, 2002). This therefore suggests that both 
IL- 6  and OSM are of potential importance in the progression of bacterial peritonitis.
OSM and IL- 6  (via IL- 6  trans-signalling) induces the release of mononuclear cell 
chemoattractants such as CCL2 from HPMC and can upregulate the production of 
adhesion molecules, further enhancing the trafficking of mononuclear cells (Hurst et 
al, 2001) (Section 1.10.3.2). Unpublished work has shown that IL- 6  deficient mice, in 
addition to being protected against experimental models of autoimmunity, are also 
resistant to membrane thickening in experimental models of peritonitis and show an 
impaired ability to clear bacteria (Fielding et al, unpublished data; Coles et al, 
unpublished data). Due to the similarities between IL- 6  and OSM in the chemokine 
driven profile, this study will aim to delineate the role of OSM in leukocyte 
trafficking during experimental models of peritonitis.
1.10.6 The potential role of OSM in peritoneal fibrosis
As discussed in Section 1.10.4, the primary reason for failure of peritoneal dialysis in 
the treatment of end-stage renal failure is fibrosis of the peritoneal membrane. This 
occurs in part due to the bio-incompatible composition of peritoneal dialysis fluid but 
predominantly due to repeated incidences of bacterial peritonitis (see Section 1.10.3). 
In addition to the observed roles of OSM in the progression of inflammation, it has 
also been implicated in the development of fibrosis (O’Hara et al, 2003; Nightingale 
et al, 2004). Currently no work has been published on the potential role of OSM in 
peritoneal epithelial to mesenchymal transition (EMT). However, a role for OSM in 
renal and lung EMT has been implicated (Nightingale et al, 2004; Pollack et al, 2007; 
O’Hara et al, 2003). The process of EMT involves attenuation of cell-to-cell and cell- 
to-extracellular matrix interactions, which enable epithelial cells to move through the 
extracellular matrix, where they take on a more mesenchymal phenotype. Such 
alterations are typically characterised by expression of smooth muscle a-actin. This 
process is integral in early embryonic development, however, dysregulation of this
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process in fully differentiated tissues can lead to damage and fibrosis (Radisky, 2005). 
Induction of EMT is cell type specific, however, in peritoneal fibrosis the major cause 
is upregulation of TGF-p (Margetts et al, 2005).
Project aims
The observed in vitro similarities between the action of OSM and IL- 6  (via IL- 6  trans­
signalling) suggest that OSM may also play a pivotal role in the progression from 
innate to acquired immunity, either by augmenting the response of IL- 6  (through its 
upregulation), or through its direct effect on chemokine-driven leukocyte recruitment. 
This, in addition to the observed role of OSM in the progression of fibrosis, makes it a 
potential target for therapeutic blocking (Pelletier & Martel-Pelletier, 2003).
This PhD project aims to investigate the inflammatory role of OSM in governing 
leukocyte recruitment within the peritoneal cavity, using in vitro and in vivo model 
systems.
Objective 1. Determine which cell populations are likely to be affected by OSM by 
defining OSMRp expression on HPMC and human leukocyte subsets.
Objective 2. Investigate the role of OSMRp (and IL-31) in leukocyte trafficking and 
adhesion using both in vivo and in vitro methods.
Objective 3. Compare the activities of OSM with responses known to be governed 
by IL- 6  using in vivo approaches.
Objective 4. Examine the OSMRp signalling events controlling leukocyte 
recruitment.
Objective 5. Investigate a potential role for OSMRp signalling in progressive 
inflammation, using an in vivo simulation of recurrent peritoneal 
inflammation.
Objective 6. Define what effect OSMRp deficiency has on tissue damage.
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Chapter 2
Materials and Methods
2.1 Reagents
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. All 
chemicals were of analytical grade or higher.
2.2 Tissue culture
2.2.1.1 Isolation of human peritoneal mesothelial cells
Human peritoneal mesothelial cells (HPMC) were isolated and cultured from 
omentum tissue derived from consenting patients undergoing elective abdominal 
surgery using an adapted version of Stylianou’s original method (Stylianou et al, 
1990; Beavis et al, 1995). Briefly, tissue sections were washed in sterile PBS 
(Dulbecco’s phosphate-buffered saline; 2.5mM KC1, 1.5mM KH2PO4 , 137mM NaCl, 
8 mM Na2HPC>4 pH7.4) (Gibco, Invitrogen, Paisley, UK), then digested in 20ml 0.1% 
(w/v) trypsin/ 0.02% (w/v) EDTA diluted in PBS and incubated for 15 minutes at 
37°C with continuous rotation. HPMC were harvested by centrifugation at 800g for 6  
minutes. Pelleted cells were suspended in growth medium.
2.2.1.2 HPMC growth conditions
Cells were cultured in complete Earle’s buffered 199-medium (Gibco, Invitrogen, 
Paisley, UK) containing 10% (v/v) heat-inactivated foetal calf serum (Hyclone, Perbio 
Science Ltd, Cranlington, UK), supplemented with 2mM L-glutamine, lOOU/ml 
penicillin, 1 OOpg/ml streptomycin, 5pg/ml transferrin, 5pg/ml insulin and 0.4pg/ml 
hydrocortisone (Li et al, 1998). Cell monolayers were grown (incubated at 37°C, 5% 
CO2) in T25 Falcon culture flasks (Beckton Dickinson, Oxford, UK) until confluent, 
once cells reach confluence they were passaged at a ratio 1:3.
2.2.1.3 Monolayer sub-culture
On reaching confluence in the primary culture flask, cells were initially transferred 
into T75 flasks before subsequent passage into the appropriate culture vessel for 
experimental purposes. Sub-culture involved the use of trypsin to remove the cells 
from the bottom of the plate. Growth media was removed by aspiration and the cells 
washed with sterile PBS, before trypsinisation with 10% (v/v) trypsin/EDTA diluted 
in sterile PBS. Cell detachment was monitored by light microscopy following brief 
incubation at 37°C. Following detachment lOmls of the appropriate growth medium 
supplemented with 10% (v/v) FCS was added to neutralise the trypsin. The cell
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suspension was transferred to a 50ml universal tube and spun at 600g for 6 minutes, 
the supernatant removed and the cell pellet resuspended in fresh FCS supplemented 
media. Cells were transferred to the appropriate culture vessel and incubated at 37°C, 
5% C02.
2.2.1.4 Growth arrest and cell stimulation
Prior to each experiment, the growth phase of the cells was synchronised by growth 
arrest in the appropriate serum free media. Briefly, growth medium was removed, the 
cells washed to remove all FCS then the media replaced with serum free medium. 
Under these conditions cells remain viable for up to 96 hours and were typically used 
after 48 hours growth arrest (Topley et al, 1991). For cell stimulation the growth 
arrest media was removed and the cells were washed with serum free medium. 
Stimulation was performed by incubation of the cells with the desired cytokine (eg. 
OSM, IL-1) as outlined within the specific Figure Legends.
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2.2.1.5 Characterization of HPMC
The morphology of HPMC monolayer cultures was examined using an inverted light 
microscope (Axiovert 25, Carl Ziess Ltd, Hertfordshire, UK). Confluent HPMC were 
typically polygonal in shape having approximately 5 sides and displaying the classical 
‘cobblestone’ appearance as demonstrated in Figure 2.1. Cells adopting this 
morphology were growth arrested (Section 2.2.1.4) to be used in experiments. 
Confluent HPMC were also characterised by their expression of cell surface markers 
including Cytokeratin 8/18, Vimentin and lack of Factor VIII related antigen 
expression (Stylianou et al, 1990; Zhang et al, 1999).
Figure 2.1 Morphology of HPMC monolayers.
Fig 2.1. Confluent monolayer of HPMC showing polygonal shape and typical 
‘cobblestone’ appearance after growth arrest (magnification x250).
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2.2.2 SV40 transformed HPMC
SV40 transformed HPMC (kindly provided by Jean-Phillipe Rougier, Department of 
Nephrology and Dialysis, Tenon Hospital, Paris, France) are derived from a primary 
HPMC line transformed with a plasmid containing a modified SV40 sequence, 
containing a deletion in the late region and a lbp insertion, which disrupts the origin 
of replication site within the SV40 genome. These cells retain many of the 
phenotypic characteristics of primary HPMC including morphology and the 
expression of Cytokeratins 8 and 18 and Vimentin (Fischereder et al, 1997).
2.2.2.1 SV40 HPMC growth conditions
SV40 transformed HPMC were cultured in DMEM (Dulbecco’s modified medium) 
(Gibco, Invitrogen, Paisley, UK) with 10% (v/v) foetal calf serum, supplemented with 
2mM L-glutamine, lOOU/ml penicillin, 1 OOpg/ml streptomycin, 5pg/ml transferrin, 
5pg/ml insulin and 0.4jig/ml hydrocortisone. Cell monolayers were then grown 
(incubated at 37°C, 5% CO2 ) in T25 Falcon culture flasks until confluent and 
passaged as previously described for HPMC (Section 2.2.1.3).
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2.2.3 Isolation and culture of peripheral blood leukocytes
Peripheral blood mononuclear cells (PBMC) were isolated from venous blood taken 
from non-smoking healthy volunteers (Ulmer et al, 1984; Kanof et al, 2001). Briefly, 
blood was layered onto Dextran 70 (6 % in 0.9% sodium chloride) with citrate (76mM 
citric acid, 169mM sodium citrate, pH5.6) and left to sediment for 1 hour at 37°C. 
The straw-coloured plasma was removed, leaving the red blood cells undisturbed. 
Leukocytes within the plasma were pelleted by centrifugation, then washed in PBS 
(pH7.4) and re-suspended in 5ml PBS (pH7.4). This was layered on Ficoll-Paque 
PLUS (Ficoll PM400 and sodium diatrizoate with a specific density of 1.077g/ml) 
then centrifuged at 400g for 35 minutes with no braking. PBMC sediment at the 
interface, whereas neutrophils (PMN) pellet at the bottom. PBMC were collected and 
washed in PBS, then re-suspended at a concentration of 2xl06 cells/ml in serum-free 
RPMI-1640 medium (Sigma-Aldrich, Poole, UK) supplemented with 2mM 
L-glutamine, lOOU/ml penicillin, lOOpg/ml streptomycin. Cells were cultured to 
remove all non-adherent cells. PMN were also collected, washed in PBS (pH7.4) and 
retained for flow cytometric analysis.
2.2.3.1 Stimulation of PBMC
After incubation for 2 hours, any non-adherent cells were removed by washing with 
PBS. Cells were subsequently stimulated overnight in the absence of serum with 
various cytokines and inflammatory mediators (as described in the appropriate Figure 
Legends). Culture supernatant samples were rendered cell-free by centrifugation and 
stored at -70°C for subsequent cytokine analysis. Cells were collected for flow 
cytometric analysis or extraction of total RNA (using methods described in section
2.5.1).
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2.3 Animal experiments
Experiments were performed on 6-12 week C57/Blk6 wild type (WT) and Oncostatin 
M Receptor p deficient (OSMR-KO) mice. Procedures were carried out following 
Home Office approval under project license number PPL-30/2269 ‘Regulation of 
leukocyte trafficking and fibrosis’.
2.3.1 Generation of OSMRp deletion
OSMR-KO mice (kindly provided by Minoru Tanaka, Institute of Molecular and 
Cellular Biosciences, University of Tokyo, Tokyo, Japan) were generated as 
previously described (Tanaka et al, 2003). Briefly, disruption of the OSMRp gene 
was achieved through replacement of the proximal region of the initiation codon with 
the LacZ gene and neomycin resistance cassette, resulting in deletion of the N- 
terminal region of the gene.
2*3.2 Genotyping OSMR-KO animals
Approximately 1mm was removed from the end of the tail of mice at between 2-4 
weeks old using a scalpel blade. This was incubated with 750pl tail buffer (50mM 
Tris-HCl (pH7.4), lOOmM EDTA, lOOmM NaCl, 1% SDS, in 100ml distilled H2 0) 
and lOpl Proteinase K (20mg/ml) overnight at 55°C. This was mixed with 5M NaCl 
and separated by centrifugation (13,000g, 25 minutes). The lower phase was 
collected and mixed with isopropanol (1:1.6), precipitated DNA was pelleted by 
centrifugation (13,000g, 10 minutes). The DNA was washed in 70% (v/v) ethanol 
and resuspended in sterile double distilled H20  prior to use.
Polymerase chain reaction (PCR) was performed using 2pl cDNA per reaction. PCR 
reactions were performed as described in Section 2.6.1. Amplification conditions 
were as follows:
Initial denaturation 94°C 2  mins
94°C 1 min '
60°C 1 min
72°C 90 secs -
Final extension 72°C 1 0  mins
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DNA banding was visualised on 2% agarose gels using ethidium bromide (5mg/ml) 
(Tanaka et al, 2003).
Primer Sequences Annealing Temp %GC content
5 ’-GTAATCAGACC AATGGCTTTCTC-3 ’ 70 43
5 ’-GATCCAACACAATCATGAAGC-3 ’ 72 45
5 ’ -GC AC AT AACTTC AGC-3 ’ 65 50
Table 2.1. Genotyping was performed by polymerase chain reaction (PCR) 
using the outlined primers from genomic DNA isolated from tail tips. Wild type 
mice generate a 364bp product, whereas OSMR-KO mice generate a 750bp 
product. Heterozygous mice show both fragments (Tanaka et al, 2003).
Figure 2.2 Genotyping OSMR-KO mice
lkb+ KO WT -PCR
650 
300 
100
Fig 2.2. cDNA was isolated from tail tips of WT and OSMR-KO mice and PCR 
performed using primers as outlined in Table 2.1 (Section 2.3.2). Wild type mice 
generate a 364bp product, whereas OSMR-KO mice generate a 750bp product.
2.3.3 Determination of baseline leukocyte numbers
Differential cell counts and FACS analysis were performed on peripheral blood and 
peritoneal leukocytes from WT and OSMR-KO animals. Peripheral blood was 
collected by cardiac puncture into tubes containing EDTA (0.5M) as an anti­
coagulant. All red blood cells were removed by hypertonic lysis (155mM NH4CI, 
7mM K2CO3, O.lmM EDTA pH 7.2). To collect peritoneal leukocytes, healthy
OSMR-KO 750bp 
WT 364bp
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animals were sacrificed by schedule 1. The peritoneal cavity was lavaged with 2ml 
ice cold sterile PBS. Leukocytes were collected by centrifugation (2000g, 5 minutes) 
and resuspended in PBS. Cell numbers were determined using a Coulter counter. 
Slides for differential cell counting were prepared by cytospin (Thermo Fisher 
Scientific, Waltham, MA, USA) and stained with GIEMSA (Sigma, Poole, UK). 
Leukocyte subsets were counted according to cell morphology as visualised by light 
microscopy. Baseline leukocyte numbers were also quantified by flow cytometric 
analysis using pan-leukocyte markers as described in Section 2.4.3.
2.3.4 Generation of peritoneal inflammation using Staphylococcus epidermidis 
cell-free supernatant
A lyophilized cell free supernatant (SES) was prepared from Staphylococcus 
epidermidis following previously stated protocol (Hurst et al, 2001). Briefly, 
S.epidermidis taken from a clinical isolate, was grown to stationary phase in nutrient 
broth 2 (Oxoid, Basingstoke, UK) at 37°C in a shaking incubator overnight. The cell 
pellet was collected by centrifugation (1800g, 20mins, 20°C) and re-suspended in 
Tyrode’s salt solution (1.8mM CaCl2 *2H2 0, ImM MgCl2 *6H2 0, 2.6mM KC1, 
137mM NaCl, 0.42mM NaH2PC>4 , 5.5mM D-glucose, with 12mM NaHC03) diluted 
to an OD6 0 0  of 0.5. The bacterial pellet was incubated in Tyrode’s salt solution at 
37°C overnight to ensure complete lysis of the bacteria. All bacterial debris was 
removed by centrifugation (5000g, 30 mins, 20°C) and excess salt removed by 
dialysis against water. Aliquoted samples were freeze-dried and stored at -80°C as a 
lyophilised powder, prior to reconstitution in sterile PBS directly before use.
Prior to use the activity of each batch of SES was assayed using SV40 HPMC. 
Monolayers of SV40 HPMC were growth arrested (Section 2.2.2.1) prior to 
stimulation with a serial dilution of SES reconstituted in serum free DMEM. Cells 
were incubated for 24 hours, culture supernatant collected and assayed for CXCL8  
using ELISA (Section 2.9). Production of CXCL8  in the range of 2500±500pg/ml in 
response to undiluted SES was used for all experiments.
For each experiment groups of mixed sex, age-matched WT and OSMR-KO animals 
were used. Induction of peritoneal inflammation was achieved by intra-peritoneal 
injection of SES (500pl). At designated time intervals of between 30 minutes and 48
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hours, mice were sacrificed by schedule 1 and the peritoneal cavity lavaged with 2 ml 
of ice cold sterile PBS. Sections of the peritoneal cavity were removed and snap 
frozen in liquid nitrogen for analysis by EMSA (Section 2.8).
Samples of peritoneal membrane were taken for histology from mice after resolution 
of four episodes of SES-induced inflammation. Groups of four OSMR-KO and five 
WT mice received four injections of SES (500pl at weekly intervals) and were 
sacrificed 21 days after the final episode to allow for resolution. Sections of 
peritoneal membrane were removed and pinned flat in PBS, exposing the 
mesothelium. Sections were fixed overnight at 4°C in 10% neutral buffered formal 
saline (Sigma, Poole, UK) prior to embedding in paraffin. Fixed sections were cut (5- 
6 pm thickness) and stained with haematoxylin and eosin or primary antibodies against 
collagen I or collagen III (Santa-Cruz Biotechnology, Santa Cruz, CA) in combination 
with an HRP-conjugated secondary antibody. All histology was performed by Central 
Biotechnology Services, Cardiff University.
Peritoneal leukocytes were collected and counted using methods outlined in Section
2.3.3. Slides were prepared by cytospin and stained for differential cell count as 
described in Section 2.3.3. Remaining leukocytes were stained for flow cytometric 
analysis of macrophage specific markers (F4/80 and CD lib ) and CCR5 expression as 
described in Section 2.4.4. Peritoneal lavage supernatant was retained and stored for 
future analysis by ELISA (Sections 2.9 and 2.9.1).
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2.4 FACS Analysis
2.4.1 Use of FACS Calibur 4CA flow cytometer
Flow cytometric analysis enables information on the relative size, granularity and 
phenotypic expression of defined cell markers.
2.4.1.1 Analysis of individual cell subsets utilising forward vs side scatter
Size and granularity can be assessed using plots of forward scatter (FSC, reflects 
particle size) versus side scatter (SSC, reflects particle granularity), thus enabling 
individual cell subsets to be identified and analysed further. As cells pass though the 
laser beam light is deflected and refracted by the cells in the stream. The scattered 
light is collected by the FSC and SSC photodiodes, which convert the light signal into 
electronic signals that are expressed as a plot of points on an axis corresponding to the 
morphology of the cells, as illustrated in Figure 2.3.
Figure 2.3 FSC vs SSC dot plot of human peripheral blood leukocytes
Figure 2.3. Density plot demonstrating forward vs side scatter of freshly isolated 
human peripheral blood leukocytes. Due to the characteristics of individual 
leukocyte subsets, each can be gated for further analysis. R1 are neutrophils, 
which are relatively small but demonstrate granular morphology. R2 are 
monocytes, which are large, relatively granular cells. R3 are lymphocytes which 
are smaller and less granular than neutrophils and monocytes.
2.4.1.2 Analysis of receptor expression using single colour staining
When using a single fluorescent dye conjugated to a monoclonal antibody, histogram 
analysis can be used to gauge the relative distribution of a surface marker. The 
amount of fluorescent signal detected by the machine (electronic events) is 
proportional to the number of flourochrome molecules.
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Specific alterations in the expression of cell markers can be calculated by monitoring 
the mean fluorescence units (MFU) associated with receptor expression. Markers can 
be placed on a histogram to specify a range of events for a single parameter. Negative 
isotype controls are used to place the marker for positive events as illustrated in 
Figure 2.4. Any events to the right of the end of the negative isotype peak are 
considered to be positive.
Figure 2.4 Histogram analysis of cells stained with a FITC positive stain and an 
isotype control
Fig 2.4. Isolated neutrophils were stained with a FITC conjugated antibody 
against CXCR1 and a FITC conjugated isotype control. The marker is set to 
enclose the positive sample but not the isotype control.
By utilising the statistics function on CellQuest Pro software, the number of positive 
events (those enclosed by the marker Ml) can be determined and the MFU calculated 
using the formula below. Calculation of the MFU enables the effect of cell 
stimulation on the relative receptor expression to be assessed, where sample 1 is the 
stimulated cell population and sample 2 is the unstimulated control cell population.
MFU (from Ml) = events from positive sample 1 -  events from negative IgG
2.4.1.3 Analysis of multiple receptors using more than one fluorochrome
More than one fluorochrome can be analysed simultaneously if the wavelengths 
required for excitation are similar and the peak emission wavelengths are far enough 
apart to be detected by separate detectors. However, the emission spectra of the 
fluorochromes used can overlap; this overlap can be compensated for by altering the
o
Key
□ Isotype control 
— FL1 positive sample
events from positive sample 2 -  events from negative IgG
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optical filters within the machine. To set the correct compensation, control samples 
stained with negative isotype and positive controls for FITC (FL1), PE (FL2), PECy5 
(FL3) and APC (FL4) (see Table 2.2) were analysed to ensure no detection of 
fluorochromes in any other detector than that stated but that there was sufficient 
positive detection by the appropriate detector.
Detector Flourochrome Abbreviation
FL1 Fluoroscein / Fluoroscien 
isothiocyanate
FITC
FL2 Phycoeryhtrin PE
FL3 Phycoerythrin cyano-5 PECy5
FL4 Allophycocyanin APC
Table 2.2. Fluorochromes used for flow cytometric analysis within this report 
and associated detectors.
Dot plots can be used to analyse two parameters together, enabling receptor 
expression to be determined on cell subsets based on additional expression of specific 
pan-leukocyte markers (see Section 2.4.3) and further quantification of specific cell 
subsets (see Section 2.4.5). Quadrant markers can be used to divide two parameter 
plots into four sections to determine populations which are negative, single positive or 
double positive. As demonstrated in Figure 2.5, isotype controls are used to set the 
position of the quadrant marker. Cells within the lower left quadrant are considered 
negative for both parameters, cells within the lower right quadrant are positive only 
for the x  axis parameter (positive for the FITC conjugated stain). The upper left 
quadrant contains cells positive only for the y  axis parameter (positive for the PE 
conjugated stain). The upper right quadrant contains cells that are positive for both 
parameters (double positive for FITC and PE). Using the quadrant statistics function 
on Cellquest Pro software, the percentage of cells in each quadrant can be calculated.
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Figure 2.5 Dot plots of isotype control and PE and FITC positive cells with 
quadrant markers
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Fig 2.5. A, isotype controls are used to set the quadrant positions. B, cells 
positive for only the FITC stain are in the lower right quadrant, cells positive for 
only the PE stain are in the upper left quadrant, cells in the upper right 
quadrant are positive for both stains.
2.4.2 Flow cytometric analysis of receptor expression on HPMC
Flow cytometric analysis was used to assess the expression of a variety cytokine 
receptors on the surface of mesothelial cells. Confluent HPMC were growth arrested 
as previously described (Section 2.2.1.4) and collected by gently scraping into PBS. 
Cells were pelleted by centrifugation and resuspended in FACS buffer (0.5% BSA, 
7.5mM NaN3 , 5mM EDTA in PBS, pH 7.4). To reduce non-specific binding, cells 
were incubated for 5 minutes in FACS blocking buffer (50% FACS buffer, 25% 
human antibody serum (HD Supplies, Aylesbury, UK), 25% rabbit serum (DAKO, 
Cambridgeshire, UK)). HPMC were assessed for cell surface expression of IL-6- 
related receptors, adhesion molecules and IL-31Ra by incubation for 1 hour with 
antibodies against the extracellular portions of named receptors as outlined in Table
2.3.
Cells incubated with antibodies against OSMRp and IL-31Ra required additional 
incubation with fluorochrome-associated secondary antibodies (phycoerythrin goat- 
F(ab’ )2  fragment was used in conjunction with antibodies against OSMRp and its 
associated isotype control, whilst anti-goat IgG FITC conjugate was used in for 
antibodies against IL-31Ra and its associated isotype control, Table 2.3). Cells were 
washed and resuspended in FACS buffer prior to analysis. Cell staining was 
quantified using a FACS Calibur 4CA cell sorter (see Section 2.4.1). Data was
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acquired from 10,000 gated events for each sample. Cells stained with secondary 
antibody alone were used as controls to eliminated non-specific binding, whilst non­
labelled cells were used to monitor the degree of autofluorescence. All antibody 
concentrations used and incubation periods were chosen in response to prior 
optimisation. Data was analysed using CellQuest-pro software, as described in 
Section 2.4.1.
2.4.3 Flow cytometric analysis of receptor expression on peripheral blood 
leukocytes
Neutrophils and mononuclear cells were separated using Ficoll density centrifugation 
(see Section 2.2.3). Cells were diluted to a concentration of 2x106 cells/ml in FACS 
buffer. To identify individual leukocyte subsets, cells were stained with FITC- 
conjugated antibodies against the extracellular portions of specific pan-leukocyte cell 
markers: CD 14 (monocytes), CXCR1 (neutrophils) and CD3 and CD4 (T cells) 
(conditions as described in Table 2.2).
Each subset was co-stained with an antibody against either receptor subunits for IL-6 - 
related cytokines (OSMRp, gpl30 or LIFRp) or IL-31Ra or related isotype controls 
(conditions as described in Section 2.3.2 and Table 2.3). To reduce non-specific 
antibody binding, cells were incubated with FACS blocking buffer for 30 minutes at 
4°C in the dark, before the addition of antibody (specific antibody combinations used 
are described in the relevant chapters) and further 1 hour incubation (in the dark, 
4°C). Cells were washed in FACS buffer then resuspended in secondary antibody (if 
required, see Section 2.4.2) and incubated for 30 minutes. Antibody-labelled cells 
were washed and resuspended in FACS buffer before acquisition (20,000 gated 
events). Autofluorescence and antibody labelling controls were included as before 
(Section 2.4.2), and the data analysed as per Section 2.4.1.
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Antibody Clone Isotype Fluoro-
chrome
Working
dilution
Source
OSMRp AN-A2 Mouse
IgGi
N/A 5(xg/ml Santa-Cruz Biotechnology
LIFRp 7G7 Mouse
IgGj,K
PE 2 pg/ml BD Pharmingen
IL-6Ra M5 Mouse
IgGi,K
PE 2 jo,g/ml BD Pharmingen
gpl30 28126.111 Mouse
IgG!
PE 2.5|ig/ml R&D Systems
IL-31Ra N-16 Goat
IgG
N/A 5pg/ml Santa-Cruz Biotechnology
ICAM-1 BBIG-I1 Mouse
IgG!
Fluoro-
scein
2 pg/ml R&D Systems
VCAM-1 BBIG-V3 Mouse
IgG2a
Fluoro-
scein
lpg/ml R&D Systems
CD3 UCHT1 Mouse
IgGi,K
FITC 1 / 1 0 0 BD Pharmingen
CD4 RPA-T4 Mouse
IgGi,K
PECy5 1 / 1 0 0 BD Pharmingen
CD14 M5E2 Mouse
IgG2a,K
FITC 1 / 1 0 0 BD Pharmingen
CXCR1 5A12 Mouse
IgG2b,K
FITC 5pg/ml BD Pharmingen
Mouse
IgGi
N/A N/A N/A 5p,g/ml Santa-Cruz Biotechnology
Anti­
goat IgG
N/A N/A FITC 1/400 Sigma-Aldrich
RPE
F(ab’)2
N/A N/A PE 0 . 1  (ig/ml Dako
Table 2.3. Primary and secondary antibodies and isotype controls used for 
FACS analysis of human peripheral blood cells and HPMC.
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2.4.4 Quantification of baseline leukocyte numbers in WT and OSMR-KO mice
Murine peritoneal and blood leukocytes were isolated as described in Section 2.3.3. 
Cells were re-suspended to a concentration of 2 x 106 cells/ml in Fc block (4pg/ml Rat 
anti-mouse CD16/CD32 FcyRl monoclonal antibody (BD Pharmingen, Oxford, UK) 
in FACS buffer) to reduce non-specific antibody binding, and incubated in the dark at 
4°C for 30 minutes. Samples were diluted to a concentration of 105 cells per sample 
in FACS buffer and incubated (in the dark, 4°C, 1 hour) with Phycoerythrin- 
conjugated antibodies against the extracellular portion of CD3 (T cells), B220 (B 
cells) and F4/80 (monocytes) as well as a related isotype control (conditions as 
outlined in Table 2.4). Expression of these cell markers was quantified from a total of
20.000 gated events using a FACS Calibur 4CA flow cytometer, (Section 2.4.1).
2.4.5 Flow cytometric analysis of CCR5 expression on murine peritoneal 
macrophages
Peritoneal leukocytes were isolated from inflammatory challenged mice and counted 
(Section 2.3.4). Cells were re-suspended in blocking buffer and incubated for 30 
minutes at 4°C (Section 2.4.4). To characterise individual monocytic subsets, cells 
were labelled (lhr incubation) with a FITC-conjugated anti-F4/80 antibody (Serotec 
AbD Ltd, Oxford, UK) in combination with an APC-conjugated anti-CD lib  (BD 
Pharmingen, Oxford, UK) (resident-like monocytes are characterised as 
F4/80h,ghCDllbhlgh, inflammatory monocytes are characterised as F4/80lowCDllb+, 
see Chapter 5.3) and CCR5 expression evaluated using a PE-conjugated anti-CCR5 
antibody (BD Pharmingen, Oxford, UK). Specific information relating to antibody 
concentrations used is presented in Table 2.4; again, all antibody concentrations were 
used dependent on prior optimisation. Cells were washed and resuspended in FACS 
buffer prior to analysis. Expression of cell markers was quantified from a total of
20.000 gated events using a FACS Calibur 4CA flow cytometer, as described in 
Section 2.4.1.
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Antibody Clone Isotype Fluoro-
chrome
Working
dilution
Source
CD16/CD32 
(Fc block)
2.4G2 Rat IgG2bK N/A 4(xg/ml BD Pharmingen
CD3 GK1.5 Rat IgG2bK FITC 5pg/ml BD Pharmingen
B220 RA3-6B Rat IgG2aK FITC 5 jig/ml BD Pharmingen
F4/80 CI:A3-1 Rat IgG2b FITC 5(xg/ml Serotec
CDllb Ml/70 Rat IgG2bK APC l|4,g/ml BD Pharmingen
CCR5 C34-3448 Rat IgG2ck PE 2  jig/ml BD Pharmingen
Rat IgG2 A95-1 Rat IgG2bK FITC 5|ig/ml BD Pharmingen
Rat IgG2 A95-1 Rat IgG2bK APC 2 pg/ml BD Pharmingen
Rat IgG2 A95-1 Rat IgG2bK PE 2 p.g/ml BD Pharmingen
Table 2.4. Primary and secondary antibodies and isotype controls used for 
FACS analysis of murine peritoneal leukocytes.
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2.5 RNA Analysis
2.5.1 Chloroform/Isopropanol RNA extraction
Total cellular RNA was extracted using TRI reagent (Sigma-Aldrich, Poole, UK). 
Cell monolayers established in 6-well microtitre plates were incubated for 5 mins with 
lml TRI reagent per well. The cell lysate was collected, chloroform added (1/10 to 
lysate) and samples incubated for 5 mins to allow separation of the aqueous phase. 
Samples were centrifuged (12,000g, 15 mins, 4°C with no braking), the colourless 
upper aqueous phase was collected, and the lower solvent phase and the interface 
were discarded. An equal volume of isopropanol was added to the aqueous phase to 
precipitate total cellular RNA at -20°C overnight. The RNA was pelleted by 
centrifugation and washed in 75% (v/v) ice cold ethanol. Samples were air dried and 
resuspended in lOpl of sterile H2 O.
2.5.2 Determination of RNA concentration
RNA concentrations were determined by spectrophotometric analysis (Beckman UV- 
DU64 spectrophotometer, Beckman Instruments Ltd, High Wycombe, UK). In an 
appropriate cuvette 1 pi of RNA was diluted in 54pl of sterile water. The absorbance 
was read at 260 and 280nm. A 260/280 ratio of above 1.8 was indicative of a 
sufficiently pure sample. The total RNA concentration was calculated using the 
following formula:
[RNA] (pg/ml) = OD2 6 0  x molar extinction coefficient x dilution factor
Molar extinction coefficient for RNA = 40 
Dilution factor = 55
An OD2 6 0  of between 0.1 -  1.0 was required to be in the linear range of the Beer- 
Lambert law, which states that there is a linear relationship between absorbance and 
the concentration of an absorbing substance, relying on both the distance light travels 
through the substance (path length) and the absorption coefficient of the substance. 
Samples were diluted where necessary and discarded if OD2 6 0  <0.1.
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2.5.3 RNA quantification
RNA integrity was determined by flat bed electrophoresis using a mini-gel system 
(Thermo Life Sciences Ltd, Basingstoke, UK) through a 2% (w/v) agarose gel 
(composed of lg electrophoresis grade agarose (Ultrapure agarose, Gibco/BRL), 50ml 
of IX TAE (40mM Tris-Acetate, lmM EDTA) buffer (Promega, Southampton, UK) 
and 5 pi ethidium bromide (5mg/ml). Into a single well, lpg RNA was loaded with 
5pl of loading buffer (15% (v/v) Ficoll Type 400 (GE Healthcare, Chalfont St Giles, 
UK) in H2O, with 0.25% (w/v) Orange G). RNA integrity was visualised under ultra
n r w
violet light in the ChemiDoc gel documentation system (Bio-Rad Laboratories, 
Hemel Hempstead, UK). The quality of the RNA was assessed by an observed 
ethidium bromide staining pattern for 28S and 18S ribosomal RNA.
Figure 2.6 Representative RNA gel demonstrating expected ethidium bromide 
staining pattern for 28S and 18S ribosomal RNA.
Sample number
1 2  3 4
$ ||f  mm wm <—  28S
'<m «** £g$ <—  18S
Fig 2.6. RNA was isolated from four individual primary HPMC isolates (Section
2.5.1). RNA integrity was determined by gel electrophoresis (2% (w/v) agarose 
gel), lpg RNA was loaded per well, staining was visualised using ethidium 
bromide under ultra violet light.
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2.5.4 Semi-quantitative reverse transcription
Reverse transcription was performed using the random hexamer method (Topley et al, 
1993). Briefly, lpg total RNA in a total volume of 20pl comprising lOOpM random 
hexamers (GE Healthcare, Chalfont St Giles, UK), 5mM mixed deoxynucleotides 
(2’deoxyadenosine 5’triphosphate (dATP), 2’deoxyguanidine 5’triphosphate (dGTP), 
2’deoxycytidine 5’triphosphate (dCTP), 2’deoxythymidine 5’triphosphate (dTTP)) 
(GE Healthcare, Chalfont St Giles, UK), IX PCR buffer (20mM Tris-HCl, pH 8.4, 
50mM KC1) (Invitrogen, Paisley, UK) and ImM DTT (Dithiothreitol) (Invitrogen, 
Paisley, UK) was heated to 95°C for 5 mins to linearise the RNA. Following 
immediate cooling on ice, 40U of recombinant ribonuclease inhibitor (RNAsin, 
Promega, Southampton, UK) and 200U Superscript II Rnase H-ve reverse 
transcriptase (Invitrogen, Paisley, UK) was added. The RNA was heated to 20°C for 
10 mins to enable primer annealing to the linearised RNA, before transferring to 42°C 
for 60 mins to allow primer extension from the random hexamers by reverse 
transcription. The reaction was stopped by denaturation at 95°C for 5 mins. Negative 
control reactions were also performed replacing the Superscript reverse transcriptase 
enzyme with distilled H2 O alone. Two microlitres of the resulting complementary 
DNA (cDNA) was used for each PCR reaction.
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2.6 DNA Analysis
2.6.1 Polymerase Chain Reaction (PCR)
Each 50pl reaction comprised 2pi cDNA, IX PCR buffer containing 1.5mM MgCb 
(lOmM Tris-HCl, pH8.3, 50mM KC1, 0.001% (w/v) gelatin) (Applied Biosystems, 
Warrington, UK), 5mM mixed deoxynucleotides (dATP, dCTP, dGTP and dTTP) 
(GE Healthcare, Chalfont St Giles, UK), 2.5U AmpliTaq Gold (Applied Biosystems, 
Warrington, UK) and ImM oligonucleotide primers (5’-3’ and 3’-5’, forward and 
reverse) (Invitrogen, Paisley, UK). Negative control reactions were also performed, 
replacing the cDNA with 2pi of distilled water. The standard PCR protocol used in 
this study is as follows:
Step 1 -  Initial Linearisation 
94°C 2 mins 
Step 2 -  Denaturation, primer annealing and extension 
94°C 30 secs "
55°C 1 min > 2 6 -3 8  cycles (dependent on primers)
72°C 1 min 
Step 3 -  Final extension and proof reading 
6 8 °C 15 mins
All PCR reactions were carried out in a GeneAmp PCR System 9700 Thermo-cycler 
(Applied Biosystems Ltd).
2.6.2 Primer design
All primers were designed using the internet based Primer 3 software 
(http://ffodo. wi.mit.edu/cgi-bin/primer 3/primer3) and purchased from Invitrogen Ltd. 
Primers were designed to have a GC content of 50-60% and an annealing temperature 
of approximately 60°C. All primers were reconstituted in sterile water to give a stock 
concentration of 200pM. Detailed sequences for forward and reverse primers are 
shown in Table 2.5.
81
Gene Sequence Tm (°C) %GC Cycle Product
No. length (bp)
P-actin F 5 ’-ATCCCCCAAAGTTCACAA-3 ’ 65 44 26 198
R 5 ’-CTGGGCCATTCTCCTTAG-3 ’ 65 55
GAPDH F 5 ’-CGAGATCCCTCCAAAATCAA-3 ’ 58 45 28 330
R 5 ’-ATCCACAGTCTTCTGGGTGG-3 ’ 58 55
IL-31Ra F 5 ’-TGGTGGAGGCCTTCTTATTC-3 ’ 60 50 35 180
R 5 ’-CACAGAGTCATCAGACTCCTTCA-3 ’ 60 48
IL -llR a F 5’-CCAACCCTGTAGAGGACCCA-3 ’ 70 55 32 230
R 5 ’-CGTTCCTTGAGCAGAACTCC-3 ’ 70 55
IL-31 F 5’-TGGACCTCGCACTAAAATCATTG-3’ 69 43 32 60
R 5 ’ -CGAAAGGAAGAGATGGCCTT AA-3 ’ 69 45
Table 2.5. Human primer sequences used in PCR reactions, outlining the 
annealing temperature (Tm), GC content, the required cycle number and 
resulting product size. All PCR reactions were performed using the 
amplification conditions specified in Section 2.6.1. Product length was estimated 
by comparison to banding exhibited by lkb+ DNA ladder. (F - forward sequence, 
R - reverse sequence).
2.6.3 Sizing of PCR products
All PCR products were run on a 2% agarose gel (as described in Section 2.5.3). 5pl 
of PCR product was loaded onto the gel along with 5 pi of loading buffer (as in section 
2.4.3) and separated by electrophoresis at 75V for 45-60 mins in TAE (Tris-Acetic 
Acid, EDTA) buffer (Promega, Southampton, UK). The DNA banding pattern was 
visualised/photographed using a ChemiDoc™ gel documentation system, and the size 
of product compared against molecular weight standards (lkb+ DNA ladder; 
Invitrogen, Paisley, UK).
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2.7 CCL5 promoter construct analysis
CCL5 promoter sequences (outlined in Table 2.6) were kindly provided by Lisa M. 
Schweibert (Department of Physiology and Biophysics, University of Alabama, 
Birmingham, Alabama, USA) and inserted into the Smal and Kpnl sites of the 
multiple cloning region of pGL2 basic luciferase reporter vector (Promega, 
Southampton, UK). Briefly, a 1.4kb 5’ noncoding sequence upstream of the CCL5 
gene was cloned as described by Moruichi et al, 1997 and found to contain the 
published promoter sequence and approximately 0.4kb sequence further upstream 
(R1.4). Additional sequences were generated via 5’ deletions and site directed 
mutations within putative cis-acting elements (Moruichi et al, 1997). Plasmids were 
inserted and stored in competent E.coli.
Putative cis- 
acting element
Position Base change in site-directed 
mutagenesis
Promoter 
sequence length
NFIL- 6 -92 TCCGTTGCATGCAATT 1.4kb
NF-kB (KB1) -44 GGAAACTTACGTAGG 1.4kb
Table 2.6 CCL5 promoter constructs. Additional CCL5 promoter constructs 
were generated to analyse putative cis-acting elements by site-directed 
mutagenesis. The base changes involved in site-directed mutagenesis are shown 
in bold type, positions are relative to the transcription start site (Moruichi et al, 
1997).
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2.7.1 Plasmid purification
Plasmids were isolated from competent cells (E.coli; Bioline, London, UK) using 
QIAGEN plasmid midi kits (Qiagen, Crawley, UK) following the manufacturers’ 
protocol. Briefly, 20pl cell stock (as stored in LB medium and glycerol, -80°C) was 
used to inoculate 50ml LB medium (10g/l tryptone, 5g/l yeast extract, 0.17M NaCl, 
pH7.0, heat sterilised) and incubated overnight with constant shaking. Cells were 
collected by centrifugation (6,000g, 15 mins) and lysed (using 200mM NaOH-1% 
(w/v) SDS buffer) resulting in the release of the cell contents. Neutralisation of the 
lysate causes SDS to precipitate, trapping chromosomal DNA and cellular debris but 
leaving plasmid DNA in solution. The precipitated cell debris was removed by 
centrifugation (13,000g, 15 mins), the plasmid DNA was bound to resin columns 
(QLAGEN-tips) and washed to remove all contaminating RNA and proteins. Plasmid 
DNA was eluted from the column, precipitated by the addition of isopropanol and 
collected by centrifugation. DNA was washed in 70% ethanol and resuspended in 
lml distilled H2 O.
The concentration of plasmid DNA isolated was quantified by UV spectrophotometry 
as described in Section 2.5.2. Briefly, lpl DNA was diluted in 54pl H2 O in an 
appropriate cuvette. The absorbance was read at 260 and 280nm. The DNA 
concentration was calculated using the following formula:
[DNA] (pg/ml) = OD2 6 0 x molar extinction coefficient x dilution factor 
Molar extinction coefficient for DNA = 50
2.7.2 Transient transfection
Transient transfection of SV40 HPMC was performed using the lipofection agent 
FuGene 6  (Roche Diagnostics, Lewes, UK). SV40 HPMC were grown as described 
in Section 2.2.2.1. When cells reached 70% confluence in 6  well plates, the growth 
medium was removed and the cell monolayer washed with PBS. Cells were 
transfected with 0.9pg pGL2 containing the CCL5 promoter sequence (Section 2.7) 
and O.lpg of Renilla luciferase vector (Promega, Southampton, UK) in accordance 
with the manufacturer’s protocol for the application of FuGene 6 . All transfections 
were carried out in serum free medium. After 24 hours the transfection medium was
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replaced with fresh medium containing the necessary stimulus for the experiment and 
incubated for a further 18 hours.
2.7.3 Reporter gene analysis
The medium was removed and the cells washed in PBS before the addition of 500pl 
of lysis buffer (supplied in Dual-Glo luciferase assay kit (Promega, UK)) per well. 
After a 15 minute incubation at room temperature, adherent cells were removed by 
scraping and the resultant supernatant transferred to an eppendorf tube, where each 
sample was vortexed to ensure complete lysis. 2 0 pl of each cell lysate was 
transferred to a white luminmetric 96-well plate, luciferase activity was assayed using 
the Dual-Glo luciferase assay kit as outlined in the manufacturer’s protocol. Briefly, 
lOOpl of Luciferase Assay Reagent II was added to each sample, immediately after 
this the luminescence of each well was read for 1 0  seconds using a luminometer 
(FLUOSTAR Optima, BMG Labtechnologies GmbH, Offenburg, Germany). lOOpl 
Stop n’ Glo reagent was then added to each well and Renilla luminescence recorded 
as before.
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2.8 Electrophoretic mobility shift assays (EMSA)
2.8.1 Generating nuclear extract from HPMC
HPMC were grown to confluence in T25 tissue culture flasks, growth arrested 
(Section 2.2.1.4) then treated with the desired stimulants over a designated time 
course. Cells were washed and scraped into ice cold PBS and pelleted by 
centrifugation. The cells were resuspended in buffer A (lOmM HEPES, 1.5mM 
MgCl2, lOmM KC1, 0.8pM PMSF, 40 pM Na3V04, 0.2mM NaF, 2pM DTT, 0.025% 
protease inhibitor cocktail (containing 4-(2-aminoethyl)benzenesulfonyl fluoride 
(AEBSF), pepstatinA, E-64, bestatin, leupeptin, and aprotinin) (Sigma-Aldrich, Poole, 
UK), 0.01% (v/v) NP-40) and incubated on ice for 10 minutes. Samples were 
centrifuged (13,000g, 5mins, 4°C), the supernatant collected (cytosolic extract), and 
the pellet resuspended in buffer B (20mM HEPES, 40mM NaCl, 1.5mM MgCl2, 
0.2mM EDTA, 25% glycerol, 0.8pM PMSF, 40 pM Na3V04, 0.2mM NaF, 2pM 
DTT, 0.025% (w/v) protease inhibitor cocktail (Sigma-Aldrich, Poole, UK)) and 
incubated on ice for 20 minutes for high salt extraction of nuclear proteins. Cell 
debris was removed by centrifugation (conditions as before); the supernatant (nuclear 
extract) was stored at -70°C. Protein concentrations were determined as outlined in 
Section 2.8.3.
2.8.2 Generating nuclear extract from murine peritoneal membrane sections
Nuclear protein was extracted from snap frozen peritoneal membrane sections taken 
during in vivo experiments. Membrane sections were kept frozen on dry ice, each was 
submerged in liquid N2 in a mortar and ground to a powder with the pestle. The tissue 
extracts were collected and suspended in buffer A and incubated on ice for 30 
minutes. Samples were centrifuged (13,000g, 5mins, 4°C), the supernatant collected 
and the pellet resuspended in buffer B, before being incubated on ice for 30 minutes. 
Cell debris was removed by centrifugation; the supernatant (nuclear extract) was 
stored at -70°C.
2.8.3 Estimation of protein concentration
The protein concentration of the nuclear extract was determined using the Bio-Rad 
protein assay (Bio-Rad Laboratories, Hemel Hempstead, UK). Protein concentration 
was determined by direct comparison with BSA (bovine serum albumin fraction V) 
standards diluted in buffer B, ranging from 0-1 mg/ml. Protein standards and samples
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diluted appropriately in buffer B (10pl total volume), were loaded in duplicate on a 
96-well plate before addition of 40% (v/v) dye binding reagent (Bio-Rad 
Laboratories, Hemel Hempstead, UK). Absorbance was read at 450nm (FLUOSTAR 
Optima, BMG Labtechnologies GmbH, Offenburg, Germany), concentrations were 
deduced using the logarithmic relationship between the standards and their 
absorbencies.
2.8.4 Radio-labelling double-stranded oligonucleotide probes with 32Phosphorous
All work involving radioactive material was performed behind a perspex shield. 
Double stranded oligonucleotide primers (sequences outlined in Table 2.7) were 
labelled using an end-labeling technique. Complementary oligonucleotide sequences 
were annealed so as to create overhanging 5’ single stranded sequences (identified by 
lower case in 5’-3’ sequences described in Table 2.7). Primers were annealed at a 
concentration of lOOng/ml in the presence of 10% 1M NaCl at 95°C for 10 minutes. 
The annealed probe was cooled slowly overnight and stored at -20°C.
Transcription
factor
Orientation Sequence
NFkB Forward 5’-gaTCCATGGGGAATTCCCC-3’
Reverse 5 ’-gaGGGGAATTCCCCATGGA-3 ’
SIE(M67) Forward 5 ’-cgaCATTTCCCGTAAATCG-3 ’
Reverse 5 ’ -cgaCGATTT ACGGGAAAT G-3 ’
NF1 Forward 5 ’-gaTCTTTTGGATTGAAGCCAATATGATAA-3 ’
Reverse 5’-gaTCTTATCATATTGGCTTCAATCCAAAA-3’
Table 2.7. Oligonucleotide sequences used for probe preparation for all EMSA 
analysis. Transcription factor binding motifs are shown in bold type.
The labeling reaction was prepared as follows: oligonucleotide probe (25ng), dNTP 
mix (dATP, dCTP, dGTP) (2.5mM each), 10X Klenow buffer (500mM Tris-HCl, 
pH7.2, lOOmM MgSC>4 , ImM DTT) (Promega, Southampton, UK), NaCl (1M) made 
up to 46pl with RNA grade H2 O. Binding of 30pCi of a-[3 2P]dTTP (GE Healthcare, 
Chalfont St Giles, UK) (30pCi) was catalysed by 2U of Klenow fragment (DNA
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Polymerase I Large) (Promega, Southampton, UK). The reaction was incubated at 
room temperature for 1 hour, after which time the reaction was stopped by the 
addition of EDTA (0.5M, pH8 ) and STE (lOOmM NaCl, lOmM Tris-HCl, ImM 
EDTA, pH8 ). Probes were purified from any free contaminating radioactivity using 
size exclusion columns (GE Healthcare, Chalfont St Giles, UK) and stored at -80°C.
2.8.5 Gel preparation
All samples were run on vertical 8 % (w/v) polyacrylamide gels (cast and run on 
Hoeffer Sturdier gel apparatus), the composition of which are outlined in Table 2.8. 
Loading wells were washed with 0.5X TBE (Tris-Boric Acid EDTA, running buffer) 
prior to use.
Distilled H2O 44.25ml
40% Acrylamide/Bis-acrylamide (29:1) 15ml
5X TBE* 7.5ml
50% Glycerol 7.5ml
10% Ammonium Persulphate (APS) 0.75ml
TEMED 0.06ml
* 5X TBE (0.45M Tris-HCl, 0.45M Boric acid, 0.01M EDTA, pH8 )
Table 2.8. Composition of 8% (w/v) polyacrylamide gels.
2.8.6 Analysis of DNA-protein complexes by electrophoresis
Experiments evaluated formation of protein-DNA complexes which showed restricted 
electrophoretic mobility. The binding reaction consisted of 5X binding buffer (50mM 
HEPES, 250mM KC1, 50% glycerol, 1 mg/ml acetylated BSA, 5mM DTT, ImM 
PMSF) (1/5 final volume), poly dl/dC (lmg/ml), nuclear extracts (2pg HPMC, lOpg 
peritoneal membrane extract) and RNA grade H2 O (to final volume minus 2pi). After 
a 10 minute incubation (RT) to allow blocking of non-specific binding sites, 
radiolabelled oligonucleotide probe containing a binding motif for a transcription 
factor was added. Samples were incubated with the probe for a further 20 minutes 
prior to loading onto the gel. Gels were run at 180V for 3hrs 30 minutes, then 
transferred to 3M Whatman paper and dried on a vacuum drier at 80°C for 2 hrs.
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Dried gels were exposed to X-ray film (GE Healthcare, Chalfont St Giles, UK) (6 hrs 
to overnight at -80°C) and developed by autoradiography.
2.8.6.1 Supershift analysis of individual subunits
Supershift analysis utilises antibodies to define the protein composition of individual 
transcription factor subunits in the DNArprotein complex. If the subunit is present, 
antibody binding to the protein bound with the probe will either directly block DNA 
binding or result in formation of a larger complex and will migrate slower upon gel 
electrophoresis (the supershift). Briefly, nuclear extracts were incubated (20 mins, 
RT) with antibodies against NF-kB subunits and ST AT subunits (as described in 
Table 2.10) prior to the addition of radio-labelled probe.
Transcription factor Subunit Clone Concentration
NF-kB p50 NL2 2 0 ng/ml
p52 C5 2 0 ng/ml
p65 A 2 0 ng/ml
c-Rel N-466 2 0 ng/ml
SIE(M67) STAT1 M-22 2 0 ng/ml
STAT3 C-20 2 0 ng/ml
STAT5 C-17 2 0 ng/ml
Table 2.10. Antibodies used for human and murine supershift analysis and 
optimal concentrations used. All antibodies were purchased from Santa-Cruz 
Biotechnology, Santa Cruz, CA.
2.8.7 Densitometry and standardisation of temporal changes
Quantification of banding intensity was performed for each individual time point 
using the Bio-Rad gel documentation system (Section 2.5.3) and QuantityOne 
software. For HPMC stimulations, temporal changes in IL-ip-mediated transcription 
factor activation following co-stimulation with OSM is expressed as a ratio of the 
banding intensity of IL-lp stimulation alone. In vivo transcription factor activation in 
OSMR-KO mice was expressed as a ratio of the banding intensity seen in WT mice at 
each time point.
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2.9 Enzyme-linked immunosorbent assays (ELISA)
Cell culture supernatant and murine peritoneal lavage fluid were assayed for cytokine 
and chemokine concentrations in accordance with the BD OptEIA™ (murine CCL2, 
KC/CXCL1, IL-6 , IL-lp; human CCL2, CXCL8 , CXCL9 and CXCL10) or the R&D 
Systems Duoset (murine CCL3, CCL4 and CCL5; human IL-6 , CCL5 and CXCL11) 
ELISA protocols. For specific antibody dilutions and concentrations see Table 2.11.
Species Chemokine
/Cytokine
Primary 
capture Ab 
concentration 
/dilution
Secondary 
detection Ab 
concentration 
/dilution
Top standard 
concentration
Limit of 
detection
Human CCL2 1/250 1/500 500pg/ml 7.8pg/ml
CCL5 lpg/ml 2 0 ng/ml lOOOpg/ml 15.1pg/ml
CXCL8 1/250 1/250 2 0 0 pg/ml 3.1pg/ml
CXCL9 1/250 1/250 2 0 0 0 pg/ml 31.3pg/ml
CXCL10 1/250 1/250 500pg/ml 7.8pg/ml
CXCL11 lpg/ml 2 0 0 ng/ml 500pg/ml 7.8pg/ml
IL- 6 2 jig/ml 2 0 0 ng/ml 600pg/ml 9.1pg/ml
Murine CCL2 1/250 1/250 lOOOpg/ml 15.1pg/ml
CCL3 0.4pg/ml lOOng/ml 500pg/ml 7.8pg/ml
CCL4 2 pg/ml lOOng/ml lOOOpg/ml 15.1pg/ml
CCL5 2 pg/ml 400ng/ml 2 0 0 0 pg/ml 31.3pg/ml
CXCL1 2 pg/ml 2 0 0 ng/ml lOOOpg/ml 15.1pg/ml
IL-lp 1/250 1/250 2 0 0 0 pg/ml 31.3pg/ml
IL- 6 1/250 1/250 lOOOpg/ml 15.1pg/ml
Table 2.11. Antibody concentrations and samples used for commercial ELISA 
kits. Kits supplied by R&D Systems and BD Biosciences.
Briefly a 96-well micro-titre plate (Immulon 4HBX, Thermo Life Sciences Ltd) was 
coated with specific monoclonal capture antibody (lOOpl per well) and incubated 
overnight. After each step the plate was washed using 0.05% (v/v) Tween 20 in PBS
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on a wellwash 4 automatic plate washer (Thermo Life Sciences Ltd). Plates were 
blocked for 1 hour with assay diluent (3% (w/v) BSA in PBS) (200pl per well), then 
washed prior to incubation with the samples and standards, followed by a 2  hour 
incubation at room temperature (samples were diluted to an appropriate 
concentration). Each well was washed again before addition of working detection 
solution (specific biotinylated monoclonal antibody and streptavidin-horseradish 
peroxidase conjugate) (lOOpl per well) and further 1 hour incubation. Immuno- 
reactivity was detected by the addition of substrate solution (Sureblue TMB 
(3,3 ’,5,5 ’ -tetramethylbenzidine) substrate, KPL), once the required colour change had 
been observed, the reaction was stopped by the addition of 2M H2 SO4 . The 
absorbance of each sample was read at 450nm (FLUOSTAR Optima, BMG 
Labtechnologies GmbH, Offenburg, Germany). Concentrations were deduced using 
the logarithmic relationship between the standards and their absorbencies.
2.9.1 Murine OSM ELISA development
Murine OSM levels were quantified using an ELISA system developed using 
0.8pg/ml goat anti-mouse OSM polyclonal IgG (AF-495-NA, R&D Systems, 
Abingdon, UK) as a capture antibody and 200ng/ml biotinylated goat anti-mouse 
OSM polyclonal IgG (BAF495, R&D Systems, Abingdon, UK) as a secondary 
antibody. Concentrations of OSM were quantified against murine OSM (495-MO- 
025, R&D Systems, Abingdon, UK) as a protein standard. Antibody concentrations 
were optimised using a ‘chequerboard’ design, as outlined in Figure 2.6. The ELISA 
protocol was followed as described in Section 2.9.
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Figure 2.6 Optimisation of murine OSM ELISA using individual antibodies 
supplied by R&D Systems.
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Fig 2.6. Murine OSM ELISA design. A plate was coated with goat anti-mouse 
polyclonal IgG diluted to the designated concentrations (0.2, 0.4 and 0.8pg/ml) in 
PBS and incubated at RT overnight. The plate was washed prior to the addition 
of recombinant murine OSM diluted to 1, 2 and 4ng/ml in 1% (w/v) BSA in PBS 
and incubated at RT for 2 hours. Again, the plate was washed prior to 
incubation with biotinylated goat anti-mouse polyclonal IgG diluted to the 
designated concentrations (50, 100, 200 and 400ng/ml) in 1% (w/v) BSA in PBS 
for 2 hours. Immuno-reactivity was quantified by the addition of streptavidin-
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horseradish peroxidase conjugate and TMB substrate. The absorbance of each 
sample was read at 450nm. As demonstrated, optimum conditions were 
observed using 0.8pg/ml capture antibody and 200ng/ml detection antibody.
2.10 Statistical analysis
Statistical analyses were performed using the Student’s Mest. A P-value of <0.05 
was considered significant. All data represent mean ± SEM. The number of repeats 
for each experiment is shown in the appropriate figure legends.
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Chapter 3
Defining the receptor signature for gpl30- 
related cytokines in mesothelial cells and 
leukocyte subsets
3.1 Introduction
Previous work has demonstrated a role for the Interleukin (IL)-6-related cytokine 
OSM in stromal cell activation, leukocyte recruitment and tissue injury (Wahl et al, 
2001; Wallace et al, 1999; Modur et al, 1997; Urn et al, 2000), however, the role of 
OSM in the progression of acute inflammation has not been extensively studied. This 
Chapter aims to examine the ability of OSM to mediate expression of chemokines and 
adhesion molecules by both HPMC and peripheral blood leukocytes.
To examine the cytokine network governing leukocyte trafficking during acute 
inflammation studies adopted the peritoneal cavity as a site in which to investigate the 
role of OSM. The peritoneum represents an easily accessible cavity, which can 
periodically become susceptible to bacterial infections (peritonitis) as a consequence 
of perforated appendicitis, rupture of the cavity wall or complications from gastric 
ulcers. However, bacterial peritonitis is a frequent complication in end-stage renal 
failure patients undergoing peritoneal dialysis treatment (Section 1.10). The primary 
cell types involved in driving the initial inflammatory response within the peritoneal 
cavity are peritoneal mesothelial cells lining the peritoneum, and smaller populations 
of resident macrophages and lymphocytes which play an important role in immune 
surveillance and initiation of an inflammatory response (Goldstein et al, 1984; Topley 
et al, 1996).
The role of IL-6 in the progression of acute inflammation, has been extensively 
studied and shown to be mechanistically reliant upon IL-6 trans-signalling and the 
transcription factor STAT3 (Hurst et al, 2001; McLoughlin et al, 2003; McLoughlin 
et al, 2005; Fielding et al, 2008). During episodes of acute inflammation, the primary 
source of sIL-6R is from infiltrating neutrophils which shed membrane-bound 
receptor as a consequence of apoptosis or inflammatory activation by chemokines and 
other chemotactic regulators (Hurst et al, 2001; Marin et al, 2001; Chalaris et al, 
2007). In addition infiltrating neutrophils produce and secrete OSM suggesting OSM 
may also be important in the progression of the immune response (Hurst et al, 2002). 
Although less extensively studied, previous work has shown that OSM can induce 
expression of pro-inflammatory mediators including IL-6 and CCL2, and also regulate 
expression of IL-1-induced neutrophil chemoattractants such as CXCL5, CXCL6 and
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CXCL8 in a similar manner to that exhibited by IL-6 (Modur et al, 1997; Hurst et al, 
2002; Cross et al, 2004; McLoughlin et al, 2004).
Due to the short-lived and synergistic nature of the cytokine network, many cytokines 
are subject to a functional hierarchy with certain factors eliciting comparable 
outcomes. In this respect, several of the IL-6-related family of cytokines have been 
shown to promote similar activities. However, each individual cytokine also has its 
own set of biological properties. This redundancy may be explained by the cellular 
expression of each specific receptor subunit. Although gpl30 is ubiquitously 
expressed, cognate receptor subunits to the various cytokine family members 
including LIFRp and OSMRp show distinct expression patterns (Ernst & Jenkins, 
2004). Previous work using peritonitis as an inflammatory model has demonstrated a 
lack of LIFRp expression on both peripheral blood leukocytes and HPMC, however 
HPMC express OSMRp (Hurst et al, 2002). This, taken in combination with the 
release of OSM from infiltrating neutrophils, suggests a role for OSM in the 
progression of peritoneal inflammation potentially in a similar manner to that seen in 
response to IL-6 trans-signalling due to the previously observed similarities in 
chemokine regulation between the two cytokines (Langdon et al, 1997; Hartner et al, 
1997; Hurst et al, 2002).
This chapter aims to examine expression of IL-6-related cytokine specific a-chains, 
LIFRp, OSMRp and IL-31Ra on HPMC, as the primary cell type orchestrating the 
immune response within the peritoneal cavity. Expression of OSMRp and IL-31Ra 
on peripheral blood leukocytes before and after activation with IFN-y and LPS 
(Nathan et al, 1983) will be determined. In addition the effect of OSM and IL-31 on 
HPMC and peripheral blood leukocytes before and after LPS and IFN-y activation 
will be examined. This will provide a basis for examining the role of OSM in 
peritoneal inflammation and also determine any potential role for IL-31 during acute 
inflammation.
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3.2 Materials and Methods
3.2.1 Flow cytometric analysis of receptor expression on unstimulated HPMC
HPMC were isolated from consenting patients undergoing elective surgery as 
described in Section 2.2.1.1. Monolayers were grown to confluence prior to growth 
arrest (Section 2.2.1.4). Cells were collected by scraping into ice cold PBS, washed 
and resuspended in FACS buffer (Section 2.4). To determine the expression of IL-6- 
related cytokine receptor expression, cells were incubated with antibodies against the 
extracellular portion of IL-6Ra, LIFRp, gpl30, OSMRp or an appropriate isotype 
control (Section 2.4.2). Cells stained with antibodies against OSMRp and the isotype 
control were washed then incubated for a further 30 minutes with a phycoerythrin- 
conjugated secondary antibody. Cells were washed and resuspended in FACS buffer 
before cell surface receptor expression analysis by flow cytometry (Section 2.4.1).
3.2.2 Flow cytometric analysis of receptor expression on freshly isolated 
peripheral blood leukocytes
Blood leukocytes were isolated from healthy volunteers as described in Section 2.2.3. 
Isolated neutrophils and PBMC were resuspended in FACS buffer at a concentration 
of 2xl06 cells/ml, prior to blocking for 30 minutes with block buffer (see Sections
2.4.1 and 2.4.2). Leukocyte subsets were identified by expression of specific pan 
leukocyte cell markers (CD3 and CD4 (T cells), CD 14 (monocytes) and CXCR1 
(neutrophils)) (see Section 2.4.2). In addition to the leukocyte-specific markers, cells 
were co-stained with antibodies against the extracellular portion of LIFRp, gpl30, 
OSMRp or a specific isotype control, as outlined in Table 3.2.1 (conditions of use 
outlined in Table 2.2). Again, cells were washed and resuspended in FACS buffer 
before cell surface receptor expression analysis by flow cytometry (Section 2.4.4).
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Leukocyte
subset
Pan-leukocyte
marker
Flouro-
chrome
Co-stain Flouro-
chrome
Secondary
antibody
Monocyte CD14 FITC OSMRP N/A RPE-goat (ab’)2
LIFRp PE N/A
gpl30 PE N/A
Mouse IgGi N/A RPE-goat (ab’)2
Neutrophil CXCR1 FITC OSMRP N/A RPE-goat (ab’)2
LIFRp PE N/A
gpl30 PE N/A
Mouse IgGi N/A RPE-goat (ab’)2
Lymphocyte CD3 FITC OSMRP N/A RPE-goat (ab’)2
LIFRP PE N/A
gpl30 PE N/A
Mouse IgGi N/A RPE-goat (ab’)2
T cell CD4 PE-Cy5 OSMRp N/A RPE-goat (ab’)2
LIFRP PE N/A
gpl30 PE N/A
Mouse IgGi N/A RPE-goat (ab’)2
Table 3.2.1. Combinations of antibodies used to determine gpl30, OSMRp and 
LIFRp expression on leukocyte subsets. Cell staining was quantified by FACS 
analysis, performed as previously described (Section 2.4.1). (FITC - flourescein 
isothiocyanate, PE - phycoerythrin, PECy5 -  phycoerythrin cyano-5).
3.2.3 Reverse-transcription PCR analysis of receptor expression on unstimulated 
HPMC
Total cellular RNA was isolated from growth arrested HPMC using TRI reagent and 
reverse transcribed into complementary DNA (cDNA) (Section 2.5). PCR was 
performed using forward and reverse primers for IL-1 IRa and IL-31Ra as outlined in 
Section 2.6.
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3.2.4 Stimulation of HPMC with OSM and subsequent quantification of induced 
cytokines and chemokine production
Growth arrested HPMC (Sections 2.2.1.1, 2.2.1.2 and 2.2.1.4) were stimulated (37°C, 
5% CO2 ) with defined doses of human recombinant OSM (R&D Systems, Abingdon, 
UK) in serum free medium. Dose- and time-dependent experiments were performed 
as outlined in the appropriate Figure Legends. Cells stimulated with recombinant 
human IL-lp (R&D Systems, Abingdon, UK) (50pg/ml, chosen based on the levels 
quantified in vivo and was shown to elicit robust chemokine induction in vitro) or 
IFN-y (500U/ml, chosen in response to previous dose response experiments (Robson 
et al, 2001)) (R&D Systems, Abingdon, UK) were used as a positive control. 
Unstimulated controls (cells treated with fresh serum free medium) provided baseline 
measurements for all mediators tested. Following stimulation culture supernatant was 
removed and rendered cell free by centrifugation. Levels of CCL2, CCL5, CXCL8, 
CXCL9, CXCL10, CXCL11 and IL-6 were quantified by ELISA (Section 2.9).
3.2.5 In vitro activation of PBMC with a combination of LPS and IFN-y
PBMC were isolated from whole blood (Section 2.2.3) and resuspended in serum free 
supplemented medium at a concentration of 2xl06 cells/ml. Cells were allowed to 
adhere for 2 hours in 12 well plates and subsequently activated overnight with a 
combination of LPS (lOng/ml) and IFN-y (500U/ml).
To assess the induction of OSMRp on ‘LPS/IFN-y-activated’ PBMC, cells were 
stimulated overnight with either OSM (30ng/ml) or IL-31 (50ng/ml). CCL2 levels in 
cell-free culture supernatant were quantified by ELISA (Section 2.9). Cells were 
collected by scraping into ice cold PBS and flow cytometry used to assess surface 
expression of OSMRp and IL-31 Ra (Section 2.4.2). Total cellular RNA was 
extracted for PCR analysis of IL-31 Ra expression (Sections 2.5 and 2.6).
3.2.6 Analysis of adhesion molecule expression on stimulated HPMC
Confluent HPMC were growth arrested (Section 2.2.1.4) and stimulated overnight 
with OSM (30ng/ml), IL-1 (50pg/ml) or TNFa (lOOpg/ml). Cells were harvested and 
incubated with antibodies against the extracellular portions of ICAM-1 and VCAM-1 
and an appropriate isotype control (conditions used are outlined in Table 2.2) for 1 
hour. Cell staining was quantified by flow cytometry (Section 2.4.1).
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3.3 Results
3.3.1 Receptor expression on HPMC at basal levels
Due to the central importance of HPMC in orchestrating cytokine production during 
peritoneal inflammation, cytokine receptor expression on HPMC was evaluated to 
determine which IL-6-related cytokines potentially govern mesothelial cell responses 
during inflammatory processes.
IL-6-related cytokines signal through a receptor system utilising at least one subunit 
of the ubiquitously expressed signal transducing receptor gpl30. As outlined in 
Section 1.8.1, signalling via gpl30 can either occur through a gpl30 homodimer 
complex, or via interaction with a secondary subunit as a heterodimeric receptor 
complex. To examine the potential of HPMC to trigger signalling events through 
these distinct modes of gpl30 activation, studies evaluated the expression of receptor 
subunits that direct gpl30-mediated responses in HPMC. As previously determined, 
HPMC do not express IL-6Ra (Hurst et al, 2001), however expression of IL-llRa 
was detected (Figure 3.3.1). In addition to gpl30 homodimers, two additional 
receptor complexes utilising gpl30 exist, comprising one subunit of gpl30 associated 
with either OSMRp or LIFRp. A variety of IL-6-related cytokines utilise 
LIFRp:gpl30 receptor complexes, including OSM, LIF, CNTF and CT-1, however, 
HPMC do not express LIFRp (Figure 3.3.1) therefore are unable to respond to these 
cytokines. As previously demonstrated HPMC express OSMRp (Figure 3.3.1) and 
are therefore able to respond directly to OSM.
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Figure 3.3.1 IL-6-related receptor expression on HPMC
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Fig 3.3.1. IL-6-related receptor expression on HPMC. A, demonstrates 
forward/side scatter of HPMC at passage 2. Stained samples were 
compared to isotype controls and secondary antibody controls (B). Growth 
arrested HPMC were incubated with antibodies against gpl30, OSMR, 
IL-6R and LIFR (C), the calculated mean fluorescence for each receptor, 
compared to the isotype control, can be seen in panel D. IL -llR a 
expression was quantified by RT-PCR (E). Data represents mean +/- SEM 
of three independent primary isolates.
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3.3.2 OSM selectively regulates inflammatory chemokine production, but not 
that of IL-6
It has previously been reported that OSM, released from infiltrating neutrophils 
during episodes of acute inflammation, is able to regulate secretion of IL-6 (Brown et 
al, 1991), which has been suggested as a contributing mechanism for OSM 
involvement in the control of leukocyte trafficking (Hurst et al, 2002). However, 
when IL-6 production in response to OSM was assayed, no significant increase in 
IL-6 was observed in either a dose- or time-dependent manner (Figure 3.3.2).
Studies have previously demonstrated the ability of OSM to upregulate expression of 
the mononuclear cell chemoattractant CCL2 in HPMC (Hurst et al, 2002). Figure
3.3.3 confirms these previous observations and shows that OSM treatment stimulates 
both a dose- and time-dependent upregulation of CCL2, which due to the magnitude 
and reproducibility of this response will be used as a positive control for further 
experiments. To further examine the potential ability of OSM to regulate mononuclear 
cell trafficking, production of two additional mononuclear chemoattractants, CCL3 
and CCL5, was assayed. However, no increase in production of either CCL3 or 
CCL5 was observed in response to OSM (Figure 3.3.3). OSM stimulation also had 
minimal effects on the T cell chemoattractants CXCL9, CXCL10 and CXCL11 
(Figure 3.3.4), with only CXCL10 production observed in response to high 
concentrations of OSM. The induction of CXCL10 by OSM, was however minimal 
when compared with the archetypal activator of CXCL10, IFN-y (Figure 3.3.4). In 
addition OSM does not induce expression of the neutrophil chemoattractant CXCL8 
(Figure 3.3.5).
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Figure 3.3.2 OSM does not regulate IL-6 expression in HPMC
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Fig 3.3.2. Growth arrested HPMC were stimulated with increasing doses of 
OSM for 18 hours, or with 30ng/ml OSM for increasing time periods. IL-6 
expression was quantified in the culture supernatant by ELISA, OSM 
treated cells were compared to IL-lp (50pg/ml) stimulated cells or non­
stimulated control cells. Data represents mean +/- SEM of three 
independent primary isolates (*p<0.05).
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Figure 3.3.3 OSM selectively increases expression of the monocyte 
chemoattractant CCL2 in HPMC
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Fig 3.3.3. OSM selectively induces expression of CCL2. Growth arrested 
HPMC were stimulated with increasing doses of OSM for 18 hours, or with 
30ng/ml OSM for increasing time periods. CCL2 (A), CCL3 and CCL5 (B) 
expression was compared to IL-lp (50pg/ml) stimulated cells or non­
stimulated control cells. Chemokine expression in the culture supernatant 
was quantified by ELISA. Data represents mean +/- SEM of three
independent primary isolates (*p<0.05).
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Figure 3.3.4 OSM selectively increases expression of the T cell 
chemoattractant CXCL10 in HPMC
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Fig 3.3.4. OSM control of ELR CXC chemokines. CXCL9, CXCL10 and 
CXCL11 expression in HPMC was quantified after overnight stimulation 
with OSM (0-30ng/ml) or IFN-y (500U/ml) (A, C, D), or OSM (30ng/ml) 
compared to non-stimulated control cells over a time course (B, E). Data 
represents mean +/- SEM of three independent primary isolates (* p<0.05).
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Figure 3.3.5 OSM does not increase expression of the neutrophil 
chemoattractant CXCL8 in HPMC
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Fig 3.3.5. Growth arrested HPMC were stimulated with increasing doses of 
OSM for 18 hours, or with 30ng/ml OSM for increasing time periods. 
CXCL8 expression in the culture supernatant was quantified by ELISA, 
OSM treated cells were compared to IL-lp (50pg/ml) stimulated cells or 
non-stimulated control cells. Data represents mean +/- SEM of three 
independent primary isolates (*p<0.05).
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3.3.3 OSM selectively promotes expression of the adhesion molecule VCAM-1
In addition to regulating chemokine expression, IL-6-related cytokines can also 
control leukocyte trafficking by controlling expression of adhesion molecules (Modur 
et al, 1997; Oh et al, 1998). Previous work has illustrated OSM induced upregulation 
of intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1) in endothelial cells (Modur et al, 1997 Fritz et al, 2006; Fearon et al, 
2006). Stimulation with OSM significantly increases surface expression of VCAM-1 
but not ICAM-1 on HPMC, which remains comparable to that observed in 
unstimulated cells (Figure 3.3.6). VCAM-1 is associated with the adhesion of a 
variety of mononuclear cells including monocytes and T cells, whereas ICAM-1 is 
more closely associated with the adherence of neutrophils (Liberek et al, 1996). The 
ability of OSM to specifically upregulate expression of VCAM-1 on HPMC provides 
further evidence for a role in mononuclear cell trafficking.
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Figure 3.3.6 OSM selectively upregulates expression of the adhesion 
molecule VCAM-1 in HPMC
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Fig 3.3.6. Growth arrested HPMC were treated with OSM (30ng/ml), 
IL-lp (50pg/ml) or TNFa (lOOpg/ml). Cells were stained with FITC 
conjugated antibodies against ICAM-1 (A) or VCAM-1 (B), compared 
back to a FITC conjugated IgG control. Data is representative of three 
independent primary isolates (* p<0.05).
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3.3.4 IL-6 related receptor expression on peripheral blood leukocytes
Inflammation is a highly orchestrated communication system, which links responses 
between stromal tissue cells local to the initial insult and infiltrating leukocytes. 
Studies outlined thus far illustrate that OSM is likely to affect mesothelial cell 
responses within the peritoneal cavity. To examine the potential impact of OSM on 
infiltrating cells, peripheral blood leukocytes were examined for OSMRp expression. 
As shown in Figure 3.3.7, freshly isolated peripheral blood leukocytes do not express 
either OSMRp or LIFRp and are unable to respond to OSM stimulation (assessed by 
production of both CCL2 and IL-6) (Figure 3.3.8) confirming PBMC do not express a 
functional receptor complex for OSM. However, PBMC produce RNA for the 
cognate IL-llRa (Figure 3.3.7) and have previously been shown to express IL-6Ra 
(McLoughlin et al, 2004), implying signalling is only mediated through gpl30 
homodimers on peripheral blood mononuclear cells.
During an inflammatory response macrophages are activated through several distinct 
mechanisms (Section 1.4.1), one of which is the classical pathway where activation is 
achieved through IFN-y and additional TLR activation by microbial products such as 
LPS. Stimulation of peripheral blood leukocytes with LPS in combination with IFN-y, 
promoted expression of OSMRp on the surface of PBMC but not PMN (Figure 3.3.9). 
This process is confined to signalling through TLR4 however, as co-stimulation with 
IFN-y and the TLR2 agonist SES, (a cell-free supernatant derived from the gram 
positive bacterium Staphylococcus epidermidis), failed to induce OSMRp expression 
on either PBMC or PMN (Figure 3.3.9). The TLR4-driven expression of OSMRP 
was functional, and OSM stimulation of these pre-activated PBMC promoted CCL2 
production (Figure 3.3.9).
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Figure 3.3.7 Freshly isolated PBMC express IL -llR a but not LIFRp or OSMRp
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Fig 3.3.7. Leukocyte subsets were gated dependent on their forward-side 
scatter (N-neutrophils, M-monocytes, L-lymphocytes) and expression of pan­
leukocyte markers (A). To identify leukocyte specific expression PBMC 
were incubated with FITC-conjugated antibodies against pan-leukocyte 
markers in combination with PE-conjugated antibodies against either gpl30
(B), LIFRp (C) or OSMRp (D), the percentage of cells expressing these 
receptors (cells in the upper right (UR) quadrant) is demonstrated in Panel 
(E). RT-PCR was performed using primers for GAPDH and IL-11R on 
cDNA isolated from growth arrested PBMC (32 cycles) (F). Data is 
representative of three individual donors.
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Figure 3.3.8 Freshly isolated PBMC are unable to respond to direct OSM
stimulation
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Fig 3.3.8. Isolated PBMC were stimulated with increasing concentrations 
of OSM (0-30ng/ml) for 18 hours. Cell culture supernatants were assayed 
for CCL2 (A) and IL-6 (B) compared to IL-1 (5 (50pg/ml) stimulated cells. 
Data represents mean +/- SEM of three independent PBMC isolates 
(*p<0.05).
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Figure 3.3.9 Induction of OSMRp expression on PBMC
PBMC
A S
CO•*->c
3Oo
□  Control B « - □  Control 6 PBMC T
■i |  — IFN-y -  IFN-y nJ1 — LPS £ - S E S
j . l \ -  IFN-y + LPS c3 SE S + IFN-y o- 3
/jtL
O
o
o  . / \ ................
2
0 l i t II
OSM RP  
PMN
OSM RP
C on tro l□  Control
-  IFN-y
-  LPS
-  IFN-y + LPS
OSMRP OSM RP
O 200
LPS + IFN-y 
+ OSM
Fig 3.3.9. Isolated PBMC and PMN were treated with LPS (50ng/ml) or 
IFN-y (500U/ml) individually and in combination overnight (A). Panel B 
shows an identical experimental set up in which LPS has been replaced 
with the TLR2 agonist SES. Changes in OSMRp were evaluated by flow 
cytometry and compared to isotype and secondary antibody controls. C, 
isolated PBMC were stimulated with LPS and IFN-y alone and in 
combination with OSM (30ng/ml). CCL2 in the culture supernatants was 
assayed by ELISA. All data represents mean +/- SEM of three 
independent PBMC isolates (*p<0.05).
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3.3.5 IL-31Ra expression on HPMC
In addition to the association with gpl30, OSMRp also interacts with the cognate 
IL-31Ra to form a functional receptor complex for IL-31 (Dillon et al, 2004). IL-31 
plays an important role in allergic responses (Dillon et al, 2004; Perrigoue et al, 2007), 
with IL-31 Ra expression detected in several cell types including keratinocytes, lung 
epithelial cells, activated monocytic cells and T lymphocytes (Dreuw et al, 2004). 
Basal IL-31 expression was detected at low levels in OSM stimulated HPMC (Figure 
3.3.10), indicating a potential role for IL-31 in peritoneal inflammation. However, 
RT-PCR analysis showed HPMC do not express IL-31 Ra, and was confirmed by an 
inability of HPMC to produce CCL2 in response to IL-31 (Figure 3.3.10) To control 
for the activity of IL-31, a similar set of experiments were performed using THP-1 
cells (a leukaemic monocytic cell line). As shown in Figure 3.3.10, IL-31 promoted 
CCL2 production by THP-1 cells and subsequent RT-PCR analysis on cDNA isolated 
from THP-1 cells exhibited low level IL-31Ra expression (Figure 3.3.10).
HPMC were however shown to upregulate IL-31 Ra expression following exposure to 
IFN-y, which was further enhanced by additional stimulation with the TLR2 and 
TLR4 agonists SES and LPS respectively (Figure 3.3.11). To substantiate the 
functional relevance of this induction, IL-31-mediated regulation of CCL2 was 
examined in LPS and IFN-y treated HPMC (Figure 3.3.11). As predicted from prior 
RT-PCR and flow cytometry studies (Figure 3.3.11), IFN-y and LPS rendered HPMC 
susceptible to IL-31 stimulation (Figure 3.3.11).
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Figure 3.3.10 HPMC do not express IL-31Ra under basal conditions
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Fig 3.3.10. Regulation of IL-31 responsiveness in HPMC (A). RT-PCR 
was performed using primers for IL-31 on cDNA isolated from OSM 
stimulated HPMC (30 cycles). Densitometry was performed comparing 
each band to the corresponding P-actin control. Expression of IL-31Ra 
on growth arrested HPMC and THP-1 cells was quantified by RT-PCR 
using primers for GAPDH and IL-31 Ra (35 cycles) (B). CCL2 
expression was assayed in the culture supernatants following IL-31 
(50ng/ml), IL-ip (50pg/ml) and OSM (30ng/ml) stimulation overnight 
(C, HPMC; D, THP-1). Data represents mean +/- SEM of three 
independent primary isolates (*p<0.05).
114
Figure 3.3.11 Induction of IL-31Ra expression on HPMC
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Fig 3.3.11. Expression of IL-31Ra on HPMC stimulated with IFN-y 
(500U/ml) alone or in combination with either LPS (50ng/ml) or SES 
overnight was quantified by RT-PCR (35 cycles) (A) and flow cytometry
(B). CCL2 expression was assayed in the culture supernatants, following 
pre-activation with LPS and IFN-y and subsequent IL-31 stimulation
(C). Data is representative of three independent primary isolates 
(*p<0.05).
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3.3.6 Analysis of IL-31Ra expression on PBMC and PMN
Studies on the role of IL-31 in allergic responses have demonstrated expression of 
IL-31 Ra on activated mononuclear cells, corresponding with expression of OSMRP 
but at substantially reduced levels (Dillon et al, 2004). RT-PCR demonstrated that 
freshly isolated PBMC do not express IL-31 Ra, however expression can be induced 
by stimulation with IFN-y (Figure 3.3.12). Changes in IL-31Ra expression on PBMC 
were confirmed by flow cytometry (Figure 3.3.12). Conversely, PMN show no 
alteration in IL-31 Ra expression following IFN-y and LPS stimulation (Figure 3.3.12).
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Figure 3.3.12 Induction of IL-31Ra expression on PBMC
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Fig 3.3.12. Expression of IL-31 Ra on PBMC stimulated with IFN-y (500U/ml) 
alone or in combination with either LPS (50ng/ml) or SES overnight was 
quantified by RT-PCR (35 cycles) (A) and flow cytometry (B). Expression of 
IL-31 Ra on PMN was quantified by flow cytometry after stimulation with LPS 
and IFN-y (C). Data is representative of three independent PBMC isolates.
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3.4 Discussion
Previous studies have outlined a potential role for the gpl30-activating cytokine OSM 
in the development of acute inflammation (Hurst et al, 2002). Using bacterial 
peritonitis as a model in which to study acute inflammation, in vitro studies described 
in this Chapter suggest a role for OSM upregulating expression of inflammatory 
mediators and adhesion molecules thereby aiding leukocyte recruitment in a similar 
manner to that observed in response to IL-6 and its soluble receptor (Hurst et al, 
2001).
Previous studies have demonstrated that IL-6 or OSM can regulate chemokine 
expression in a variety of stromal cells. In many instances, these two gpl30- 
activating cytokines are similar in their capacity to control these inflammatory 
regulators (Modur et al, 1997; Hurst et al, 2002; McLoughlin et al, 2004; Langdon et 
al, 1997). For example, both cytokines demonstrate the ability to upregulate 
expression of the mononuclear cell chemoattractant CCL2, which in the case of IL-6 
aids the progression of inflammation by mediating recruitment of mononuclear cells 
(Hurst et al, 2001; Romano et al, 1997). This shared role taken in combination with 
the observed ability of OSM to upregulate expression of adhesion molecules suggests 
OSM may be of importance in orchestrating leukocyte recruitment and activation 
during acute inflammation.
Acute inflammation is a beneficial response to infection or injury ensuring successful 
resolution of the condition and a return to tissue homeostasis. Pivotal to the 
resolution of inflammation is the transition from innate to acquired immunity, which 
is defined by precise regulation of leukocyte recruitment, activation and clearance 
(Jones, 2005). Previous work using an in vivo model of acute bacterial peritonitis has 
demonstrated the importance of IL-6 in this transition, through control of chemokine- 
driven leukocyte recruitment and regulation of apoptosis (Hurst et al, 2001; 
McLoughlin et al, 2003; McLoughlin et al, 2004; McLoughlin et al, 2005). However, 
previous work based on OSM reconstitution studies in experimental models of disease 
has been unable to determine whether OSM has a beneficial or detrimental effect in 
vivo (Wallace et al, 1999; Langdon et al, 2000; Plater-Zyberk et al, 2001; De Hooge 
et al, 2003).
118
Regulation of OSM activity is governed by the cellular expression of OSMRp. In this 
context, we identified two central events affecting OSM responsiveness. During acute 
inflammation, the primary cell types expressing OSMRp and therefore able to respond 
to OSM are stromal cells, with leukocyte subsets not expressing OSMRp or LIFRp 
(Hurst et al, 2002). However, in response to activation with LPS and IFN-y, OSMRp 
expression can be induced on mononuclear cells, suggesting that in more progressive 
disease OSM may have two distinct modes of action.
As previously mentioned this project uses a model of bacterial peritonitis in which to 
study the inflammatory response. In addition to in vitro analysis of HPMC, 
subsequent studies will also utilise an in vivo mouse model which uses a cell-free 
supernatant derived from S. epidermidis to induce acute peritoneal inflammation. The 
application of OSMRp-deficient mice will help to define the inflammatory role of 
both OSM and IL-31 to disease progression, although in vitro studies suggest that 
IL-31 is not involved in chemokine-directed leukocyte trafficking during acute 
inflammation. However, because factors including IFN-y and LPS can induce 
IL-31 Ra expression, IL-31 may serve an additional role in more progressive forms of 
disease as demonstrated by the involvement of IL-31 in dermatitis and type 2 lung 
inflammation (Dillon et al, 2004; Perrigoue et al, 2007).
In summary, studies outlined in this Chapter implicate OSM, acting through 
OSMRP:gpl30 heterodimers, in the progression of an inflammatory response by 
upregulating mononuclear cell chemoattratants and adhesion molecules. These 
effects are similar to those observed by IL-6 and its soluble receptor. Future chapters 
will aim to delineate the regulatory abilities of OSM, in comparison to those 
previously observed by IL-6 and any differences in signalling pathways initiated 
through activation of gpl30 hetero- and homodimers.
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Chapter 4
OSM-mediated regulation of inflammatory 
chemokine expression in HPMC
4.1 Introduction
Studies outlined in Chapter 3 demonstrate the ability of OSM to selectively upregulate 
expression of inflammatory mediators specific for trafficking of mononuclear cells. 
Many of these activities are shared by IL-6, with IL-6 trans-signalling known to 
govern neutrophil clearance and mononuclear cell recruitment (McLoughlin et al, 
2004; Hurst et al, 2001). This Chapter aims to compare the ability of OSM to 
regulate chemokine expression with those observed by IL-6.
The ability of OSM to modulate chemokine activation has previously been outlined in 
several cell types (Hurst et al, 2002; Richards et al, 1996; Langdon et al, 1997). In 
many instances, these activities closely mirror those exhibited by IL-6 when utilising 
gpl30 homodimeric receptor complexes (McLoughlin et al, 2004; Hurst et al, 2001). 
In vivo studies using IL-6 deficient mice have shown that IL-6-mediated control of 
these processes is pivotal for successful resolution of neutrophil infiltration and the 
development of acquired immunity through increased T cell recruitment (Hurst et al, 
2001; McLoughlin et al, 2005; Jones, 2005). The contribution of OSM to this 
immunological switch, however, has not previously been examined.
Both in vitro and in vivo studies have illustrated the ability of IL-6 signalling, to 
selectively inhibit the IL-lp-induced production of the neutrophil chemoattractants 
CXCL1 and CXCL8, while enhancing secretion of other inflammatory chemokines 
including CCL2 and CCL8 thereby aiding the resolution of the neutrophil infiltration 
and promoting mononuclear cell recruitment (Romani et al, 1997; Hurst et al, 2001; 
McLoughlin et al, 2003; McLoughlin et al, 2004; Jones, 2005). Similar in vitro 
analysis has demonstrated that OSM is able to inhibit IL-lp-directed production of 
CXCL8 and to mediate production of CCL2 (Hurst et al, 2002), consequently OSM 
has the potential to regulate leukocyte trafficking in a similar manner to that of IL-6. 
However, in contrast to IL-6, OSM is able to selectively increase expression of the 
adhesion molecule VCAM-1 (Chapter 3). This data, taken in combination with the 
ability of OSM to upregulate mononuclear cell chemoattractants including CCL2 and 
CXCL10 (Chapter 3) suggests a distinct role for OSM in governing mononuclear cell 
recruitment.
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Studies outlined within this Chapter aim to further examine the ability of OSM to 
regulate the expression inflammatory chemokines. In addition, the ability of OSM to 
regulate downstream signalling pathways will be studied, with an aim to outline the 
mechanisms by which OSM may regulate chemokine-driven leukocyte recruitment.
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4.2 Materials and Methods
4.2.1 Stimulation of HPMC and subsequent quantification of induced cytokines 
and chemokine production
To examine the effects of OSM stimulation on the IL-lp- and IFN-y-induced 
production of inflammatory mediators, growth arrested HPMC (Section 2.2.1.4) were 
stimulated with human recombinant IL-ip (R&D Systems, Abingdon, UK) (at 
concentrations between 0 and 50pg/ml) or human recombinant IFN-y (R&D Systems, 
Abingdon, UK) (at concentrations between 0 and 500U/ml) both alone and in 
combination with 30ng/ml human recombinant OSM (R&D Systems, Abingdon, UK). 
To investigate the effects of IL-31 on IL-ip-induced chemokine production, HPMC 
were first treated with LPS (50ng/ml) and IFN-y (500U/ml) (Section 3.2.5) for 18 
hours and subsequently stimulated with human recombinant IL-ip (at concentrations 
between 0 and 50pg/ml) either alone or in combination with 50ng/ml human 
recombinant IL-31. Unstimulated controls (cells treated with fresh serum free 
medium) were used for all experiments to provide baseline chemokine production.
Following stimulation (37°C, 5% CO2) culture supernatants were removed and 
rendered cell free by centrifugation. Analysis of CCL2, CCL5, CXCL8, CXCL9, 
CXCL10, CXCL11 and IL-6 was performed using commercial ELISA (Section 2.9).
4.2.2 Luciferase analysis of CCL5 promoter constructs
SV40 HPMC were grown to 70% confluence (Section 2.2.2) and transiently 
transfected overnight with 0.9pg CCL5 luciferase promoter constructs in pGL2 and 
0.1 pg Renilla luciferase vector (Section 2.7.2). Cells were washed with PBS then 
stimulated for 24 hours with a combination of PM A (15ng/ml) and Ionomycin (lpM) 
or IL-1 p (1 ng/ml). Medium was removed and the cells lysed prior to luciferase 
analysis (Section 2.7.3).
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4.2.3 EMSA analysis of ST AT and NF-kB activation in response to IL-lp and 
OSM stimulation of HPMC
Nuclear extracts were isolated from HPMC stimulated with IL-ip (50pg/ml) and 
OSM (30ng/ml) alone or in combination (Section 2.8.1). Prior to EMSA analysis, the 
protein concentration was determined as described in Section 2.8.3. EMSA using 
[a- PjdTTP labelled oligonucleotide probes containing consensus sequences for 
NF-kB and total STAT were performed using 2pg of nuclear extract (Section 2.8.6.1). 
Supershift analyses were performed using antibodies against individual transcription 
factor subunits as outlined in Section 2.8.6.2. Quantification of the banding intensity 
was performed for each time point as described in Section 2.8.7.
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4.3 Results
4.3.1 OSM selectively regulates inflammatory cytokine and chemokine 
production
IL-6 signalling through its soluble receptor has been shown to inhibit IL-lp-induced 
production of several ELR+ CXC chemokines, including CXCL1 and CXCL8. In 
accordance with this observation, IL-6 deficient mice show significantly enhanced KC 
and MIP-2 (the functional murine homologues of CXCL1 and CXCL8) expression in 
comparison to wild type animals following induction of peritoneal inflammation, 
which results in increased trafficking of neutrophils into the peritoneal cavity of IL-6 
deficient animals (McLoughlin et al, 2004). We therefore assessed whether OSM 
could elicit similar activities in vitro. Although prior studies had shown that OSM 
could induce IL-6 expression (Brown et al, 1991; Hurst et al, 2002), studies outlined 
in Chapter 3 showed no significant increase in IL-6 expression in HPMC in response 
to OSM. In addition OSM was also unable to regulate the IL-lp-induced production 
of IL-6 (Figure 4.3.1).
Studies in Chapter 3 showed that OSM governs CCL2 expression but not that of 
CXCL8, CCL3 or CCL5. We therefore tested whether OSM could manipulate the 
IL-lp-mediated control of inflammatory chemokines. Consistent with previous 
studies OSM significantly inhibits IL-lp-mediated CXCL8 expression (Figure 4.3.1; 
Hurst et al, 2002; Langdon et al, 1997; Richards et al, 1996). In addition OSM 
selectively controlled expression of mononuclear cell chemoattractants, 
synergistically upregulating CCL2 production by IL-ip (Figure 4.3.1), whilst 
inhibiting IL-lp-induced production of CCL5 (Figure 4.3.1). The observed ability of 
OSM to control expression of CCL5 was in direct contrast to IL-6, which had no 
effect on IL-lp-induced CCL5 expression (Figure 4.3.1).
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Figure 4.3.1 OSM regulates IL-ip-induced chemokine expression
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Fig 4.3.1. Growth arrested HPMC were stimulated with increasing doses of 
IL-ip (0-50pg/ml), either alone or in combination with OSM (30ng/ml) for 
18 hours. Expression of CCL2, IL-6, CXCL8 and CCL5 in the culture 
supernatant was quantified by ELISA (A). Growth arrested HPMC were 
stimulated with IL-ip (0-50pg/ml) either alone or in combination with IL-6 
(lOng/ml) and sIL-6R (50ng/ml) for 18 hours (B). CCL5 expression in the 
culture supernatant was quantified using ELISA. Data represents mean +/- 
SEM of three independent primary isolates (*p<0.05).
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4.3.2 IL-31 is unable to regulate expression of inflammatory chemokines
As mentioned in Chapter 3, the related cytokine IL-31 also utilises OSMRP as a 
P-signalling unit following binding to a cognate IL-31 receptor (Dillon et al, 2004). 
Due to the shared use of the OSMRP subunit by OSM and IL-31 it was important to 
assess the role of IL-31 to fully appreciate the contribution of OSMRp signalling. 
Stimulation of HPMC with IFN-y and LPS induced IL-3 IRa expression enabling cells 
to respond to IL-31 signalling (Chapter 3, Figure 3.3.10). However, unlike OSM, 
IL-31 is unable to suppress IL-lp-induced expression of either CXCL8 or CCL5 by 
HPMC (Figure 4.3.2), suggesting that IL-31 does not share the ability of OSM to 
govern chemokine-driven leukocyte trafficking in this context.
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Figure 4.3.2 IL-31 does not regulate IL-10-induced chemokine expression
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Fig 4.3.2. Growth arrested HPMC were stimulated with increasing doses 
of IL-lp (0-50pg/ml) alone or in combination with IL-31 (50ng/ml) for 18 
hours. Chemokine expression was quantified in the culture supernatant by 
ELISA. This data represents mean +/- SEM of three independent primary 
isolates.
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4.3.3 OSM significantly impairs IL-lp-mediated NF-kB signalling
The inhibition of IL-lp-driven expression of CCL5 by OSM infers that OSM 
signalling may inhibit NF-kB signalling. To assess this, EMSA analysis was 
performed using oligonucleotide probes containing the consensus sequence for 
NF-kB. Analysis of nuclear extracts isolated from HPMC stimulated with IL-1 P and 
OSM demonstrated the ability of OSM to suppress the IL-lp-mediated activation of 
NF-kB (Figure 4.3.3). Stimulation of HPMC with OSM alone did not result in NF-kB 
activation (Figure 4.3.3). Supershift analysis of the protein-DNA complex from IL-1 p 
stimulated cells demonstrated classical activation of the NF-kB pathway, with 
evidence of both p50 and p65 subunits (Figure 4.3.3). OSM-mediated suppression of 
NF-kB activation was not specific for an individual subunit, but globally affected both 
p50 and p65 subunits (Figure 4.3.3).
Conversely, IL-lp had no effect on OSM-mediated STAT activation (Figure 4.3.4). 
Analysis of OSM-induced STAT activation in nuclear extracts isolated from OSM 
and IL-lp stimulated HPMC demonstrated no alteration in total STAT activation in 
comparison to that stimulated with OSM alone (Figure 4.3.4). Supershift analysis of 
the STAT subunits identified a predominant activation of STAT3, whilst STAT1 and 
STAT5 were activated to a lesser extent (Figure 4.3.4).
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Figure 4.3.3 OSM inhibits IL-lp-induced NF-kB activation
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Fig 4.3.3. Temporal activation of NF-kB in nuclear extracts derived from 
HPMC incubated with IL-lp (50pg/ml) and OSM (30ng/ml) alone or in 
combination was monitored by EMSA (A). Alteration in NF-kB induction 
was quantified by densitometry by calculating the ratio of activation 
elicited by OSM and IL-ip, which was compared to activation with IL-ip 
alone (B). Composition of the NF-kB complex was verified by supershift 
analysis of nuclear extracts derived from HPMC cultures. Cells were 
stimulated for 30 minutes as indicated and supershift performed with 
antibodies against p50, p52, p65 and c-Rel subunits (C). Data is 
representative of mean +/- SEM of three individual primary isolates 
(*p<0.05).
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Figure 4.3.4 OSM stimulation upregulates STAT activation in HPMC
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Fig 4.3.4. Temporal activation of STAT in nuclear extracts derived from 
HPMC incubated with IL-lp (50pg/ml) and OSM (30ng/ml) alone or in 
combination was monitored by EMSA (A). Alterations in STAT 
activation were quantified by densitometry by calculating the ratio of 
activation elicited by OSM and IL-lp, which was compared to activation 
with OSM alone (B). Composition of the STAT complex was verified by 
supershift analysis of nuclear extracts derived from HPMC. Cells were 
stimulated for 30 minutes as indicated and supershifts performed using 
antibodies against STAT1, STAT3 and STAT5 (C). Data is 
representative of mean +/- SEM of three individual primary isolates.
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4.3.4 CCL5 promoter construct analysis
Studies into the molecular mechanism of CCL5 expression utilising CCL5 promoter 
sequences have demonstrated that NF-kB upregulates the promoter activity of CCL5 
(Moruichi et al, 1997). Due to the observed OSM-mediated inhibition of 
IL-ip-induced NF-kB activation and parallel suppression of CCL5 in HPMC, further 
analysis using a series of luciferase reporter constructs containing the CCL5 promoter 
sequence was undertaken. Due to difficulties in transfecting primary HPMC, SV40 
transformed HPMC were used in their place. Cells were transfected with luciferase 
reporter constructs containing either the full length CCL5 promoter sequence (R1.4), 
or the full length CCL5 promoter sequence containing mutations in the putative 
binding sites for NF-IL-6 (NFIL-6) or NF-kB (kBI) respectively. These vectors were 
co-transfected with the Renilla luciferase vector, which was used to internally assess 
transfection efficiency. As previously reported in several cell types (Moruichi et al,
1997), stimulation with PMA and ionomycin significantly increased reporter activity 
of the full length promoter sequence, which was inhibited by mutation within one of 
the putative NF-kB binding sites (Figure 4.3.5) thus providing further evidence of the 
importance of NF-kB in promoting CCL5 activity.
Previous work using CCL5 promoter constructs has also shown upregulation of CCL5 
promoter activity in response to stimulation with IL-lp, which is inhibited by 
mutation within the kBI site (Moruichi et al, 1997). However, IL-lp stimulation does 
not appear to significantly upregulate CCL5 promoter activity in SV40 transformed 
HPMC, when compared with unstimulated controls (Figure 4.3.6).
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Figure 4.3.5 Effects of site-directed mutations of CCL5 promoter sequences
on the promoter activity
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Fig 4.3.5. SV40 transformed HPMC were transfected overnight with 0.9pg 
of the indicated plasmid. Cells were either unstimulated or stimulated 
with PMA (15ng/ml) and ionomycin (lpM) for 24 hours. The fold 
increase of luciferase activity of stimulated compared to unstimulated 
cells was calculated. Data is representative of mean +/- SEM of three 
individual experiments performed in duplicate (*p<0.05).
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Figure 4.3.6. The effect of IL-lp stimulation on CCL5 promoter activity
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Fig 4.3.6. SV40 transformed HPMC were transfected overnight with 0.9pg 
of the indicated plasmid. Cells were either unstimulated or stimulated 
with IL-ip (lng/ml) for 24 hours. The fold increase of luciferase activity 
of stimulated compared to unstimulated cells was calculated. Data is 
representative of mean +/- SEM of three individual experiments 
performed in duplicate.
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4.3.5 OSM selectively regulates expression of IFN-y-inducible chemokines
The ability of OSM to regulate expression of CCL5 suggests that in addition to aiding 
monocyte trafficking, OSM may also affect the trafficking of lymphocytes in 
particular lymphocytes with a Thl phenotype. As previously mentioned, CCL5 
utilises chemokine receptors present on a variety of mononuclear cells including Thl 
cells, which express CCR5 (Loetscher et al, 1998). Thl cell trafficking is also reliant 
on another group of chemokines which utilise CXCR3, also expressed on the surface 
of Thl lymphocytes (Loetscher et al, 1998). This group of ELR' CXC chemokines 
are reliant on induction by IFN-y and include CXCL9, CXCL10 and CXCL11. 
HPMC can be induced to selectively express one of these chemokines, CXCL10, in 
response to OSM stimulation (Chapter 3, Figure 3.3.4). In addition, OSM was able to 
significantly inhibit IFN-y-induced production of all three chemokines (Figure 4.3.7). 
These observations provide evidence that OSM, although unlikely to induce T cell 
trafficking, may play some accessory role in controlling the migration of certain T cell 
subsets, again this will require further study in vivo.
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Figure 4.3.7 OSM inhibits IFN-y-induced chemokine production
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Fig 4.3.7. Growth arrested HPMC were stimulated with increasing doses 
of IFN-y (0-500U/ml) alone or in combination with OSM (30ng/ml). 
Chemokine expression was quantified in the culture supernatant by 
ELISA. Data represents mean +/- SEM of three independent primary 
isolates (* p<0.05).
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4.4 Discussion
Studies outlined in this Chapter demonstrate the ability of OSM to regulate IL-lp- 
mediated chemokine expression. Although both IL-6 and OSM suppress CXCL8 
expression, OSM also drives suppression of IL-ip-mediated CCL5 production 
potentially through attenuation of NF-kB activation.
The role of IL-6 in the progression from innate to acquired immunity has been well 
documented (Jones, 2005). Both in vitro and in vivo studies utilising IL-6KO mice 
emphasise that IL-6 trans-signalling, aids the clearance of neutrophils by suppressing 
expression of the neutrophil chemoattractants CXCL1 and CXCL8 (Hurst et al, 2001; 
McLoughlin et al, 2004). As previously shown, OSM is also able to inhibit IL-ip- 
mediated CXCL8 expression, therefore suggesting a similar role for OSM in aiding 
resolution of the neutrophil influx. However, in direct contrast to IL-6, OSM also 
inhibits IL-ip-mediated expression of the mononuclear cell chemoattractant CCL5. 
CCL5 signals via several receptors including CCR1, CCR3 and CCR5 present on the 
surface of monocytes, eosinophils, basophils and activated T cells (Loetscher et al,
1998). Therefore the ability of OSM to control expression of CCL5 may affect 
mononuclear cells globally or be specific for certain subsets. This will be explored in 
more detail in Chapter 5. In addition OSM inhibits the IFN-y-induced expression of 
CXCL9, CXCL10 and CXCL11, which signal via CXCR3 expressed on the surface of 
T cells again implying a potential role for OSM in governing chemokine-driven 
mononuclear cell trafficking.
Studies have outlined a potential mechanism for the OSM-mediated control of CCL5 
expression through attenuation of NF-kB signalling. Parallel EMSA show no 
significant effect of IL-lp on OSM induced STAT activation. Supershift analysis of 
the DNA-protein complex confirms IL-lp mediates classical activation of NF-kB and 
suggests that OSM globally knocks down both the p50 and p65 subunits. It is 
mechanistically unclear whether this response results from co-operative manipulation 
of NF-kB signalling, competition for DNA binding within overlapping consensus 
sites for NF-kB and STAT factors, or NF-kB regulation via cytokine mediated 
increases in unphophorylated STAT3, all of which have been implicated in the gpl30
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control of NF-icB-mediated events (Zhang & Fuller, 1997; Yu et al, 2002; Yang et al, 
2007).
Transcriptional studies using CCL5 reporter constructs will hopefully help to fully 
define the nature of the interaction between OSMRp-mediated signalling and NF-kB 
activation. Initial studies outlined within this Chapter demonstrated the potential 
importance of NF-kB in promoting CCL5 activity. However, transcriptional studies 
were unsuccessful in response to IL-lp stimulation, therefore preventing further 
analysis. Although it is unclear why this was unsuccessful, it could potentially be due 
to the cells used for this experiment. SV40 transformed HPMC retain many of the 
characteristics of primary HPMC (Fischereder et al, 1997), however, the process of 
immortalisation is likely to result in alteration in the cellular responses to cytokine 
stimulation. Therefore these experiments would need to be performed in primary 
HPMC, but due to difficulties in transfecting these cells, this is not currently possible.
In vitro analysis of the regulatory abilities of OSM suggest its ability to govern 
chemokine-driven leukocyte trafficking. Although signalling through OSMRp shares 
some functions with those previously attributed the IL-6-mediated gpl30 homodimer 
activation, for example down-regulation of CXCL8, the ability of OSM to suppress 
the IL-lp-induced expression of CCL5 is clearly distinct from that of IL-6. This, 
taken in combination with the ability of OSM to regulate expression of the Thl 
chemokines CXCL9, CXCL10 and CXCL11 suggests a role for OSM in governing 
mononuclear cell trafficking. The next chapter will utilise OSMRp deficient mice to 
study the effects of OSMRp-mediated signalling on leukocyte recruitment during 
episodes of acute peritoneal inflammation.
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Chapter 5
OSMRp-mediated control of leukocyte 
trafficking during acute inflammatory challenge
5.1 Introduction
Previous chapters have emphasised a potential role for OSM in governing leukocyte 
trafficking through the in vitro upregulation of mononuclear cell chemoattractants 
(CCL2), adhesion molecules (VCAM-1) and the control of IL-lp-directed expression 
of inflammatory chemokines. Using OSMRp deficient (OSMR-KO) mice, this 
chapter aims to further examine the role of OSM-mediated signalling during an acute 
inflammatory response.
Signalling of IL-6-related cytokines is mediated through either gpl30 homodimers, 
initiated by IL-6, IL-11 and IL-27 binding to non-signalling receptor subunits, or 
through gpl30 heterodimerised with either LIFRp or OSMRp, which can be initiated 
by other IL-6-related cytokines including LDF, OSM, CT-1 and CNTF. Unlike human 
OSM, which can utilise both gpl30:LIFRp and gpl30:OSMRp receptor complexes, 
murine OSM has only one functional receptor complex comprised of gpl30 and the 
selective OSMRp, therefore, animals deficient in OSMRp are unable to respond to 
OSM-mediated signalling (Tanaka et al, 1999).
In vitro analysis has highlighted functions for OSM in stromal cell activation, 
leukocyte recruitment and tissue injury (Wahl et al, 2001; Modur et al, 1997). In 
many instances, the effects of OSM are similar to those observed in response to the 
gpl30 activating cytokine IL-6. However, due to the differences in signalling, with 
OSM utilising gpl30 heterodimer complexes and IL-6 utilising gpl30 homodimers, it 
would be expected that activation would result in distinct biological activities. In this 
respect, in vitro studies presented in Chapter 4 emphasise defined differences in the 
control of CCL5 by IL-6 and OSM. Indeed, distinct differences are evident in the 
control of haematopoiesis in OSMR-KO mice, when compared with IL-6KO, 
IL-11KO and LIFR-KO mice (Tanaka et al, 2003; Nandurkar et al, 1997; Escary et al, 
1993). However, such differences are not well defined during inflammation.
Acute inflammation is characterised by an initial influx of neutrophils, which are later 
replaced by a more sustained population of mononuclear cells. The role of IL-6 in the 
progression of inflammation has been well characterised; IL-6, acting via its soluble 
receptor (IL-6 trans-signalling) is responsible for the switch from an innate to an
140
acquired response (Jones, 2005). Both in vitro and in vivo studies have demonstrated 
the ability of IL-6 to suppress chemokine-mediated neutrophil recruitment and 
concurrently promote neutrophil clearance in addition to preventing the apoptosis of T 
cells and upregulating production of mononuclear cell chemoattractants (Hurst et al, 
2001; McLoughlin et al, 2005). The contribution of OSMRp signalling in this 
immunological switch, however, has not been examined. This Chapter demonstrates 
OSM-mediated signalling is able to selectively control monocytic cell trafficking, but 
does not alter clearance and recruitment of neutrophils or lymphocytes. These results 
highlight a clear distinction between gpl30 activation by OSMRp and IL-6R during 
acute inflammation.
141
5.2 Materials and Methods
5.2.1 Generation of SES-induced acute peritoneal inflammation
All animal experiments were performed under Home Office License PPL-30/2269 on 
6-12 week-old WT C57/B16 mice and OSMR-KO mice (see Section 2.3.1).
Peritoneal inflammation was induced using a cell-free supernatant derived from a 
clinical isolate of Staphylococcus epidermidis (SES) as described in Section 2.3.4. 
Experiments were performed on groups of 4-6 age-matched, mixed sex, WT and 
OSMR-KO mice. Peritoneal inflammation was induced by intraperitoneal injection of 
500pl SES, groups of mice were sacrificed at designated intervals and the peritoneal 
cavity lavaged with 2ml ice-cold PBS. Peritoneal membrane sections were also 
collected for subsequent EMSA analysis.
5.2.2 Determination of leukocyte numbers by differential cell count
Leukocytes were isolated from the peritoneal lavage fluid and peripheral blood of 
mice either prior to or after induction of inflammation (Section 2.3.3). Cytospin 
slides were prepared and stained as described in Section 2.3.3. A total of 200 
leukocytes were counted per slide, the percentage of each cell type was multiplied by 
the total number of cells isolated from the peritoneal cavity (as determined by Coulter 
count) to give the relative number of each leukocyte subset.
5.2.3 Flow cytometric analysis of peritoneal leukocytes
Peritoneal leukocytes were isolated (Section 2.3.3) and stained for expression of 
macrophage specific markers (F4/80 and CD lib ) and CCR5 as outlined in Section 
2.4.5. Peritoneal monocytic cells were identified and gated according to forward vs 
side scatter profiles as shown in Figure 5.2.1. To assess the relative cell number of 
each population, the percentage of events present in each gate was multiplied by the 
total number of peritoneal leukocytes isolated from the mouse. CCR5 expression was 
quantified on F4/80+CDllb+ monocytic cells by gating the upper right quadrant and 
assessing CCR5 expression on those cells. All flow cytometry data was compared 
with appropriate isotype controls.
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Figure 5.2.1 Identification of ‘resident-like’ and ‘inflammatory’ peritoneal 
monocytes
CD11b
Fig 5.2.1. Murine peritoneal leukocyte subsets isolated in response to SES- 
induced peritoneal inflammation. Forward vs side scatter enables identification 
of individual leukocyte subsets (R1 -  macrophages, R2 -  monocytes, R3 -  
neutrophils, R4 -  lymphocytes). CDllb and F4/80 staining was quantified on 
peritoneal monocytes (cells in gate R2). Two distinct populations are identified, 
F4/80highCD llbhigh ‘resident-like’ monocytes (R5) and F4/80lowC D llb+ 
‘inflammatory’ monocytes (R6).
5.2.4 ELISA quantification of inflammatory mediators expressed in response to 
SES-induced peritoneal inflammation
Following SES-induced peritoneal inflammation, commercial ELISA was used to 
quantify expression of IL-lp, IL-6, CXCL1/KC, CCL2, CCL3, CCL4 and CCL5 in 
the peritoneal lavage fluid (Section 2.9). Levels of murine OSM were quantified 
using an ELISA system developed using goat anti-mouse OSM polyclonal IgG as a 
capture antibody and biotinylated goat anti-mouse OSM polyclonal IgG as a detection 
antibody (Section 2.9.1).
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5.2.5 EMSA analysis of STAT and NF-kB activation in peritoneal membrane 
sections in response to SES-induced peritoneal inflammation
Nuclear extracts from peritoneal membrane sections were harvested following SES- 
induced peritoneal inflammation (Section 2.8.2). Prior to EMSA analysis, the protein 
concentration was determined as described in Section 2.8.3. EMSA using [a-32P] 
dTTP labelled oligonucleotide probes containing consensus sequences for NF-kB and 
total STAT (SIE m67) were performed using 10pg of nuclear extract as described in 
Section 2.8.6.1. Supershift analyses were performed on the blank (time zero) and 6 
hour time point groups of both WT and OSMR-KO mice using antibodies against 
individual transcription factor subunits (Section 2.8.6.2). Densitometry of the 
banding intensity was quantified for each time point as outlined in Section 2.8.7.
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5.3 Results
5.3.1 OSMR-KO mice show increased monocytic cell trafficking following 
inflammatory challenge
To examine the role of OSMRp signalling during acute inflammatory challenge, 
peritoneal inflammation was induced in WT and OSMRp-deficient (OSMR-KO) mice 
using SES (Section 5.2.1). Prior to assessing the role of OSMRp mediated signalling 
during an acute inflammatory response, baseline leukocyte numbers in both the 
peritoneal cavity and peripheral blood of OSMR-KO mice were assessed and shown 
to be comparable to WT mice (Figure 5.3.1).
As shown in Figure 5.3.2, administration of SES causes an initial influx of neutrophils 
into the peritoneal cavity that was later replaced by a more sustained population of 
lymphocytes and monocytes. Comparative analysis between WT and OSMR-KO 
mice demonstrated that an absence of OSMRp signalling led to a significant increase 
in monocytic cell trafficking into the peritoneal cavity. However, deficiency in 
OSMRp signalling did not appear to affect trafficking of neutrophils or lymphocytes. 
This is in contrast to the response exhibited by IL-6 deficient mice, which display 
increased neutrophil migration but no alteration in monocytic cell trafficking (Hurst et 
al, 2001; McLoughlin et al, 2003; McLoughlin et al, 2005; Hams et al, 2008).
The observed increase in monocyte trafficking was substantiated by flow cytometric 
analysis of F4/80+CDl lb+ cells (Figure 5.3.3). Two distinct populations of monocytic 
cells were identified within the peritoneal cavity: resident-like F4/80hlghCD llbhlgh 
cells, which are the predominant cell type in the peritoneal cavity of mice prior to 
inflammatory challenge, and inflammatory F4/80lowCD llb+ cells, which emerge 
following inflammatory activation. SES stimulation results in an exodus of the 
resident-like monocytes together with in influx of the inflammatory monocytes. 
However, a re-emergence of the resident-like monocytes was observed as 
inflammation progressed (24hrs post-induction). This pattern of monocytic cell 
trafficking was observed in both WT and OSMR-KO mice, however, both populations 
were significantly increased in OSMR-KO mice.
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Figure 5.3.1 Leukocyte numbers are comparable between WT and 
OSMR-KO animals prior to inflammatory challenge
Peritoneal Cavity
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Peripheral B lood
□  WT
■  OSMR-KO
Fig 5.3.1. Baseline leukocyte numbers in WT and OSMR-KO mice. 
Differential cell counts were performed on peripheral blood and peritoneal 
leukocytes isolated from healthy animals. Data represents mean +/- SEM of 
four WT and four OSMR-KO animals.
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Figure 5.3.2 OSMR-KO mice show increased monocyte infiltration 
during SES-induced peritoneal inflammation
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Fig 5.3.2. Peritoneal inflammation was induced in WT and OSMR-KO 
animals by i.p. injection of SES, mice were sacrificed at designated time 
points and differential cell counts performed on peritoneal leukocytes 
isolated from peritoneal lavage fluid. Data represents mean ± SEM of 
twelve WT and twelve OSMR-KO mice for each time point (*p<0.05).
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Figure 5.3.3 OSMR-KO mice show significantly increased monocyte 
trafficking during acute inflammation 
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Fig 5.3.3. SES-induced peritoneal inflammation was established in WT and 
OSMR-KO mice. At designated intervals FACS analysis was performed on 
leukocytes lavaged from the peritoneal cavity, using antibodies against 
F4/80 and CDllb. Representative flow cytometry plots for WT and 
OSMR-KO mice together with temporal changes in the number of 
resident-like F4/80highC D llbhigh monocytic cells (R) and infiltrating 
F4/80,owCDllb+ monocytic cells (I) are shown. Data represents mean +/- 
SEM of four WT and four OSMR-KO mice for each time point (*p<0.05).
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5.3.2 OSMRp mediated signalling selectively controls expression of inflammatory 
chemokines
OSM has previously been detected in the peritoneal fluid of patients with clinical 
peritonitis, the source of which was shown to be infiltrating neutrophils (Hurst et al, 
2002). Analysis of OSM in the peritoneal cavity of WT and OSMR-KO mice 
following SES-induced peritoneal inflammation showed that the initial increase of 
OSM corresponds with the neutrophil influx and OSM levels are comparable between 
WT and OSMR-KO mice (Figure 5.3.4). Expression of IL-1 p and IL-6, two principal 
regulators of inflammatory chemokines, were determined in response to SES-induced 
inflammation. Expression of both increased at between 1 and 3 hours post 
inflammatory induction, with levels comparable between WT and OSMR-KO mice, 
implying that any observed effect of OSM was not due to an aberrant control of these 
cytokines (Figure 5.3.5).
To evaluate the ability of OSMRp signalling to control expression of inflammatory 
chemokines, CXCL1, CCL2 and the CCR5 ligands CCL3, CCL4 and CCL5 were 
quantified in response to SES-induced inflammatory challenge. Expression of CCL5 
was significantly increased in OSMR-KO mice in response to SES challenge; 
however, CCL3 and CCL4 remained consistent between WT and OSMR-KO mice 
(Figure 5.3.6). Studies presented in Chapter 3 highlighted the in vitro control of 
CCL2 by OSM. However, no significant difference in CCL2 was observed between 
WT and OSMR-KO mice (Figure 5.3.6). Expression of CXCL1/KC was also 
significantly decreased in OSMR-KO mice in comparison to WT mice (Figure 5.3.7), 
however as previously mentioned, no corresponding alteration in neutrophil 
trafficking was observed.
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Figure 5.3.4 OSM production in the peritoneal cavity is comparable 
between WT and OSMR-KO mice
1000 1
O WT
•  OSMR-KO
E
600 -&
S(0o
200
9 123 60
Time (hrs)
Fig 5.3.4. SES-induced inflammation was established in WT and OSMR-KO 
mice, and OSM levels in peritoneal lavage fluid quantified using ELISA. 
Data represents mean ± SEM of fifteen WT and fifteen OSMR-KO mice.
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Figure 5.3.5 The temporal expression of IL-lp and IL-6 is unaltered in
OSMR-KO mice
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Fig 5.3.5. SES-induced inflammation was established in WT and 
OSMR-KO mice. Levels of IL-6 (A) and IL-lp (B) in peritoneal lavage 
fluid were quantified using ELISA. Data represents mean ± SEM of twelve 
WT and twelve OSMR-KO mice.
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Figure 5.3.6 OSMR-KO mice display a selective increase in CCL5 
expression following inflammatory activation
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Fig 5.3.6. SES-induced inflammation was established in WT and 
OSMR-KO mice. ELISA was used to quantify CCL2, CCL3, CCL4 and 
CCL5 levels in peritoneal lavage fluid at designated time points. Data 
represents the mean ± SEM of twelve WT and twelve OSMR-KO mice 
(*p<0.05).
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Figure 5.3.7 OSMR-KO mice show decreased CXCL1/KC expression in 
response to inflammatory challenge
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Fig 5.3.7. SES-induced inflammation was established in WT and 
OSMR-KO mice. ELISA was used to quantify levels of CXCL1/KC in 
the peritoneal lavage fluid at designated time points. Data represents 
mean +/- SEM of twelve WT and twelve OSMR-KO mice (*p<0.05).
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5.3.3 OSMRp signalling does not alter expression of the inflammatory chemokine 
receptor CCR5
To determine whether the observed increase in CCL5 corresponds to increased 
monocytic expression of CCR5, flow cytometric analysis was performed on isolated 
peritoneal leukocytes after SES-induced inflammation. Prior to the induction of 
inflammation, resident-like F4/80h,ghCDllbhlgh monocytes are either CCR5,0W or 
CCR5nu11. During the progression of inflammation, F4/80+CDllb+ monocytes 
increase expression of CCR5, implying that activation of monocytes induces 
expression of CCR5. However, no difference in CCR5 expression was observed 
between WT and OSMR-KO mice (Figure 5.3.8).
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Figure 5.3.8 CCR5 expression is comparable on peritoneal monocytes of
WT and OSMR-KO mice
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Fig 5.3.8. SES-induced peritoneal inflammation was established in WT and 
OSMR-KO mice. At designated intervals FACS analysis was performed on 
the peritoneal leukocyte population using antibodies against F4/80, C D llb 
and CCR5. Monocytes were identified and gated through cell surface 
expression of F4/80 and CDllb. CCR5 expression (—) on monocytes is 
compared to corresponding isotype controls (■). Data is representative of 
mean +/- SEM of four WT and four OSMR-KO mice.
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5.3.4 OSMR-KO mice demonstrate decreased ST AT activation
As previously discussed, OSM signalling predominantly activates the Jak-STAT 
pathway, through association of Jak subunits with the OSMRJ3:gpl30 receptor 
complex. Therefore mice deficient in OSMRp would be expected to demonstrate 
decreased ST AT signalling. Analysis of SES-induced ST AT activation in nuclear 
extract isolated from peritoneal membranes of OSMR-KO and WT mice 
demonstrated decreased peritoneal STAT activation in OSMR-KO mice (Figure 5.3.9). 
Supershift analysis of the STAT/DNA complex showed evidence of STAT3, and to a 
lesser extent STAT1. Prior studies have shown that OSM-mediated signalling can 
induce STAT5 activation (Heinrich et al, 1998), however, this was not seen in this 
experiment. The decreased STAT activation observed in OSMR-KO mice was not 
however specific for an individual STAT transcription factor, but globally affected 
both STAT1 and STAT3 activation.
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Figure 5.3.9 OSMR-KO mice show decreased STAT activation 
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Fig 5.3.9. Temporal activation of STAT signalling in nuclear extracts 
derived from peritoneal membranes of WT and OSMR-KO mice was 
monitored by EMSA following SES activation (A). Alterations in STAT 
activation were quantified by densitometry by calculating the ratio of 
activation elicited in OSMR-KO mice, which was compared to activation 
in WT mice (B). Composition of the STAT complex was verified by 
supershift analysis of nuclear extracts isolated from both non-challenged 
mice and mice exposed to SES for 6 hours using antibodies against 
STAT1, STAT3 and STAT5 subunits (C). Data is representative of three 
WT and three OSMR-KO mice (*p<0.05).
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5.3.5 OSMR-KO mice demonstrate altered NF-kB activity
As discussed in Chapter 4, EMSA analysis of nuclear extracts isolated from HPMC 
highlight the potential for OSM to block NF-kB activation (Section 4.3.4). To 
substantiate these observations, NF-kB activation following SES-induced 
inflammation was profiled in both WT and OSMR-KO mice. As illustrated in Figure 
5.3.10, NF-kB activation was markedly enhanced in OSMR-KO mice. Subsequent 
supershift analysis of the NF-kB complex confirmed a role for both the p50 and p65 
subunits. Enhanced NF-kB signalling in OSMR-KO mice does not appear to be 
specific for an individual subunit, instead globally affecting both subunits. The 
apparent ability of OSM to regulate NF-kB activation may be responsible for the 
alterations in monocytic cell trafficking observed during acute inflammation.
158
Figure 5.3.10 OSMR-KO mice show increased NF-kB activation
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Fig 5.3.10. Temporal activation of NF-kB in nuclear extracts derived 
from peritoneal membranes of WT and OSMR-KO mice was monitored 
by EMSA following SES activation (A). Alterations in NF-kB activation 
were quantified by densitometry by calculating the ratio of activation 
elicited in OSMR-KO mice, which was compared to activation in WT 
mice (B). Composition of the NF-kB complex was verified by supershift 
analysis of nuclear extracts isolated from both non-challenged mice and 
mice exposed to SES for 6 hours using antibodies against p50, p52, p65 
and c-Rel subunits (C). Data is representative of three WT and three 
OSMR-KO mice (*p<0.05).
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5.4 Discussion
Studies outlined in this Chapter suggest that OSMRp signalling selectively affects the 
inflammatory trafficking of monocytic cells. This is distinct from the action of IL-6, 
which is known to affect the recruitment and clearance of neutrophils and T cells 
(Hurst et al, 2001; McLoughlin et al, 2005; Hams et al, 2008). These data provide the 
first evidence for a role to OSM in controlling acute inflammation and point to clear 
distinction from the activity of IL-6 under a similar inflammatory constraint.
The model of acute peritoneal inflammation used in this project is designed to profile 
episodes of clinical peritonitis as seen in patients on peritoneal dialysis (Topley et al, 
1996). The pattern of leukocyte recruitment observed in response to inflammatory 
challenge is integral to the resolution of inflammation and subsequent outcome of the 
condition (Topley et al, 1996; Beutler et al, 2004; Jones, 2005). Therefore the switch 
from the initial influx of neutophils to a more sustained mononuclear cell infiltrate is 
vital for the resolution of inflammation (Topley et al, 1996). Other studies have 
shown that IL-6 trans-signalling, aids this transition through differentially regulating 
leukocyte apoptosis and chemokine-mediated leukocyte trafficking (Hurst at al, 2001). 
As seen in other inflammatory conditions, the initial neutrophil influx is associated 
with an increase in the expression of a variety of inflammatory cytokines (Kasama et 
al, 2005; Corvol et al, 2003). Previous studies have shown that neutrophils are the 
primary source of sIL-6Ra (McLoughlin et al, 2004; Jones et al, 1999; Hurst et al, 
2001; Marin et al, 2002). Clinical evaluation of OSM in acute peritonitis has 
illustrated a direct correlation between OSM levels and neutrophil numbers (Hurst et 
al, 2002). In this present study we demonstrate a similar trend with the profile of 
OSM closely resembling the neutrophil influx.
Previous in vitro analysis on HPMC demonstrate significant similarities between IL-6 
and OSM-mediated signalling. However, as outlined in this Chapter, there appears to 
be a hierarchy in the ability of each cytokine to control the in vivo expression of 
inflammatory chemokines and to affect recruitment of leukocytes. IL-6-mediated 
signalling may override the ability of OSM to affect neutrophil clearance, whereas 
OSMRp-mediated signalling selectively governs monocytic cell recruitment. This 
could potentially explain the ability of OSM to regulate expression of neutrophil
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activating chemokines both in vitro and in vivo, but lack of effect on neutrophil 
clearance observed in response to acute inflammatory challenge. In this respect, we 
show a marginal effect of OSM on CXCL1/KC expression, yet it is unclear whether 
OSM or IL-6 control of other neutrophil activating chemokines (for example MIP-2/ 
CXCL8 or CXCL5) could affect this outcome (Hurst et al, 2001; Modur et al, 1997; 
McLoughlin et al, 2004).
The OSMRP-mediated control of monocytic cell trafficking appears to centre on the 
ability of OSM to control expression of CCL5. Previous in vitro analyses have 
demonstrated than OSM can suppress the IL-ip induced expression of CCL5 by 
HPMC, whilst CCL5 expression in response to SES-induced inflammation is 
significantly increased in OSMRp deficient mice. This is in direct contrast to that of 
IL-6, which is unable to promote expression of CCL5 in vitro or in vivo (McLoughlin 
et al, 2005; Hams et al, 2008). However, IL-6 represents a principle regulator of 
CCL2 in vivo, a chemokine upregulated by OSM in vitro but not affected by a lack of 
OSM-mediated signalling in vivo (Hams et al, 2008). Despite the ability of IL-6 to 
regulate expression of CCL2, no significant alteration in monocytic cell recruitment 
has been observed in IL-6KO mice (Hams et al, 2008; McLoughlin et al, 2005; 
Nowell et al, 2008 submitted). In this respect, CCL2 may predominantly affect T cell 
trafficking since IL-6KO mice display impaired T cell migration in acute 
inflammation (McLoughlin et al, 2005). Such findings highlight functional 
differences in the gpl30-mediated control of the mononuclear cell chemoattractants 
CCL2 and CCL5. Studies outlined herein infer an important role for OSMRp- 
mediated control of CCL5 in selectively governing monocytic cell recruitment. 
However, further work would be required to evaluate the potential role of other 
chemokines and adhesion molecules involved in monocytic cell recruitment before 
confirming OSM-mediated control of CCL5 as the primary mechanism orchestrating 
the control of monocytic cell recruitment.
Studies examining differential cellular changes in expression of inflammatory 
chemokine receptors provide evidence for the potential importance of CCL5 in 
governing monocytic cell recruitment. For example, monocytic cell CCR2 expression, 
one of the receptors for CCL2, defines a population of monocytes actively recruited to 
sites of inflammation. However, terminally differentiated macrophages lose
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expression of CCR2, whilst increasing expression of the CCL5 receptors CCR1 and 
CCR5 (Fantuzzi et al, 1999; Kaufmann et al, 2001). The gpl30-activating cytokines 
IL-6, LIF and OSM have been shown to regulate various aspects of monocyte 
differentiation, including macrophage formation, induction of receptors for G-CSF 
and CM-CSF and the activation and expansion of dendritic cells (Tanigawa et al, 
1995; Clutterbuck et al, 2000; Chomarat et al, 2000; Jenkins et al, 2004). However, 
these activities are not universally regulated by all three gpl30-activating cytokines 
(Tanigawa et al, 1995), suggesting OSMRp-mediated signalling may have a unique 
role in monocytic cell trafficking.
OSM-mediated control of monocytic cell trafficking appears to rely on the ability of 
OSM to regulate NF-kB signalling. Work in Chapter 4 demonstrated the regulation of 
IL-lp-induced NF-kB activation by OSM. Such signalling interplay may be 
responsible for the OSM regulation of inflammatory chemokine production in vivo. 
Nuclear extracts from the peritoneal membrane of OSMR-KO mice showing 
significantly increased NF-kB activation as compared to WT animals. Comparative 
analysis using OSMR-KO and IL-6KO mice imply the regulation of NF-kB activation 
is specific for OSMRP-mediated signalling and is not regulated by gpl30- 
homodimeric receptor complexes (Hams et al, 2008). As expected, OSMR-KO mice 
show impaired STAT signalling due to the lack of gpl30:OSMRp heterodimers. 
However, significant decreases in STAT-activated chemokines such as CCL2 were 
not observed, again suggesting a hierarchy of gpl30-activating cytokines. It would 
therefore be important to monitor IL-6-mediated STAT signalling in OSMR-KO mice.
Studies outlined in this Chapter highlight a unique role for OSMRP-mediated 
signalling in controlling monocytic cell recruitment during acute inflammation. 
Regulation of this response was associated with a signalling interplay between OSM 
and NF-kB. However, it remains unclear whether these signalling mechanisms 
underpin the inflammatory control of chemokines including CCL5. Further 
transcriptional studies would be required to fully define the nature of this interaction. 
The next aim is to investigate whether these activities observed during acute 
inflammation impact progression of a chronic inflammatory state. This may have 
significant bearing on the potential modulation of OSMRP signalling for therapeutic 
benefit.
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Chapter 6
Defining a role for OSMRp-mediated signalling 
in recurrent inflammatory challenge and tissue
injury
6.1 Introduction
Studies outlined in Chapters 3-5 have demonstrated the ability of OSM both in vitro 
and in vivo to regulate chemokine-mediated leukocyte trafficking during acute 
inflammation. Using repeated episodes of inflammation (Section 6.2.1) to simulate 
the consequence of recurrent bouts of peritonitis, this Chapter aims to gauge whether 
OSM-mediated control of inflammation becomes modified in more progressive 
inflammatory processes.
As mentioned previously, leukocyte recruitment in acute inflammation is 
characterised by an initial influx of neutrophils, which are subsequently replaced by 
populations of inflammatory monocytes and T cells (Jones, 2005). Inappropriate 
regulation of leukocyte recruitment can lead to impaired neutrophil clearance and 
increased tissue damage due to the accumulation and retention of activated leukocytes 
at the site of immunological challenge including inflammatory bowel disease, sepsis, 
renal injury and chronic peritonitis (Brannigan et al, 2000; Brown et al, 2006; 
Heinzelmann et al, 1999).
Previous studies have illustrated a distinction in the role IL-6-related cytokines 
perform during acute and chronic inflammation. For example, although IL-6 is 
integral for the resolution of acute inflammation, its activities give rise to more 
detrimental consequences during more progressive inflammatory conditions. For 
example, in rheumatoid arthritis IL-6 has been shown to induce proliferation of 
synovial fibroblasts and promote cartilage damage by decreasing aggrecan and 
collagen II production in chondrocytes (Mihara et al, 1995; Legendre et al, 2003). 
These deleterious effects of IL-6-mediated signalling have been confirmed in vivo, 
where IL-6 deficient mice are protected against development of chronic inflammatory 
conditions including collagen-induced arthritis and colitis (Alonzi et al, 1997; 
Yamamoto et al, 2000; Kallen, 2002). In addition to these observations, the 
therapeutic use of an antibody against IL-6 receptor (Tocilizumab, Actemra) has 
proven effective in the treatment of rheumatoid arthritis, Castleman’s disease and 
Crohn’s disease (Nishimoto et al, 2003; Nishimoto et al, 2005; Ito et al, 2004).
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However, the role of IL-6-related cytokines in chronic inflammatory conditions 
appears to be dependent on the particular gpl30-activating cytokine. In vivo studies 
using experimental arthritis have suggested that IL-6 is the primary gpl30-activating 
cytokine governing these inflammatory processes as both IL-llRa- and OSMRJ3- 
deficient mice develop disease hallmarks comparable with those observed in WT mice 
(Wong et al, 2006). However, OSM has also been implicated in tissue damage 
associated with recurrent inflammation, including epithelial-to-mesenchymal 
transition (Bamber et al, 1998; Goren et al, 2006; Nightingale et al, 2004; Pollack et 
al, 1997), which could be of potential significance in the development of peritoneal 
fibrosis (Masunaga et al, 2003; Kalluri & Neilson, 2003; Topley et al, 1996; Lai et al, 
2000). However, it is unclear whether these activities are disease (tissue) specific, 
whilst the coordination of these responses in disease is ill-defined.
This Chapter will use recurrent episodes of SES-induced peritoneal inflammation, 
with an aim to simulate the progression of chronic peritoneal inflammation and 
fibrosis as is associated with recurrent episodes of bacterial peritonitis. Using 
repeated intraperitoneal introduction of SES at weekly intervals allows for clearance 
of the resulting leukocyte infiltrate between episodes thereby simulating the effect of 
repeated episodes of clinical peritonitis, and allowing the potential role for OSM- 
mediated signalling in the progression of chronic inflammatory conditions to be 
examined.
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6.2 Materials and Methods
6.2.1 Generation of SES-induced acute and chronic peritoneal inflammation
All animal experiments were performed under Home Office License PPL-30/2269 on 
6-12 week-old WT C57/B16 mice and OSMR-KO mice (see Section 2.3.1).
Peritoneal inflammation was induced using a cell-free supernatant derived from a 
clinical isolate of Staphylococcus Epidermidis (SES) as described in Section 2.3.4. 
Experiments were performed on groups of 4-5 age-matched, mixed sex, WT and 
OSMR-KO mice. Recurrent peritoneal inflammation was induced by four sequential 
intraperitoneal injections of 500pl SES at 7 day intervals. After the final injection 
groups of five WT and four OSMR-KO mice were sacrificed at designated time 
intervals and peritoneal membrane sections and lavage fluids obtained. In addition, a 
group of WT and OSMR-KO mice were treated with four recurrent doses of SES (as 
described above) and left for 21 days after the final injection. At which time 
peritoneal membranes were taken and prepared for histological analysis (Section
2.3.4). Inflammatory parameters and leukocyte recruitment was monitored as 
outlined in Chapter 5.
Figure 5.2.1 Flow diagram of recurrent inflammation model procedure
Assess leukocyte profile Assess leukocyte profile
♦ ♦ Take membrane sections
\
7 /
0 7 14 21 49 Days
ft ft ft ft
1st 2nd 3rd 4th Episode™  (SES ip.)
Fig 5.2.1. To simulate recurrent peritoneal inflammation, groups of WT and 
OSMR-KO mice received four ip injections of SES at weekly intervals. 
Peritoneal leukocytes were sampled after the first and fourth episodes of 
inflammation. Peritoneal membrane sections were recovered from mice that had 
received 4 episodes of inflammation, 49 days after the initial SES administration.
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6.3 Results
6.3.1 Recurrent episodes of peritoneal inflammation heightens the increase in 
monocytic cell infiltration seen in OSMR-KO mice
Under basal conditions in both WT and OSMR-KO mice, the peritoneal leukocyte 
population consists predominantly of mononuclear cells. However, comparative 
analysis of neutrophil, monocytic cell and lymphocyte numbers in the peritoneal 
cavity prior to the induction of a fourth SES challenge shows a significant increase in 
the retention of neutrophils in addition to mononuclear cells. Moreover a direct 
comparison between WT and OSMR-KO mice showed increased retention of 
lymphocytes in the peritoneal cavity of WT mice (Figure 6.3.1, Table 6.3.1). The 
pattern of leukocyte recruitment associated with repeated episodes of peritoneal 
inflammation was also characterised by an initial influx of neutrophils, subsequently 
replaced by a mononuclear cell infiltrate (Figure 6.3.1). However, leukocyte 
trafficking was significantly enhanced after four inflammatory episodes.
Table 6.3.1 WT and OSMR-KO mice show increased retention of leukocytes 
within the peritoneal cavity after repeated episodes of inflammation
Neutrophils (xlO6) Macrophages (xlO6) Lymphocytes (xlO6)
WT OSMR-KO P WT OSMR-KO P WT OSMR-KO P
Episode 1 0.06±0.04 0.01±0.01 0.12 2.32±0.17 2.44±0.35 0.38 0.47±0.09 0.33±0.06 0.14
Episode 4 0.50±0.46 0.44±0.22 0.45 4.24±0.29 4.86±1.28 0.33 1.72±0.41 0.93±0.16 0.06
P 0.19 0.07 0.00 0.07 0.01 0.01
Table 6.3.1. Peritoneal leukocytes were collected from WT and OSMR-KO mice 
prior to the first and fourth episode of SES-induced peritoneal inflammation. 
The relative composition of the resident population was compared by differential 
cell count. Data represents mean ± SEM of five WT and four OSMR-KO mice.
Studies outlined in Chapter 5 demonstrated that during a single acute inflammatory 
episode, an absence of OSMRp signalling significantly enhances monocytic cell 
recruitment into the peritoneal cavity, whilst appearing not to alter trafficking of either 
neutrophils or lymphocytes (Chapter 5, Figure 5.3.1). To examine whether recurrent 
sequential bouts of inflammation modified this response profile, leukocyte
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recruitment was compared in mice that received a single dose of SES and mice that 
had received four repeated SES challenges (7 days apart). Consistent with the data 
presented in Chapter 5, OSMR-KO mice showed significantly increased monocytic 
cell recruitment when compared with WT mice both after one and four episodes of 
SES-induced inflammation (Figures 6.3.1 and 6.3.2).
Flow cytometric analysis of F4/80+CDllb+ cells, confirmed significant increases in 
both the ‘resident-like’ F4/80highCDllbhigh cells and ‘inflammatory’ F4/80lowCDl lb+ 
cells in OSMRp deficient mice (Figure 6.3.2). The magnitude of the inflammatory 
response was significantly enhanced in both murine strains following four episodes of 
inflammation (Figure 6.3.2).
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Figure 6.3.1 Leukocyte infiltration into the peritoneal cavity of WT and 
OSMR-KO mice following acute and recurrent inflammation
Episode 1
8
~  6- <DO
J  4vO
Neutrophils
0<^— .----- . . «
12 18 24
Episode 4
toO
w
®O
0 6 12 18 24
8 Macrophages
6
4
2
0
0 6 12 18 24
8 -
6 -
4
2
0
Lymphocytes
i i i i
0 6  12 18 24
O WT
•  OSMR-KO
Time (hrs)
12 18 24 12 18 24
Fig 6.3.1. SES-induced inflammation was established in WT and 
OSMR-KO mice. Data is presented for mice receiving a single SES dose 
and mice treated with four individual doses of SES at weekly intervals. At 
designated time points the peritoneal cavity was lavaged and the 
composition of the inflammatory infiltrate compared by differential cell 
count. Data represents mean ± SEM of five WT and four OSMR-KO 
mice for each time point (*p<0.05).
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Figure 6.3.2 OSMR-KO mice show increased monocytic cell infiltration
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Fig 6.3.2 Single (Episode 1) and recurrent (Episode 4) SES-induced 
peritoneal inflammation was established in WT and OSMR-KO mice. At 
designated intervals FACS analysis was performed on peritoneal 
leukocytes to determine numbers of resident-like F4/80hlghC D llbhlgh 
monocytic cells and infiltrating F4/80,owC D llb+ monocytic cells. Data 
represents mean +/- SEM of five WT and four OSMR-KO mice (*p<0.05).
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6.3.2 OSMRp mediated signalling selectively regulates CCL5 expression during 
recurrent inflammatory challenge
Analysis of OSM expression during acute inflammatory conditions has defined 
neutrophils as the primary source of OSM (Hurst et al, 2002), however, during 
chronic inflammation the cellular source of OSM is predominantly activated 
macrophages and T cells (Modur et al, 1997; Langdon et al, 2000). Mice exposed to 
an acute SES-induced inflammatory challenge demonstrated low levels of OSM 
expression within the peritoneal cavity, which coincided with the neutrophil influx 
(Figure 6.3.3), confirming observations outlined in Chapter 5 (Figure 5.3.4). This 
profile was somewhat delayed and more sustained as a consequence of repeat SES 
challenge, and may reflect the more prolonged neutrophil infiltration observed in 
response to recurrent inflammation (Figure 6.3.3). Furthermore, OSM levels were 
observed to be higher in WT mice, however, due to the low expression and low 
number of replicates, this would need to be substantiated by additional studies.
Expression of the mononuclear chemoattractants CCL2 and CCL5 in response to 
acute and repeated episodes of inflammation was also quantified. Interestingly the 
profile of CCL2 expression is comparable between acute and repeated inflammation 
(Figure 6.3.4). Due to the increased and sustained mononuclear infiltrate, increased 
expression of mononuclear cell chemoattractants would be expected with repeated 
inflammation. However, analysis of CCL2 levels in the peritoneal cavity 
demonstrated only slightly enhanced expression in response to repeated inflammatory 
assault, with OSMR-KO mice demonstrating significantly higher CCL2 in 
comparison to WT mice (Figure 6.3.4).
In vivo and in vitro experiments previously outlined in Chapters 4 and 5 illustrated an 
ability of OSM to control CCL5 expression (Figure 4.3.1; Figure 5.3.7). The profile 
of CCL5 expression is similar between single and repeated episodes of inflammation, 
however, the observed profile of CCL5 expression was notably more sustained 
following repeated SES activation, with significantly elevated CCL5 levels detected 
24 hours post SES activation (Figure 6.3.5). In response to repeated episodes of 
inflammation, OSMR-KO mice demonstrate significantly increased CCL5 expression 
in comparison to WT animals (Figure 6.3.5), thereby suggesting a role for 
OSMRp-mediated signalling in regulating CCL5 in recurrent and acute inflammation.
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Figure 6.3.3 OSM expression in response to acute and repeated episodes
of inflammation in WT and OSMR-KO mice
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Fig 6.3.3. Single (Episode 1) and recurrent (Episode 4) SES-induced 
inflammation was established in WT and OSMR-KO mice. ELISA was 
used to quantify OSM levels in peritoneal lavage fluid at designated time 
points. Data represents the mean ± SEM of five WT and four OSMR-KO 
mice.
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Figure 6.3.4 CCL2 expression in response to acute and repeated episodes of
inflammation in WT and OSMR-KO mice
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Fig 6.3.4. Single (Episode 1) and recurrent (Episode 4) SES-induced 
inflammation was established in WT and OSMR-KO mice. Temporal 
changes in CCL2 concentration were quantified in peritoneal lavage fluid 
using ELISA. Data represents the mean ± SEM five WT and four OSMR- 
KO mice (*p<0.05).
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Figure 6.3.5 CCL5 expression in response to acute and repeated episodes of
inflammation in WT and OSMR-KO mice
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Fig 6.3.5. Single (Episode 1) and recurrent (Episode 4) SES-induced 
inflammation was established in WT and OSMR-KO mice. Temporal 
changes in CCL5 concentration were quantified in peritoneal lavage fluid 
using ELISA. Data represents the mean ± SEM five WT and four OSMR- 
KO mice (*p<0.05).
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6.3.3 OSMR-KO mice demonstrate decreased STAT activation
As predicted by the data generated following a single acute inflammatory challenge 
OSMR-KO mice demonstrate decreased STAT activation (Figure 5.3.9). Analysis of 
SES-induced STAT activation in nuclear extracts isolated from peritoneal membranes 
of OSMR-KO and WT mice after both single and repeated episodes of SES-induced 
inflammation demonstrated decreased STAT activation in OSMR-KO mice (Figure
6.3.5). During acute inflammation the peak of STAT activation occurs between 1 and 
3 hours post induction (Figure 5.3.9; Figure 6.3.6). However in response to repeated 
episodes of inflammation, the degree of STAT activation was more pronounced 
potentially reflecting alterations in other STAT3 activating cytokines including IL-6 , 
IL-10 and IL-11. Supershift analysis of the DNA/protein complex subsequently 
highlighted activation of STAT1, and to a greater extent STAT3 (Figure 6.3.6).
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Figure 6.3.6 STAT activation is enhanced in response to recurrent 
episodes of SES-induced inflammation
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Fig 6.3.6. (A) Temporal activation of STAT in nuclear extracts from
peritoneal membranes of WT and OSMR-KO mice was monitored by 
EMSA following acute (Episode 1) and repeated episodes of peritoneal 
inflammation (Episode 4). Banding intensity was quantified by 
densitometry by calculating the ratio of activation elicited in OSMR-KO 
mice, which was compared to activation in WT mice (B). Composition of 
the STAT/DNA complex was verified by supershift analysis of extracts 
isolated from unchallenged mice and mice exposed to SES for 3 hours (C). 
Data is representative of EMSA performed using nuclear extracts from 
three WT and three OSMR-KO mice.
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6.3.4 OSMR-KO mice demonstrate altered NF-kB activity
Studies outlined in Chapters 4 and 5 demonstrated an ability of OSM to regulate 
NF-kB activation both in vitro (Chapter 4, Figure 4.3.3) and during an acute 
inflammatory challenge in vivo (Chapter 5, Figure 5.3.10). To examine potential 
alterations in NF-kB activation as a consequence of repeated inflammatory challenge 
nuclear extracts were prepared from peritoneal membranes obtained during the course 
of the inflammatory response (episode 1 and episode 4) from WT and OSMR-KO 
mice (Figure 6.3.7). NF-kB activation followed a similar pattern in both single and 
repeated episodes of inflammation, with increased activation seen in OSMR-KO mice 
in comparison with WT mice in response to single and repeated inflammation (Figure 
6.3.7). Subsequent supershift analysis of the NF-kB subunits involved confirms 
classical activation, with expression of both the p50 and p65 subunits in response to 
both acute and repeated induction of inflammation. The apparent sustained activation 
of NF-kB in response to repeated inflammatory challenge appears to correspond with 
both sustained CCL5 expression and mononuclear cell trafficking into the peritoneal 
cavity.
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Figure 6.3.7 OSMR-KO mice demonstrate increased NF-kB signalling 
in response to acute and recurrent inflammatory challenge
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Fig 6.3.7. (A) Temporal activation of NF-kB in nuclear extracts from 
peritoneal membranes of WT and OSMR-KO mice was monitored by 
EMSA following acute (Episode 1) and repeated episodes of peritoneal 
inflammation (Episode 4). Banding intensity was quantified by 
densitometry by calculating the ratio of activation elicited in OSMR-KO 
mice, which was compared to activation in WT mice (B). Composition of 
the NF-kB complex was verified by supershift analysis of extracts isolated 
from unchallenged mice and mice exposed to SES for 3 hours (C). Data is 
representative of EMSA performed using nuclear extract from three WT 
and three OSMR-KO mice (*p<0.05).
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6.3.5 OSMR-KO mice develop peritoneal membrane thickening comparable to 
that observed in WT mice
Chronic inflammatory conditions are often characterised by accumulation of a 
persistent leukocyte infiltrate at the site of inflammation (Buckley, 2003). In this 
respect, peritoneal membrane biopsies taken from PD patients who had encountered 
repeated episodes of bacterial peritonitis display increased evidence of histological 
abnormalities including membrane thickening and EMT (Suassuna et al, 1994). As 
illustrated in Figure 6.3.8, mice exposed to repeated episodes of SES-induced 
inflammation develop significantly increased thickening of the peritoneal membrane, 
potentially due to increased leukocyte infiltration and deposition of collagen. OSMR- 
KO mice appear to develop membrane thickening comparable to that observed in WT 
mice, however, OSMR-KO mice appear to have thickened peritoneal membranes 
prior to induction of peritoneal inflammation, although the reasons for this remain 
unclear (Figure 6.3.8).
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Figure 6.3.8 OSMR-KO mice develop peritoneal membrane thickening 
comparable to that observed in WT mice
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Fig 6.3.8. SES-induced inflammation was established in WT and OSMR-KO 
mice using four individual doses of SES at weekly intervals (SES x4). Peritoneal 
membrane sections were taken 49 days after the initial dose of SES and 
compared to membrane sections taken from unchallenged, age-matched mice. 
Sections were stained with haematoxylin and eosin (A) and an antibody against 
collagen I (B). The thickness of the mesothelium was assessed and the average 
thickness for each section calculated. Data is representative of three WT and 
three OSMR-KO mice (*p<0.05).
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6.4 Discussion
Studies outlined in this Chapter suggest that OSMRp-mediated signalling plays an 
important role in maintaining control of monocytic cell trafficking during recurrent 
episodes of inflammation. As indicated by the results outlined in previous chapters, 
the ability of OSM to selectively control monocytic cell trafficking may be due to 
enhanced NF-kB activation as evidenced by changes in CCL5 expression.
Resolution of inflammation is dependent on the effective clearance of the leukocyte 
infiltrate, which if not cleared can lead to chronic inflammation and tissue damage 
(Buckley, 2003). In accordance with this, both WT and OSMR-KO mice demonstrate 
an increased population of resident peritoneal leukocytes after repeated inflammatory 
episodes. Corresponding to the sustained neutrophil influx, OSM expression within 
the peritoneal cavity also appears increased and sustained. Collectively, these data 
infer that OSM activity is associated with the control of leukocyte retention within 
inflamed tissue, with OSM expression becoming heightened and more sustained.
As discussed in Chapter 5, IL-6 and OSM regulate distinct roles in governing 
leukocyte trafficking during acute inflammation, with IL-6 primarily affecting the 
neutrophil and T cell populations, and OSM controlling monocytic cell recruitment 
(McLoughlin et al, 2005; Hurst et al, 2001; Hams et al, 2008). However, both 
cytokines appear to be of significant importance in the transition of innate to acquired 
immunity (Jones, 2005; Hams et al, 2008). This pattern is maintained in response to 
recurrent inflammatory challenge, suggesting that during progressive inflammation 
OSM remains the predominant gpl30-activating cytokine controlling monocytic cell 
recruitment. Analysis of the inflammatory chemokines CCL2 and CCL5 suggests that 
OSMRP-mediated control of CCL5 expression is maintained in response to repeated 
inflammatory challenge and be a principle regulator of monocytic cell trafficking.
As previously discussed, although pivotal in bacterial clearance, IL-6 is also 
associated with tissue damage as exemplified in a variety of chronic inflammatory 
disorders, with IL-6KO mice protected against a variety of experimental inflammatory 
conditions (Alonzi et al, 1998; Yamamoto et al, 2000; Onogawa, 2005; Ramshaw et 
al, 1997). In addition, IL-6 deficient mice are also resistant to membrane thickening
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in experimental models of peritonitis (Fielding et al, unpublished data). However, a 
deficiency in OSM-mediated signalling does not exhibit this protective phenotype, 
with OSMR-KO mice developing experimental arthritis (Wong et al, 2006). As 
demonstrated within this Chapter, OSMR-KO mice also develop peritoneal membrane 
thickening as associated with chronic peritoneal inflammation. This also implies that 
within the inflammatory setting used in this project, OSM-mediated signalling does 
not have a significant effect on EMT as has previously been reported in renal fibrosis 
(Pollack et al, 2007; Nightingale et al, 2004), however, further analysis of the typical 
markers of EMT in OSMR-KO mice in response to recurrent inflammatory 
stimulation would be required to support this idea.
These results suggest that during repeated episodes of peritoneal inflammation OSM 
continues to direct CCL5-mediated monocytic cell recruitment in a similar manner to 
that observed in response to a single episode of acute inflammation. This 
upregulation of chemokine expression, taken in combination with a more sustained* 
profile of OSM expression, due to the delayed clearance of the neutrophil influx, may 
prove to be detrimental resulting in an increased population of monocytic cells within 
the peritoneum. However, studies outlined within this Chapter were unable to find any 
evidence for a role for OSM in membrane thickening or tissue injury associated with 
repeated inflammatory assault, suggesting that OSM does not play an important role 
in tissue damage within this inflammatory context.
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Chapter 7
General Discussion
7. Discussion
Previous in vitro and in vivo investigations have outlined potential roles for the 
gpl30-activating cytokine OSM in inflammation, tissue remodelling and 
haematopoiesis (Zarling et al, 1986; Modur et al, 1997; Langdon et al, 2000; Tanaka 
et al, 2003; Hurst et al, 2002; Richards et al, 1996). However, these investigations 
have not evaluated the in vivo contribution of OSM during acute inflammation. Using 
an in vivo model of acute bacterial peritonitis, supported by in vitro studies, this thesis 
illustrates that OSMRp signalling selectively affects the inflammatory trafficking of 
monocytic cells (Hams et al, 2008). This OSM-mediated response is distinct from 
that elicited by IL-6, which predominantly regulates recruitment and clearance of 
neutrophils and lymphocytes (Hurst et al, 2001; McLoughlin et al, 2005; Jones, 2005; 
Hams et al, 2008). Such findings highlight a distinction between the inflammatory 
activities controlled by a gp 130 homodimer receptor complex and those governed by 
OSMRP:gpl30 heterodimeric receptor.
Studies outlined in Chapters 3 and 4 illustrate an ability of OSM to selectively 
upregulate inflammatory chemokines and adhesion molecules in vitro when utilising a 
OSMRp:gpl30 receptor complex expressed on HPMC. In addition, OSM can 
selectively control IL-lp-mediated chemokine production, suppressing expression of 
the neutrophil chemoattractant CXCL8 and the mononuclear cell chemoattractant 
CCL5. The potential importance of OSM-mediated control of CCL5 was confirmed 
in vivo, where OSMR-KO mice demonstrated significantly enhanced CCL5 
expression following acute inflammatory activation. Such coordinated regulation of 
inflammatory chemokine expression, as highlighted by the impact of OSM on CCL5 
secretion, may represent a potential mechanism for the OSMRp-mediated control of 
monocytic cell recruitment. Subsequent examination of transcriptional events 
highlighted a role for OSM in negatively regulating the level of NF-kB activation. 
The orchestrated control of NF-kB signalling by OSM may explain the regulation of 
CCL5 (and CXCL8 production), and provides an additional mechanism for the 
OSM-mediated control of mononuclear cell trafficking. However, the specific 
interplay between OSM/OSMRp and NF-kB activation requires further analysis.
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7.1 The differential roles of IL-6 and OSM in leukocyte recruitment during acute 
inflammation.
The leukocyte profile following an acute inflammatory challenge can be characterised 
by an initial influx of neutrophils, which are subsequently replaced by a more 
sustained population of activated mononuclear cells (Topley et al, 1996). This 
transition marks a switch from innate to acquired immunity, which is vital for the 
effective resolution of inflammation (Jones, 2005; Beutler, 2004). The importance of 
IL-6 in this transition has been well documented in several recent review articles 
(Jones, 2005; Rose-John et al, 2006), however, the roles of other gpl30-activating 
cytokines are less well defined. Analysis of effluent from peritoneal dialysis patients 
with acute bacterial peritonitis has shown expression of both IL-6 and OSM, but not 
LIF, suggesting that within this inflammatory context the two primary 
gpl30-activating cytokines of potential importance are IL-6 and OSM (Hurst et al, 
2002). However, it should be noted that other IL-6-related cytokines including IL-11 
and IL-27 have prominent inflammatory roles as defined by their involvement in other 
models of inflammation. For example, IL-11 has been described as the principle 
cytokine promoting STAT1 and STAT3 mediated gastric-inflammation and 
tumourigenesis, whilst IL-27 plays a pivotal role in governing T-cell effector 
functions (Ernst et al, 2008; Villarino et al, 2003; Artis et al, 2004). Collectively, 
these studies emphasise a hierarchy of gpl30-activating cytokines in governing 
specific inflammatory activities. While other family members such as LIF, CLC and 
CNTF may provide homeostatic functions not typically associated to immunological 
processes (Taga & Kishimoto, 1997; Nakashima & Taga, 1998).
The archetypal gpl30-activating cytokine IL-6 plays an integral role in the transition 
from innate to acquired immunity by regulating both the chemokine-driven 
recruitment and apoptotic clearance of both neutrophils and T cells (Hurst et al, 2001; 
Jones, 2005). Initial in vitro investigations outlined both within this project and in 
previous studies have documented similarities between OSM and IL-6 in their 
capacity to regulate chemokine-driven responses (Hurst et al, 2002; Nowell et al, 
2006; Modur et al, 1997; McLoughlin et al, 2004; Richards et al, 1996). For example 
both cytokines exhibit an ability to suppress expression of the neutrophil 
chemoattractant CXCL8, although unlike IL-6KO mice, OSMR-KO mice do not 
display any alteration in neutrophil influx (Chapters 4 and 5; McLoughlin et al, 2003;
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McLoughlin et al, 2004; Fielding et al, 2008; Hams et al, 2008). Likewise, although 
m vfrro analysis has suggested the potential for OSM to regulate T cell trafficking 
through the control of mononuclear cell chemoattractants, including CCL2, CCL5 and 
CXCL10, in vivo analysis illustrated OSMRp-mediated signalling does not control 
lymphocyte recruitment (Chapters 4 and 5; Hams et al, 2008). Consequently in vitro 
studies would infer a role for OSM in the control of neutrophil and T cell trafficking. 
However, this is not borne out in vivo suggesting that a hierarchy exists where IL-6 is 
of more importance in orchestrating certain chemokine-mediated events.
In direct contrast to IL-6, OSM appears to be of importance in the recruitment of 
monocytic cells. In vitro and in vivo analysis illustrates that IL-6 is the principle 
gpl30-activating cytokine involved in governing CCL2 expression. In this respect 
OSMR-KO mice show a comparable profile of CCL2 production to WT mice 
following inflammatory activation (Chapter 5). CCL2 was originally described as a 
monocytic cell chemoattractant, however, IL-6 deficiency has no significant impact 
on monocytic cell recruitment (Hurst et al, 2001; McLoughlin et al, 2005; Hams et al, 
2008). It is therefore questionable as to whether CCL2 is a more prominent regulator 
of activated T cells (Loetscher et al, 1996). A principle mechanism for controlling 
monocytic cell recruitment appears to be the OSM-mediated control of CCL5 and 
regulation of NF-kB signalling. These specific activities are distinct from the action 
of IL-6 (Chapters 4 and 5; McLoughlin et al, 2005; Hams et al, 2008). These findings 
suggest that during acute inflammation the OSM-mediated regulation of CCL5 may 
override IL-6-mediated control of CCL2 when recruiting monocytic cells to the site of 
inflammation. Such observations may support the notion that CCL2 preferentially 
control T cell recruitment, whilst CCL5 governs monocyte trafficking.
This contrasting ability of OSM and IL-6 to differentially regulate monocytic and T 
cell chemoattractants may further relate to studies into the receptors known to bind 
CCL2 and CCL5. Monocytic cells expressing CCR2, the primary functional receptor 
for CCL2, are defined as ‘inflammatory’ monocytes, which are actively recruited to 
sites of inflammation. Conversely, terminally differentiated macrophages lose 
cellular CCR2 expression, and instead upregulate CCR1 and CCR5, both of which act 
as receptors for CCL5 (Fantuzzi et al, 1999; Kaufmann et al, 2001). Previous studies 
have demonstrated the importance of gpl30-activating cytokines in the differentiation
186
of monocytes, with OSM and IL-6 having unique roles in macrophage formation and 
the expansion of dendritic cells (Tanigawa et al, 1995; Chomarat et al, 2000; 
Kitamura et al, 2005). Therefore, differential regulation of CCL2 and CCL5 by IL-6 
and OSM may mediate the controlled recruitment of specific subpopulations of 
monocytic cells during inflammation. Initial studies into the monocyte subsets 
recruited into the peritoneal cavity following inflammatory challenge suggest that 
OSMRp-mediated signalling does not result in an alteration of the proportion of 
CCR5 expressing infiltrating monocytes, implying that the increase in CCL5 
expression does not increase the recruitment of terminally differentiated macrophages 
(Chapter 5). However, CCL5 also utilises CCR1 and to a lesser extent, CCR3, 
therefore to further understand the implications of CCL5 on mononuclear trafficking, 
cellular expression of these receptors would also have to be determined.
As previously mentioned, the OSMRp-mediated control of NF-kB signalling has been 
suggested as the principle mechanism regulating CCL5 expression (Moriuchi et al, 
1997), which may be in part responsible for the observed alteration in monocytic cell 
recruitment. This was demonstrated in vitro, where OSM inhibition of the 
IL-ip-induced expression of CCL5 was associated with suppression in NF-kB activity 
(Chapter 4). Similarly, in vivo activation of NF-kB as a consequence of SES-driven 
TLR2 activation suggests that OSM may also regulate TLR-mediated NF-kB 
signalling (Figure 7.1). As TLR activation is associated with the innate immune 
response (Beutler & Rietschel, 2003), the OSM-mediated control of NF-kB suggests 
the potential for OSM to regulate innate immune activation, in addition to regulating 
mononuclear cell recruitment associated with an acquired immune response. The 
observed suppression of NF-kB in inflammatory activated OSMR-KO mice is unique 
and is not seen in IL-6KO mice. Since IL-6 and OSM utilise gpl30, changes in 
NF-kB activation may arise from signals triggered via OSMRp. However, the shared 
effects of OSM and IL-6, for example the ability of both cytokines to upregulate 
CCL2 and control the IL-lp-induced expression of CXCL8 (Chapters 3 and 4; Hurst 
et al, 2001), are potentially mediated through gpl30.
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Figure 7.1 OSMRp-mediated signalling regulates NF-kB activity
IL-1B
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Fig 7.1. OSM-mediated signalling regulates both IL-lp- and TLR2-mediated 
activation of NF-kB. Both in vivo and in vitro analysis has illustrated the ability 
of OSM to suppress NF-kB activation, resulting in the inhibition of chemokines 
such as CCL5. This mechanism is unique to OSM, suggesting it is mediated 
through the OSMRp subunit rather than gpl30. This ability of OSM to regulate 
NF-kB activation may be responsible for regulation of monocytic cell 
recruitment observed in response to OSMRp-mediated signalling. It remains 
unclear whether OSM acts on both signalling events (TLR and IL-lp) or if OSM 
acts solely on IL-lp responses which are triggered through TLR activation.
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F igure 7.2 IL -6 and O SM  have u n iq u e  roles in the tran sition  from  in n ate  to
a cq u ired  im m u n ity
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Fig 7.2. T he leukocyte profile  g en era ted  in resp on se to  S E S -in d u ced  p er ito n ea l 
in flam m ation  in W T, IL -6K O  and O S M R -K O  m ice d em o n stra tes  th e ab ility  o f  IL -6  to 
regulate both neutrophil and ly m p h o cy te  recru itm en t an d  c learan ce. C o n v erse ly , 
O SM R -K O  m ice d em onstrate  n eu trop h il and  ly m p h o cy te  tra ffick in g  co m p a ra b le  to  
that seen in W T  m ice, however, O SM  selectively  regu lates tra ffick in g  o f  m o n o cy tes , in  
an in d ep en d en t fashion.
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Taken in combination, this data suggest that while IL-6 critically governs the pattern 
of neutrophil and T cell recruitment, monocytic cell trafficking is co-ordinated by 
OSM/OSMRp (Figure 7.2). However, these studies suggest that OSM is also of 
significance in the transition from innate to acquired immunity and resolution of 
inflammation as increased monocytic cell infiltration may lead to enhanced 
phagocytic clearance of dying neutrophils (Savill et al, 2002; Brown & Savill, 1999). 
Further functional studies will be required to define the role of OSM in governing the 
clearance of apoptotic cells.
7.2 Differential roles for OSM and IL-6 in chronic inflammation and tissue 
injury
Chronic inflammatory conditions are characterised by an increased retention of 
activated mononuclear cells at sites of inflammation. The maintenance of a persistent 
leukocyte infiltrate reflects an imbalance between factors that promote cellular 
recruitment and those which promote cell death (Buckley, 2003). Chronic 
inflammation is often associated with tissue injury, for example articular cartilage 
damage in rheumatoid arthritis and development of fibrosis, characterised by 
excessive deposition of extracellular matrix components (Wynn, 2008; Arend & 
Dayer, 1990; Feldmann et al, 1990). As previously mentioned, gpl30-activating 
cytokines are integral in governing leukocyte recruitment during acute inflammation, 
it is therefore conceivable that dysregulation of these cytokines may play a role in 
chronic inflammation.
This assumption has proved correct for IL-6, which has been shown to be detrimental 
in chronic inflammatory conditions, encouraging mononuclear cell infiltrate both 
through increasing expression of mononuclear cell chemoattractants and protecting T 
cells from apoptotic clearance (Salmon et al, 1997; Atreya et al, 2000; Teague et al, 
2000; Nowell et al, 2008 in press). The detrimental effects of IL-6 have been 
demonstrated in several experimental models of chronic inflammatory disease, where 
IL-6KO mice are protected against models of arthritis, EAE and renal fibrosis (Alonzi 
et al, 1998; Yamamoto et al, 2000; Kallen, 2002). Initial studies have suggested that 
these activities are unique to IL-6 as OSMRP and IL-llRa deficient mice develop 
classic hallmarks of experimental arthritis (synovial hyperplasia, leukocyte infiltration 
and joint erosion), comparable to those observed in WT mice (Wong et al, 2006). In
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addition, OSMR-KO mice are not protected against membrane thickening in response 
to repeated peritoneal inflammation, unlike IL-6KO mice (Chapter 6; Fielding et al, 
unpublished data). This data further suggests that there is a hierarchy in the activities 
of gpl30-activating cytokines, with IL-6 playing the primary role in governing 
leukocyte retention in chronic inflammation, which may contribute to excessive tissue 
damage. However, OSM has previously been shown to be of importance in tissue 
injury associated with fibrosis and EMT (Pollack et al, 2007; Nightingale et al, 2004), 
therefore suggesting potentially unique roles during chronic inflammatory conditions 
which require further analysis.
Studies have detected expression of OSM in chronic inflammatory conditions, 
however, it appears that the primary source switches from the infiltrating neutrophils 
to activated macrophages and T cells (Cawston et al, 1998). This suggests that unlike 
its involvement in acute inflammatory events, where OSM expression is transient, 
expression is more sustained at the site of inflammation. This implies that OSM may 
play a role in the pathogenesis of chronic inflammatory conditions, however, studies 
have demonstrated both pro- and anti-inflammatory roles for this cytokine in tissue 
injury (Nagata et al, 2003; Sohara et al, 2002; Li et al, 2001; Plater-Zyberk et al, 
2001; Langdon et al, 2000). These contrasting roles for OSM may relate to changes 
in the cellular distribution of OSMRp. In this respect stromal cells, but not 
inflammatory cells express OSMRp (Chapter 3). Here again, we see that OSMRp 
expression has the potential to be modulated on both HPMC and leukocytes, with 
IFN-y and bacterial agonists affecting the repertoire of cells responsive to OSM 
(Chapter 3).
One interesting observation from this study is the apparent upregulation of OSMRp 
expression on monocytic cells in response to activation with LPS and IFN-y (Chapter 
3; Dillon et al, 2004). Stimulation with LPS and IFN-y is associated with an 
enhancement in macrophage responsiveness (Nathan et al, 1983; Taylor et al, 2005), 
suggesting that during more progressive forms of disease where there is an 
accumulation of activated mononuclear cells, OSM may perform additional 
inflammatory roles as a consequence of OSMRP induction on activated monocytic 
cells. These activities could be potentially distinct from the cellular responses 
directed by OSM in stromal cells. However, the observed upregulation of OSMRp on
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monocytic cells also corresponds to an increase in expression of IL-31 Ra, both of 
which form the functional receptor complex for IL-31 (Chapter 3). Although initial 
studies have found no involvement for IL-31 in the in vitro control of 
chemokine-mediated leukocyte trafficking, previous studies have implicated both 
IL-31 and OSM in more chronic inflammatory conditions such as dermatitis and 
asthma (Dreuw et al, 2004; Dillion et al, 2004; Boniface et al, 2007). Further 
differential analysis of both IL-31 and OSM signalling in activated monocytes would 
be required to establish any additional role this pathway may have.
It still remains unclear whether OSM plays an important role in the progression of 
chronic inflammation and associated tissue injury. Studies outlined in this thesis 
taken in combination with the observation that OSMR-KO mice do not share the 
protective phenotype exhibited by IL-6KO mice in experimental models of 
autoimmunity suggest that during chronic inflammation, IL-6 overrides 
OSMRp-mediated signalling. However, further analysis of OSMRp-mediated 
signalling in experimental models of chronic inflammation would be necessary to 
fully determine the inflammatory role of OSM. In this respect fibrosis following 
repeated SES-induced inflammatory stimulation is mild, a more aggressive model of 
fibrosis would be required to fully assess the role of OSM.
7.3 Is OSM pro- or anti-inflammatory?
Previous studies have demonstrated the therapeutic benefits of selectively blocking 
certain pro-inflammatory cytokines, for example the use of pharmaceuticals to inhibit 
both TNF (eg. Enbrel, Etanercept) and IL-6 (eg. Atlizumab, Tocilizumab) (Maini & 
Taylor, 2000; Papadakis & Targan, 2000; Choy et al, 2002; Ito et al, 2004). There is 
evidence for OSM to have both beneficial and detrimental roles in inflammation and 
from the information currently available through published literature and studies 
outlined in this project, it still remains unclear whether OSM represents a suitable 
therapeutic target. This is therefore an avenue for future studies.
However, the apparent ability of OSM to selectively regulate monocytic cell 
trafficking may prove to be of importance as more is discovered about the specific 
roles of monocytes and macrophages during inflammatory activation. Although the 
roles of lymphocytes during progressive inflammation are well defined, the potential
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role of the macrophage is less clearly defined. Therefore, as more is understood about 
the potential implications of macrophage activation, the therapeutic benefits of OSM 
in regulating monocytic cell recruitment may become apparent. Although effective, 
concerns are now being raised about the use of anti-TNF therapies (such as 
Etanercept) due to the increased risk of severe bacterial and viral infections associated 
with the effects of blocking TNF on the immune system (Desai & Furst, 2006; Domm 
et al, 2008; Winthrop, 2006). Therefore it may be advantageous to investigate the use 
of anti-cytokine therapies which are more specific, such as the potential therapeutic 
use of soluble gpl30, which specifically blocks IL-6 trans-signalling whilst leaving 
classical IL-6R signalling unaffected (Rose-John et al, 2007; Richards et al, 2006).
Studies have thus far emphasised both pro- and anti-inflammatory roles for OSM in 
the progression of an immune response (Chapters 3-6; Modur et al, 1997; Wahl & 
Wallace, 1999). Both in vitro and in vivo analysis have shown OSM to promote 
wound healing and to upregulate expression of acute phase proteins and protease 
inhibitors (eg. TIMP1 and TIMP3), which have been implicated in modulating 
cytokine function and limiting tissue damage at sites of inflammation (Wallace et al, 
1995; Cross et al, 2004; Li et al, 2001; Goren et al, 2006). In addition, OSM can 
regulate inflammatory chemokine expression, and may aid the resolution of 
inflammation (Chapters 3-6). Such data suggest the potential for the therapeutic use 
of OSM in inflammatory disorders. Initial studies have demonstrated that OSM can 
protect against LPS-induced toxicity and reduce inflammation in experimental models 
of arthritis and inflammatory bowel disease (Wallace et al, 1999; Wahl & Wallace, 
2001; Loy et al, 1999). However, these studies were performed using human OSM, 
which in mice utilises the LIF receptor complex (Yoshimura et al, 1996), and as such 
do not appropriately reflect the potential contribution or impact of OSM via OSMRp.
Subsequent studies have also implicated OSM as a pro-inflammatory mediator able to 
upregulate expression of inflammatory cytokines and tissue destruction both in vitro 
and in vivo (Langdon et al, 2000; Brown et al, 1991; Nowell et al, 2006; Plater- 
Zyberk et al, 2001). In accordance with these observations, the use of antibodies 
against OSM has shown some success in inhibiting joint destruction in experimental 
models of arthritis (Plater-Zyberk et al, 2001). In addition, OSM has been implicated 
in renal EMT, which is fundamentally linked to the pathogenesis of fibrosis (Pollack
193
et al, 2007; Nightingale et al, 2004). Although studies outlined herein fail to 
demonstrate a role for OSM in EMT within the peritoneum, future studies using a 
more aggressive model of peritoneal fibrosis may better illustrate a defined role for 
OSM in this process.
7.4 Future directions
Although this project has clearly outlined a role for OSM in governing monocytic cell 
recruitment during acute inflammation there are several questions that remain 
unanswered:
- Does OSM regulation of CCL5 represent the primary mechanism orchestrating 
the OSMRp-mediated control of monocytic cell recruitment? To answer this 
question a full evaluation of inflammatory mediators involved in governing 
monocytic cell trafficking in response to OSM would be required. However, 
this is currently restricted by the lack of suitable blocking agents for murine 
OSM or OSMRp. In addition, further analysis of the interplay between 
OSMRp-mediated signalling and the inhibition of NF-kB using transcriptional 
analysis with suitable reporter assays would be required to fully understand the 
interaction between the two pathways.
- Does IL-31 play any role in the progression of acute or progressive peritoneal 
inflammation? Although in vitro analysis suggests that during acute 
inflammation IL-31 does not share the ability of OSM to regulate 
inflammatory chemokine expression, the observation that IL-31Ra expression 
can be induced on HPMC in response to IFN-y stimulation implies that IL-31 
may play an additional role in more progressive forms of disease. The use of 
OSM-KO mice in comparison with OSMRp-KO mice within the same 
inflammatory model could be used to outline any potential role of IL-31 in the 
observed effects of OSMRp-mediated signalling during peritoneal 
inflammation.
- Does OSMRp-mediated signalling on activated monocytic cells play a role in 
progressive inflammatory disorders? The apparent induction of OSMRp 
expression on monocytic cells activated with LPS and IFN-y suggests the 
potential for unique signalling events in chronic inflammatory conditions, 
either mediated by OSM or IL-31. The use of mice deficient in stromal
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OSMRp expression could be used to assess the potential importance of 
OSMRp-mediated signalling solely on monocytic cells.
7.5 Concluding comments
Studies outlined within this thesis suggest a role for OSM in regulating monocytic cell 
trafficking during inflammation, potentially through altering NF-kB activity thereby 
inhibiting production of specific downstream chemoattractants. Monocytes play an 
important role in the immune response, both in the removal of pathogen and in the 
clearance of apoptotic cells (Fadok et al, 1998; Savill et al, 2002), however, 
accumulation of activated monocytes and macrophages at inflammatory sites is 
associated with tissue damage (Buckley, 2003). These observations suggest 
OSM-mediated regulation of monocytic cells may have a beneficial role during 
progressive inflammatory conditions. However, OSM control of mononuclear cell 
chemoattractants appears to be limited to CCL5 in vivo suggesting the effects of OSM 
may be confined to specific subsets of monocytic cells. In this respect the impact of 
OSM on NF-kB may be more pertinent. These observations and their implications 
would require further analysis in vivo. Studies into the potential role of OSM in 
peritoneal fibrosis were inconclusive and would require further analysis in a more 
robust fibrosis model, however, it would appear from previous studies that OSM does 
not represent the primary gpl30-activating cytokine involved in tissue damage (Wong 
et al, 2006). From studies outlined within this thesis it remains unclear whether OSM 
would provide a suitable therapeutic target, however, results have demonstrated 
unique and previously undefined roles for OSMRp-mediated signalling in the 
progression of inflammation.
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